Attached files
file | filename |
---|---|
EX-5.1 - Bohai Pharmaceuticals Group, Inc. | v176024_ex5-1.htm |
EX-21.1 - Bohai Pharmaceuticals Group, Inc. | v176024_ex21-1.htm |
EX-23.1 - Bohai Pharmaceuticals Group, Inc. | v176024_ex23-1.htm |
As
filed with the Securities and Exchange Commission on March 2, 2010
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
Bohai
Pharmaceuticals Group, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
2834
|
98-0588402
|
||
(State
or other jurisdiction of
incorporation or organization) |
(Primary
Standard Industrial
Classification Code Number) |
(I.R.S.
Employer Identification
No.) |
c/o
Yantai Bohai Pharmaceuticals Group Co. Ltd.
No.
9 Daxin Road, Zhifu District
Yantai,
Shandong Province, China 264000
+86
(535)-685-7928
(Address,
including zip code, and telephone number, including area code, of registrant’s
principal
executive offices)
executive offices)
Mr.
Hongwei Qu
President
and Chief Executive Officer
Bohai
Pharmaceuticals Group, Inc.
c/o
Yantai Bohai Pharmaceuticals Group Co. Ltd.
No.
9 Daxin Road, Zhifu District
Yantai,
Shandong Province, China 264000
+86
(535)-685-7928
(Name,
address including zip code, and telephone number, including area code, of agent
for service)
Copies
to:
Barry
I. Grossman, Esq.
Lawrence
A. Rosenbloom, Esq.
Ellenoff
Grossman & Schole LLP
150
East 42nd Street, 11th Floor
New
York, NY 10017
212-370-1300
212-370-7889
(fax)
Registrant’s
telephone number: +86 (535)-685-7928
APPROXIMATE
DATE OF PROPOSED SALE TO PUBLIC: From time to time after this
Registration
Statement becomes effective.
If any of
the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, check
the following box: x
If this
Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective
registration statement for the same offering. o
If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer,” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer
|
o
|
Accelerated
filer
|
o
|
Non-accelerated
filer
|
o
|
Smaller
reporting company
|
x
|
(Do
not check if a smaller reporting
company) |
CALCULATION
OF REGISTRATION FEE
Title of each class of securities
to be registered
|
Amount to be
registered(1)
|
Proposed
maximum
offering
price per
unit
|
Proposed
maximum
aggregate
offering price |
Amount of
registration fee
|
||||||||||
common
stock, par value $0.001 per share,
offered
by certain selling stockholders
|
7,032,529
shares
|
$ | 1.00 | (2) | $ | 7,032,529 | $ | 501.42 | ||||||
common
stock, par value $0.001 per share, underlying convertible notes held by
certain selling stockholders (1)
|
6,000,000
shares (3)
|
$ | 2.00 | $ | 12,000,000 | $ | 855.60 | |||||||
common
stock, par value $0.001 per share, underlying warrants held by certain
selling stockholders (1)
|
6,000,000 shares
(4)
|
$ | 2.40 | $ | 14,400,000 | $ | 1,026.72 | |||||||
common
stock, par value $0.001 per share, underlying placement agent warrants
held by certain selling stockholders
|
600,000
shares (6)
|
$ | 2.40 | $ | 1,440,000 | $ | 102.67 | |||||||
TOTAL
|
19,632,529 shares
|
$ | 34,872,529 | $ | 2,486.41 |
(1)
|
Pursuant
to Rule 416 of the Securities Act of 1933, also registered hereby are such
additional and indeterminable number of shares as may be issuable due to
adjustments for changes resulting from stock dividends, stock splits and
similar changes as well as anti-dilution provisions applicable to the
notes and warrants.
|
(2)
|
Estimated
pursuant to Rule 457(f)(2) under the Securities Act of 1933 solely for the
purpose of calculating the amount of the registration fee, based on the
book value of such securities received by the Company in the Share
Exchange.
|
(3)
|
The
6,000,000 shares of common stock are being registered for resale by
certain selling stockholders named in this registration statement, which
shares are issuable by the registrant upon the conversion of the
registrant’s 8% Convertible Notes due January 5,
2012.
|
(4)
|
The
6,000,000 shares of common stock are being registered for resale by
certain selling stockholders named in this registration statement, which
shares are issuable by the registrant upon the exercise of the
registrant’s common stock purchase warrants issued on January 5,
2010.
|
(5)
|
The
600,000 shares of common stock are being registered for resale by certain
selling stockholders named in this registration statement, which shares
are issuable by the registrant upon the exercise of the placement agent
warrants issued on January 5, 2010.
|
The registrant hereby amends this
registration statement on such date or dates as may be necessary to delay its
effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act of 1933 or until
the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to Section 8(a) may
determine.
The
information in this prospectus is not complete and may be changed. We
may not sell these securities until
the registration statement filed with the Securities and Exchange Commission
(“SEC”) is effective. This prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these securities in any state
where the offer or sale is not permitted.
Preliminary
Prospectus
|
Subject
to Completion, dated March 2, 2010
|
19,632,529
Shares of
Common
Stock
This
prospectus relates to the sale of up to a total of 19,632,529 shares of common
stock of Bohai Pharmaceuticals Group, Inc., a Nevada corporation, that may be
sold from time to time by the selling stockholders named in this prospectus and
their successors and assigns. The shares of common stock subject to
this prospectus include: (i) 5,482,529 shares of common stock issued in
connection with our January 5, 2010 share exchange transaction and 1,550,000
other shares of restricted common stock; (ii) 6,000,000 shares issuable upon
conversion by certain selling stockholders of our 8% Convertible Notes due
January 5, 2012, which we refer to herein as the Notes; (iii) 6,000,000 shares
issuable upon the exercise by certain selling stockholders of our common stock
purchase warrants issued on January 5, 2010, which we refer to herein as the
Warrants; and (iv) 600,000 shares upon issuable upon the exercise by certain
selling stockholders of placement agents’ warrants issued on January 5, 2010,
which we refer to herein as the Placement Agent Warrants. The
securities offered for resale hereby were issued to the applicable selling
stockholders in private placement or other exempt transactions completed
prior to the filing of the registration statement of which this prospectus is a
part.
The
selling stockholders may sell all or a portion of their shares through public or
private transactions at prevailing market prices or at privately negotiated
prices. Information regarding the selling stockholders and the times
and manner in which they may offer and sell the shares under this prospectus is
provided under “Selling Stockholders” and “Plan of Distribution” in this
prospectus. We have agreed to pay all the costs and expenses of this
registration.
We will
not receive any of the proceeds from the sale of shares by the selling
stockholders. We may receive proceeds upon exercise of Warrants or
the Placement Agent Warrants, and any proceeds we receive will be used for
general corporate purposes and for working capital.
Our
common stock is listed for quotation on the Over-the-Counter Bulletin Board, or
OTCBB, under the symbol “BOPH”. As of the date of this prospectus,
there has been no trading in our common stock. You are urged to
obtain current market quotations of our common stock before purchasing any of
the shares being offered for sale pursuant to this prospectus.
An
investment in our securities is highly speculative, involves a high degree of
risk and should be considered only by persons who can afford the loss of their
entire investment. See “Risk Factors” beginning on page 6 of this
prospectus.
Neither
the SEC nor any state securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this prospectus. Any
representation to the contrary is a criminal offense.
The
date of this prospectus
is
, 2010.
TABLE
OF CONTENTS
Page
|
|
Number
|
|
About
This Prospectus
|
-i-
|
Prospectus
Summary
|
1
|
Risk
Factors
|
6
|
Cautionary
Note Regarding Forward-Looking Statements
|
29
|
Use
of Proceeds
|
30
|
Determination
of Offering Price
|
30
|
Management’s
Discussion and Analysis of Financial Conditions and Results of
Operations
|
31
|
Business
|
40
|
Management
|
55
|
Executive
Compensation
|
56
|
Certain
Relationships and Related Transactions
|
57
|
Security
Ownership of Certain Beneficial Owners and Management
|
59
|
Description
of Securities
|
60
|
Selling
Stockholders
|
62
|
Plan
of Distribution
|
70
|
Market
for Common Equity and Related Stockholder Matters
|
72
|
Legal
Matters
|
72
|
Experts
|
72
|
Changes
In and Disagreements With Accountants on Accounting and Financial
Disclosure
|
73
|
73
|
|
Index
to Financial Statements
|
F-1
|
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement we filed with the
SEC. You should rely only on the information provided in this
prospectus and incorporated by reference in this prospectus. We have
not authorized anyone to provide you with information different from that
contained in or incorporated by reference into this prospectus. This
prospectus does not constitute an offer to sell or a solicitation of an offer to
buy any securities other than the common stock offered by this
prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any common stock in any circumstances in which
such offer or solicitation is unlawful. The selling stockholders are
offering to sell, and seeking offers to buy, shares of common stock only in
jurisdictions where offers and sales are permitted.
Neither
the delivery of this prospectus nor any sale made in connection with this
prospectus shall, under any circumstances, create any implication that there has
been no change in our affairs since the date of this prospectus or that the
information contained by reference to this prospectus is correct as of any time
after its date. The information in this prospectus is accurate only
as of the date of this prospectus, regardless of the time of delivery of this
prospectus or of any sale of common stock. The rules of the SEC may
require us to update this prospectus in the future.
i
PROSPECTUS
SUMMARY
The
following summary highlights selected information contained in this
prospectus. This summary does not contain all the information you
should consider before investing in the securities. Before making an
investment decision, you should read the entire prospectus carefully, including
the information set forth under the headings “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” and
the financial statements and the notes to the financial statements included in
this prospectus.
As
used throughout this prospectus, the terms “BOPH”, “Company”, “we,” “us,” or
“our” refer to Bohai Pharmaceuticals Group, Inc., a Nevada corporation, together
with: (i) its wholly owned subsidiary, Chance High International Limited, a
British Virgin Islands company (“Chance High”); (ii) its indirect wholly foreign
owned subsidiary, Yantai Shencaojishi Pharmaceuticals Co., Ltd., a PRC company
(“WFOE”), and the WFOE’s variable interest entity, Yantai Bohai Pharmaceuticals
Group Co., Ltd, a PRC company (“Bohai”). In this prospectus, we
sometimes refer to BOPH, Chance High, WFOE and Bohai collectively as the
“Group.”
As
used in this prospectus, “China” or “the PRC” refers to the People’s Republic of
China.
Our
Company
We are
engaged in the production, manufacturing and distribution in China of herbal
pharmaceuticals based on traditional Chinese medicine, which we refer to herein
as Traditional Chinese Medicine or TCM. We are based in the city of
Yantai, Shandong Province, China and our operations are exclusively in
China.
Our
medicines address rheumatoid arthritis, viral infections, gynecological
diseases, cardio vascular issues and respiratory diseases. We
obtained Drug Approval Numbers for 29 varieties of traditional Chinese herbal
medicines in 2004 and currently produce 10 varieties of approved traditional
Chinese herbal medicines in seven delivery systems: tablets, granules, capsules,
syrup, concentrated powder, tincture and medicinal wine. Of these 10
products, 4 are prescription drugs and 6 are over the counter, or OTC,
products. In a significant development, on December 1, 2009, two of
our lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, became
eligible for reimbursement under China’s National Medical Insurance
Program.
Background
and Key Events
We were
incorporated under the laws of the State of Nevada under the name Link Resources
Inc. on January 9, 2008. Our principal office was in Calgary,
Alberta, Canada. Prior to January 5, 2010, we were a public “shell”
company in the exploration stage since our formation and had not yet realized
any revenues. We entered into a Mineral Lease Agreement on April 1,
2008 for two mining claims in Pershing County, Nevada, in an area known as the
Goldbanks East Prospect. We terminated the lease on July 7,
2009.
1
Share
Exchange with Chance High
Pursuant
to the Share Exchange Agreement entered into on January 5, 2010 (the “Share
Exchange Agreement”), and related share exchange (the “Share Exchange”) by and
among us, Chance High, and the shareholders of Chance High (the “Chance High
Shareholders”), we acquired Chance High and its indirect, controlled subsidiary
Bohai, a Chinese company engaged the production, manufacturing and distribution
in China of herbal medicines, including capsules and other products, based on
Traditional Chinese Medicine. The closing of the Share Exchange (the
“Closing”) took place on January 5, 2010. As of the Closing, pursuant
to the terms of the Share Exchange Agreement, we acquired all of the outstanding
equity securities (the “Chance High Shares”) of Chance High from the Chance High
Shareholders, and the Chance High Shareholders transferred and contributed all
of their Chance High Shares to us. In exchange, we issued to Chance
High Shareholders an aggregate of 13,162,500 newly issued shares of our common
stock. Certain of the Chance High Shareholders are selling
stockholders hereunder.
In
addition, pursuant to the terms of the Share Exchange Agreement, Anthony
Zaradic, our former sole officer and director (“Zaradic”), cancelled a total of
1,500,000 shares of common stock owned by him. As a further condition
of the Share Exchange, effective as of January 5, 2010, Zaradic resigned from
all of his positions with our company and Hongwei Qu (“Qu”), the former
principal stockholder and Executive Director of Bohai, was appointed as our
President, Chief Executive Officer, Interim Chief Financial Officer, Treasurer
and Secretary and also, effective January 16, 2010, as our sole
director.
January
5, 2010 Private Placement and Related Agreements
Securities Purchase
Agreement. On January 5, 2010, we entered into a Securities
Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited
investors, who are selling stockholders hereunder (the “Investors”) and Euro
Pacific Capital, Inc. (“Euro Pacific”), as representative of the Investors,
relating to a private placement by us of 6,000,000 units consisting of Notes and
Warrants, which we refer to herein as the private placement. The
consummation of the private placement resulted in gross proceeds to us of
$12,000,000 and net proceeds of approximately $9,700,000. Each unit
consisted of a $2 principal amount, two year convertible Note and a three year
Warrant to purchase one share of our common stock at $2.40 per share, subject to
certain conditions. Euro Pacific acted as the lead placement agent
and Chardan Capital Markets, LLC acted as co-placement agent of the private
placement.
Registration Rights
Agreement. In connection with the private placement, we
entered into Registration Rights Agreement (the “Registration Rights Agreement”)
with the Investors which sets forth the rights of the Investors to have the
shares of common stock underlying the Notes and Warrants issued in the private
placement registered with the Securities and Exchange Commission (“SEC”) for
public resale. The filing of the registration statement of which this
prospectus is a part is intended to satisfy certain of our obligations the
Registration Rights Agreement.
Securities Escrow
Agreement. Also in connection with the private placement, we
entered into a Securities Escrow Agreement (the “Securities Escrow Agreement”)
with Euro Pacific, as representative of the Investors, our principal
stockholder, Glory Period Limited, a British Virgin Islands company that we
refer to herein as Glory Period and which was the majority shareholder of Chance
High prior to the Share Exchange, and Escrow, LLC, as escrow agent (the “Escrow
Agent”). Pursuant to the Securities Escrow Agreement, Glory Period
has pledged and deposited a stock certificate representing 1 million shares of
our common stock (the “Escrow Shares”) into escrow in order to provide security
to the Investors in the event of an occurrence of an event of default under the
Notes. Upon the earlier to occur of the full repayment of all amounts
due to the Investors under the Notes or the conversion of fifty percent of the
principal face value of Notes into shares of common stock, the Investors’ rights
in and to the Escrow Shares shall terminate. Glory Period is
controlled by Qu through certain contractual relationships described elsewhere
in this prospectus.
2
Closing Escrow Agreement.
Pursuant to a Closing Escrow Agreement (the “Closing Escrow Agreement”)
that we entered into in connection with the private placement on December 10,
2009, we placed a total of $240,000 of proceeds from the private placement (the
“Holdback Amount”) with the Escrow Agent. The Holdback Amount
represents an amount sufficient to satisfy the payment to the Investors of one
quarterly interest payment due on the aggregate principal amount of all Notes
issued in the private placement. If, subject to certain conditions
and after applicable notice and cure periods, an event of default is declared by
Euro Pacific with respect to our failure to make a quarterly interest payment to
Investors, the Escrow Agent shall disburse such portion of the Holdback Amount
to the Investors, and we shall be obligated to deposit additional amounts equal
to the Holdback Amount with Escrow Agent. At such time as
seventy-five percent of the aggregate shares of common stock underlying the
Notes have been issued upon conversion of the Notes, all remaining funds of the
Holdback Amount shall promptly be disbursed to us.
Corporate
Name Change
On
January 29, 2010, we entered into an Agreement and Plan of Merger (the “Merger
Agreement”) pursuant to which we merged with a newly formed, wholly owned
subsidiary called Bohai Pharmaceuticals Group, Inc., a Nevada corporation
(“Merger Sub” and such merger transaction, the “Merger”). Upon the
consummation of the Merger, the separate existence of Merger Sub ceased and our
stockholders became stockholders of the surviving company named Bohai
Pharmaceuticals Group, Inc. As permitted by Chapter 92A.180 of Nevada
Revised Statutes, the sole purpose of the Merger was to effect a change of our
corporate name.
Change
of Our Independent Registered Accounting Firm
Effective
January 29, 2010, upon the approval of our board of directors, we dismissed John
Kinross-Kennedy as our independent registered public accountant and appointed
Parker Randall CF (H.K.) CPA Limited as our independent registered public
accounting firm
Corporate
Structure and Related Agreements
Our post
Share Exchange organization structure is summarized below:
3
Chance
High owns 100% of the issued and outstanding capital stock of the
WFOE. On December 7, 2009, the WFOE entered into a series of variable
interest entity contractual agreements (the “VIE Agreements”) with Bohai and its
three shareholders, including Qu. Pursuant to the VIE Agreements,
WOFE effectively assumed management of the business activities of Bohai and has
the right to appoint all executives and senior management and the members of the
board of directors of Bohai. The VIE Agreements are comprised of a
series of agreements, including a Consulting Services Agreement, Operating
Agreement and Proxy Agreement, through which WFOE has the right to advise,
consult, manage and operate Bohai for an annual fee in the amount of Bohai’s
yearly net profits after tax. Additionally, Bohai’s shareholders have
pledged their rights, titles and equity interest in Bohai as security for WFOE
to collect consulting and services fees provided to Bohai through an Equity
Pledge Agreement. In order to further reinforce WFOE’s rights to
control and operate Bohai, Bohai’s shareholders granted WFOE an exclusive right
and option to acquire all of their equity interests in Bohai through an Option
Agreement.
In
addition, on December 7, 2009, Mr. Qu entered into a call option agreement (the
“Call Option Agreement”) with Joshua Tan (“Tan”), the sole shareholder of Glory
Period. The Call Option Agreement became effective upon the closing
of the Share Exchange. Under the Call Option Agreement, Tan shall
transfer up to 100% shares of Glory Period within the next 3 years to Qu for
nominal consideration, which would give Qu indirect ownership of a significant
percentage of our common stock. The Call Option Agreement provides
that Tan shall not dispose any of the shares of Glory Period without Qu’s prior
written consent.
Following
the consummation of the Share Exchange, Glory Period holds 55% of the issued and
outstanding shares of our common stock (not taking into consideration the shares
of common stock underlying the Notes and Warrants issued in the private
placement). The shares of our common stock held by Glory Period are
not being offered for resale pursuant to this prospectus.
Executive
Offices
Our
executive office is located at No. 9 Daxin Road, Zhifu District, Yantai,
Shandong Province, P.R. China 264000. Our telephone number is
+86(535)-685-7928.
4
THE
OFFERING
Common
stock outstanding before the offering
|
16,250,000
|
Common
stock offered by selling stockholders
|
Up
to 19,632,529 shares of common stock held by the selling stockholders or
underlying securities held by the selling stockholders.
|
Common
stock to be outstanding after the offering
|
Up
to 28,850,000 shares, assuming full conversion or exercise of the Notes,
Warrants and Placement Agent Warrants.
|
OTBCC
Symbol
|
BOPH. No
market for our common stock presently exists.
|
Use
of proceeds
|
We
will not receive any proceeds from the sale of the common stock offered
hereby. However, we may receive up to a maximum of $15.84
million of proceeds from the exercise of the warrants held by certain
selling stockholders, which proceeds we would expect to use for general
working capital. No assurances can be given, however, that all
or any portion of such warrants will ever be
exercised.
|
5
RISK
FACTORS
Our
business, operations and financial condition are subject to various significant
risks. Some of these risks are described below and you should take
these risks into account in making a decision to invest in our common
stock. If any of the following risks actually accurs, we may not be
able to conduct our business as currently planned and our financial condition
and operating results could be seriously harmed. In that case, the
market price of our common stock could decline and you could lose all or part of
your investment in our common stock.
Risks
Related to Our Business
Our
limited operating history may not serve as an adequate basis to judge our future
prospects and results of operations.
Our
limited operating history in the traditional Chinese herbal medicines industry
may not provide a meaningful basis for evaluating our business. Bohai
entered into its current line of business in September 2004. Although Bohai’s
revenues have grown rapidly since its inception, we cannot guarantee that we
will maintain profitability or that we will not incur net losses in the
future. We will continue to encounter risks and difficulties that
companies at a similar stage of development frequently experience, including the
potential failure to:
|
·
|
obtain
sufficient working capital to support our
expansion;
|
|
·
|
maintain
or protect our intellectual
property;
|
|
·
|
maintain
our proprietary technology;
|
|
·
|
expand
our product offerings and maintain the quality of our
products;
|
|
·
|
manage
our expanding operations and continue to fill customers’ orders on
time;
|
|
·
|
maintain
adequate control of our expenses allowing us to realize anticipated
revenue growth;
|
|
·
|
implement
our product development, marketing, sales and acquisition strategies and
adapt and modify them as
needed;
|
|
·
|
integrate
any future acquisitions; and
|
|
·
|
anticipate
and adapt to changing conditions in the Chinese herbal medicines industry
resulting from changes in government regulations, mergers and acquisitions
involving our competitors, technological developments and other
significant competitive and market
dynamics.
|
If we are
unable to address any or all of the foregoing risks, our business may be
materially and adversely affected.
6
We
will likely need to raise additional funds in the future to grow our business,
which funds may not be available on acceptable terms or at all, and, without
additional funds, we may not be able to maintain or expand our
business.
We expect
that the net proceeds from our January 2010 private placement, together with
cash generated from our operations, will be sufficient to fund our projected
operations for at least the next 12 months. It is likely however that
in the future we will require substantial funds in order to fund operating
expenses and growth plans, to develop manufacturing, marketing and sales
capabilities and to cover public company costs. Without enough funds,
we may not be able to meet these goals. We may seek additional
funding through public or private financing or through collaborative
arrangements with strategic partners.
You
should also be aware that in the future:
|
·
|
We
cannot be certain that additional capital will be available on favorable
terms, if at all;
|
|
·
|
Any
available additional financing may not be adequate to meet our goals;
and
|
|
·
|
Any
equity financing would result in dilution to our
stockholders.
|
If we
cannot raise additional funds when needed, or on acceptable terms, we may not be
able to effectively execute our growth strategy, take advantage of future
opportunities, or respond to competitive pressures or unanticipated
requirements. In addition, we may be required to scale back or
discontinue our production and development program, or obtain funds through
strategic alliances that may require us to relinquish certain
rights.
We
have significant short-term debt obligations, which mature in less than one
year. Our inability to extend the maturities of, or to refinance,
this debt could result in defaults, and in certain instances, foreclosures on
our assets. Moreover, we may be unable to obtain financing to fund
ongoing operations and future growth.
We
currently depend on short-term bank loans and net revenues to meet our
short-term cash requirements. As of December 31, 2009, our total bank
debt outstanding was $4.93 million or RMB 29.95
million, which carries maturity periods ranging from six months to one year,
while the short-term and revolving nature of these credit facilities is common
in China. Part of these short-term credit facilities are guaranteed by our
inventories and fixed assets and the rest of them are guaranteed by
third-parties and our CEO, Mr. Qu. In China, short-term bank loans
generally mature in one year or less and contain no specific renewal
terms. However, it is customary practice for banks and borrowers to
negotiate roll-overs or renewals of short-term borrowings on an on-going basis
shortly before they mature. Although we have renewed our short-term
borrowings in the past, we cannot assure you that we will be able to renew these
loans in the future as they mature. If we are unable to obtain
renewals of these loans or sufficient alternative funding on reasonable terms
from banks or other parties, we will have to repay these borrowings with the
cash on our balance sheet or cash generated by our future operations, if
any.
Moreover,
we cannot assure you that our business will generate sufficient cash flow from
operations to repay these borrowings. Failure to obtain extensions of
the maturity dates of, or to refinance, these obligations or to obtain
additional equity financing to meet these debt obligations would result in an
event of default with respect to such obligations and could result in the
foreclosure on the collateral. The sale of such collateral at
foreclosure would significantly disrupt our ability to produce products for our
customers in the quantities required by customer orders or deliver products in a
timely fashion, which could significantly lower our revenues and
profitability.
7
In
addition, we may be exposed to changes in interest rates. If interest
rates increase substantially, our results of operations could be adversely
affected.
We
have not yet developed independent corporate governance.
As of the
date of this prospectus, we only have one director, Mr. Qu, serving on our board
of directors. While we are currently seeking “independent” directors
(as defined under Nasdaq Marketplace Rules) for our board of directors, we do
not presently have such directors. Additionally, we have no audit,
compensation, or nominating committees of our board of
directors. This lack of independence and independent controls over
our corporate affairs may result in potential or actual conflicts of interest
between Mr. Qu and our stockholders. We presently have no policy to resolve such
conflicts. As a result, Mr. Qu has the ability to, among other
things, determine his own level of compensation. Until we comply with
such corporate governance measures to appoint a majority of independent
directors and form audit and other board committees in a manner consistent with
Nasdaq Marketplace Rules as part of our obligations under the Securities
Purchase Agreement in connection with our January 2010 private placement, the
absence of such standards of corporate governance may leave our stockholders
without protections against interested director transactions, conflicts of
interest, if any, and similar matters and any potential investors may be
reluctant to provide us with funds necessary to expand our
operations.
We
have been heavily dependent on sales of four key products.
Four of
our products, namely Tongbi Capsules, Tongbi Tablets, Lung Nourishing Cream and
Tongshangning Tablets represented approximately 22%, 16%, 26%, and 15%,
respectively, of total sales for the fiscal year ended June 30,
2009. We expect that a significant portion of our future revenue will
continue to be derived from sales of these four products. If one or more of
these products were to become subject to a problem such as loss of Certificates
of Protected Variety of Traditional Chinese Medicine, unexpected side effects,
regulatory proceedings, publicity adversely affecting user confidence or
pressure from competing products, or if a new, more effective treatment should
be introduced, the negative impact on our revenues could be
significant. We hold the Certificates of Protected Variety of
Traditional Chinese Medicine (Grade Two) issued by State Food and Drug
Administration of China (“SFDA”) for Tongbi Capsules and Shangtongning Tablets
which give us exclusive or near-exclusive rights to manufacture and distribute
these two medicines. The terms of certificates for both Tongbi
Capsules and Shangtongning Tablets expired in September 2009 and we have filed
an application for extending the protection period on March 12, 2009 for Tongbi
Capsules and are in the process of applying for extending the protection period
for Shangtongning Tablets. We can not assure you that we will get the approvals
and the loss of Certificates of Protected Variety of Traditional Chinese
Medicine will a material adverse effect on our revenues. If we can’t get
approvals, these products can be manufactured and sold by other pharmaceutical
manufacturers in China once the relevant protection periods elapse.
We
may not be able to adequately protect our intellectual property, which could
cause us to be less competitive and negatively impact our business.
We regard
our trademarks, trade secrets, patents and similar intellectual property as
critical to our success. We hold the trademark “Xian Ge” registered
with the PRC Trademark Bureau under the State Administration for Industry and
Commerce with a valid term effective through February 23, 2013. We
have applied for a patent for lung nourishing cream with its production method
for the treatment of Lung-qi Deficiency Cough and Chronic
Bronchitis. The application was accepted by the State Intellectual
Property Office of the PRC on September 20, 2007. No assurances can
be given that such application will be approved. If we are unable to
obtain or maintain registered intellectual property protections for our
proprietary products or methods, these products or methods could be infringed
upon, which could materially adversely affect our business.
8
We rely
on trademark, patent and trade secret law, as well as confidentiality agreement
with certain of our employees to protect our proprietary rights. For
senior managers, we include a standard confidentiality clause into the
employment agreement to prevent them from disclosing the formula or processing
procedure to outside parties. No assurance can be given that our intellectual
property will not be challenged, invalidated, infringed or circumvented, or that
our intellectual property rights will provide competitive advantages to
us. Any material impairment of our intellectual property rights could
have a material adverse effect on our business.
We
face competition in the pharmaceutical market in the PRC and such competition
could cause our sales revenue and profits to decline.
According
to SFDA in China, there were approximately 5,071 pharmaceutical manufacturing
companies in the PRC as of the end of June 2004, of which approximately 3,237
manufacturers obtained certificates of Good Manufacturing Practices
Certification (“GMP”). After GMP certification became a mandatory
requirement on July 1, 2004, approximately 1,834 pharmaceutical manufacturers
were forced to cease production. Only the 3,237 pharmaceutical
manufacturers with GMP certifications may continue their manufacturing
operations. As of the end of 2006, there were 4,682 enterprises
manufacturing medicines and formulation in China. The certificates,
permits, and licenses required for pharmaceutical operation in the PRC create a
potentially significant barrier for new competitors seeking entrance into the
market. Despite these obstacles, we face competitors that will
attempt to create, or are already marketing, products in the PRC that are
similar to ours. Many of our current and potential competitors have
significantly longer operating histories and significantly greater managerial,
financial, marketing, technical and other competitive resources, as well as
greater name recognition, than we do. These competitors may be able
to respond more quickly to new or changing opportunities and customer
requirements and may be able to undertake more extensive promotional activities,
offer more attractive terms to customers or adopt more aggressive pricing
policies. We cannot assure you that we will be able to compete
effectively with current or future competitors or that the competitive pressures
we face will not harm our business.
Our
business depends and will depend substantially on the continuing efforts of our
present and future executive officers, and our business may be severely
disrupted if we lose, are unable to obtain or unable to replace their
services.
Our
future prospects depend substantially on the continued services of our executive
officers, especially Mr. Qu, our President and Chief Executive Officer. We do
not maintain key man life insurance on Mr. Qu’s life. If one or more
of our present our future executive officers are unable or unwilling to continue
in their present positions, we may not be able to replace them readily, if at
all. Therefore, our business may be severely disrupted, and we may
incur additional expenses to recruit and retain new officers. In
addition, if any of our executives joins a competitor or forms a competing
company, we may lose some of our customers.
We
do not presently have a Chief Financial Officer with U.S. public company
experience.
We do not
presently have a Chief Financial Officer that is familiar with the accounting
and reporting requirements of a U.S. publicly-listed
company. Although we have agreed to retain the services of such an
executive within 6 months of the closing of the private placement, no assurances
can be given that we will be able to identify or afford the financial
requirements of qualified candidates. The position of Chief Financial
Officer of a U.S. publicly-listed company is critical to the operations of such
a company, and our failure to fill this position in a timely and effective
manner will negatively impact our business.
9
Our
business and growth will suffer if we are unable to hire and retain key
personnel that are in high demand.
Our
future performance depends on our ability to attract and retain highly skilled
chemists, pharmaceutical engineers, technical, marketing and sales personnel,
especially qualified personnel for our operations in China. Qualified
individuals are in high demand in China, and there are insufficient experienced
personnel to fill the demand. Therefore, we may not be able to
attract or retain the personnel we need to succeed. Our business
development would be hindered if we lost the services of some key
personnel.
Our
business is highly dependent on continually developing or acquiring new and
advanced products, technologies, and processes and failure to do so may cause us
to lose our competitiveness in the pharmaceutical industry and may cause our
profits to decline.
To remain
competitive in the pharmaceutical industry, it is important to continually
develop new and advanced products, technologies and processes. There
is no assurance that our competitors’ new products, technologies and processes
will not render our company’s existing products obsolete or
non-competitive. Our company’s competitiveness in the pharmaceutical
market therefore relies upon our ability to enhance our current products,
introduce new products, and develop and implement new technologies and
processes. Our company’s failure to technologically evolve and/or
develop new or enhanced products may cause us to lose our competitiveness in the
pharmaceutical industry and may cause our profits to decline. It is
likely that our efforts to grow our products lines will be focused on
acquisitions of such products from third parties. There are many
risks attendant to the acquisition of assets or companies, including
availability, pricing, competition and, if acquisitions are consummate,
integration. If we are unable to so acquire and integrate new
products, our revenue and profitability may suffer.
Our
research and development may be costly and/or untimely, and there are no
assurances that our research and development will either be successful or
completed within the anticipated timeframe, if ever at all.
The
research and development of our new and existing products and their subsequent
commercialization plays an important role in our success. Development
of new products requires significant research, development and clinical testing
efforts, and we currently have limited resources to devote to and limited
capabilities to conduct the development of new products. We have only one
full-time employee who is engaged in research and development, so we mainly
dependent on a third-party, Yantai Tianzheng Medicine Research and Development
Co., Ltd., to perform research and development for us. Accordingly,
the failure of the third-party research to perform under agreements entered into
with us, or our failure to renew important research agreements with the third
party, may delay or curtail our research and development efforts.
As of the
date of this prospectus, we have two products, namely Forsythia Capsule and Fern
Injection, under research and development. The research and
development of new products is costly and time consuming, and there are no
assurances that our research and development of new products will either be
successful or completed within the anticipated time frame, if ever at
all. There are also no assurances that if the product is developed,
that it will lead to actual commercialization and sales.
10
The
commercial performance of our products depends upon the degree of market
acceptance among the medical community and failure to attain market acceptance
among the medical community may have an adverse impact on our operations and
profitability.
The
commercial performance of our products depends upon the degree of market
acceptance among the medical community, such as hospitals and
physicians. Even if our products are approved by SFDA, and even if
our products are authorized to be eligible for reimbursement under Chinese
national medical insurance programs, there is no assurance that physicians will
prescribe or recommend our products to patients. Furthermore, a
product’s prevalence and use at hospitals may be contingent upon our
relationship with the medical community. The acceptance of our
products among the medical community may depend upon several factors, including
but not limited to, the product’s acceptance by physicians and patients as a
safe and effective treatment, cost effectiveness, potential advantages over
alternative treatments, and the prevalence and severity of side
effects. Failure to attain market acceptance among the medical
community may have an adverse impact on our operations and
profitability.
We
may not be able to obtain the regulatory approvals or clearances that are
necessary to commercialize our products.
The PRC
and other countries impose significant statutory and regulatory obligations upon
the manufacture and sale of pharmaceutical products. Each regulatory
authority typically has a lengthy approval process in which it examines
pre-clinical and clinical data and the facilities in which the product is
manufactured. Regulatory submissions must meet complex criteria to
demonstrate the safety and efficacy of the ultimate products. Addressing these
criteria requires considerable data collection, verification and analysis. We
may spend time and money preparing regulatory submissions or applications
without assurances as to whether they will be approved on a timely basis or at
all.
Our
product candidates, some of which are currently in the early stages of
development, will require significant additional development and pre-clinical
and clinical testing prior to their commercialization. These steps and the
process of obtaining required approvals and clearances can be costly and
time-consuming. If our potential products are not successfully developed, cannot
be proven to be safe and effective through clinical trials, or do not receive
applicable regulatory approvals and clearances, or if there are delays in the
process:
|
·
|
the
commercialization of our products could be adversely
affected;
|
|
·
|
any
competitive advantages of the products could be diminished;
and
|
|
·
|
revenues
or collaborative milestones from the products could be reduced or
delayed.
|
Governmental
and regulatory authorities may approve a product candidate for fewer indications
or narrower circumstances than requested or may condition approval on the
performance of post-marketing studies for a product candidate. Even if a product
receives regulatory approval and clearance, it may later exhibit adverse side
effects that limit or prevent its widespread use or that would force us to
withdraw the product from the market.
Any
marketed product and its manufacturer will continue to be subject to strict
regulation after approval. Results of post-marketing programs may limit or
expand the further marketing of products. Unforeseen problems with an approved
product or any violation of regulations could result in restrictions on the
product, including its withdrawal from the market and possible civil
actions.
11
In
manufacturing our products we will be required to comply with applicable good
manufacturing practices regulations, which include requirements relating to
quality control and quality assurance, as well as the maintenance of records and
documentation. If we cannot comply with regulatory requirements, including
applicable good manufacturing practice requirements, we may not be allowed to
develop or market the product candidates. If we or our manufacturers fail to
comply with applicable regulatory requirements at any stage during the
regulatory process, we may be subject to sanctions, including fines, product
recalls or seizures, injunctions, refusal of regulatory agencies to review
pending market approval applications or supplements to approve applications,
total or partial suspension of production, civil penalties, withdrawals of
previously approved marketing applications and criminal
prosecution.
Our
current and future products may have inadvertent and/or harmful side effects
which would expose us to the risks of litigation and a loss of
revenue.
All
medicines have certain side effects. Although all of our medicines
sold on market have passed proper testing and are approved by SFDA, the products
may still inadvertently adverse effects on the health of the consumers. If such
side effect is identified after marketing and sale of the products, the products
may be required to be withdrawn from the market, or have a change in labeling.
If a product liability claim is brought against us, it may, regardless of merit
or eventual outcome, result in damage to our reputation, breach of contracts
with consumers, decreased demand for our products, costly litigation and loss of
revenue.
Natural
disasters, weather conditions and other environmental factors affect our raw
material supply, and a reduction in the quality or quantity of our herb supplies
may have material adverse consequences on our financial results.
Our
business may be adversely affected by weather and environmental factors beyond
our control, such as natural disasters and adverse weather
conditions. The production of our products depends on the
availability of raw materials, a significant portion of which are herbs.
These herbs tend to be very sensitive crops, which can be readily damaged
by harsh weather, by disease, and by pests. If our suppliers’ crops are
destroyed by drought, flood, storm, blight, or the other woes of farming, we
will not be able to meet the demands of our customers, which will have a
material adverse effect on our business and financial condition and
results.
Our
certificates, permits, and license are subject to governmental control and
renewal, and the failure to obtain renewal would cause all or part of our
operation to be suspended and have a material adverse effect on our financial
condition.
We are
subject to various PRC laws and regulations pertaining to the pharmaceutical
industry. We have obtained certain certificates, permits, and
licenses required for the operation of a pharmaceutical enterprise and the
manufacturing and distribution of pharmaceutical products in the
PRC. Some of the permits and license have expired or are about to
expire. We hold a Permit for the Production of Medicine (Lu
Zb20050330) issued by Shandong Branch of SFDA on January 1, 2006 which allows us
to engage in the production of tablets, capsules, granules, syrup, concentrated
decoctions, tincture (for oral use) and medical wine. Such permit
expires on December 31, 2010. We also hold a GMP Certificate (No. Lu
K0587) issued by Shandong Branch of SFDA on June 18, 2009, the scope of
inspection of which is tablets, capsules, granules, syrup, concentrated
decoctions, tincture and medical wine. Such certificate expires on
June, 14, 2014. The Permit for the Production of Medicine and GMP
certificates are each valid for a term of five years and must be renewed before
their expiration.
12
We hold a
Drug Approval Number (“DAN”) for each of our products, and the valid terms of
such DANs have expired. We submitted the applications for
re-registration on June 29, 2007 which were accepted by SFDA, although the
approvals have not yet been granted. We have been advised that the
approval processes for these drugs have been started to be reviewed by the
Shandong Branch of SFDA. During the renewal period, we will be
permitted to continue manufacturing these drugs as if the renewals had been
approved. Our license to produce medical wine has a term valid
through December 31, 2010.
During
the application or renewal process for our licenses and permits, we will be
evaluated and re-evaluated by the appropriate governmental authorities and must
comply with the prevailing standards and regulations, which may change from time
to time. In the event that we are not able to obtain or renew the
certificates, permits and licenses, all or part of our operations may be
suspended by the government, which would have a material adverse effect on our
business and financial condition. Furthermore, if escalating
compliance costs associated with governmental standards and regulations restrict
or prohibit any part of our operations, it may adversely affect our results of
operations and profitability.
Our
failure to fully comply with PRC labor laws, including laws relating to social
insurance, may expose us to potential liability and increased
costs.
Companies
operating in China must comply with a variety of labor laws, including certain
pension, health insurance, unemployment insurance and other welfare-oriented
payment obligations. Our failure to comply with these laws could have
a material adverse effect on our business. For example, we are
currently paying social insurance for our 105 full-time employees. We also
have 304 sales representatives that we believe we are not required to pay social
insurance for as these sales representatives are not legally employees of ours,
but are rather independent contractors. We have not paid social insurance
for 195 of our full-time employees whose personal identification files cannot be
transferred to us since they are not registered residents in Yantai, Shandong
Province, and as an alternative we have paid these employees compensations
included in their monthly salary with an amount equals to the amount of monthly
social insurance that we are required to pay and the employees could pay the
social insurance by themselves. We believe these employees have been
covered by social insurance and we are not required to make any contributions to
the government in addition to the amount we have paid to these
employees. However, our interpretation of these requirements may be
wrong, and the PRC regulatory authorities may not take the same view as we do on
this subject. If the PRC regulatory authorities take the view that we are
required to pay social insurance for our independent contractors or other
employees, our failure to make previous payments may be in violation of
applicable PRC labor laws and we cannot assure you that PRC governmental
authorities will not impose penalties on us for failure to comply. In
addition, in the event that any current or former employee files a complaint
with the PRC government, we may be subject to making up the social insurance
payment obligations as well as paying administrative fines. The total cost
of these payments and any related fines or penalties could be very significant
and could have a material adverse effect on our working capital.
In
addition, the new PRC Labor Contract Law took effect January 1, 2008 and governs
standard terms and conditions for employment, including termination and lay-off
rights, contract requirements, compensation levels and consultation with labor
unions, among other topics. In addition, the law limits
non-competition agreements with senior management and other employees who have
access to confidential information to two years and imposes restrictions or
geographical limits. This new labor contract law will increase our
labor costs, which could adversely impact our results of
operations.
13
We
are subject to PRC government price control of drugs which may limit our
profitability and even cause us to stop manufacturing certain
products.
The State
Development and Reform Commission of the PRC (“SDRC”) and the price
administration bureaus of the relevant provinces of the PRC in which the
pharmaceutical products are manufactured are responsible for the retail price
control over our pharmaceutical products. The SDRC sets the price
ceilings for certain pharmaceutical products in the PRC. All of our products
except those under the protection periods are subject to such price controls as
of the date of this Memorandum and we prices our medicines well under
government-mandated caps. There is no assurance that whether our other products
will remain unaffected by the price control. Where our products are
subject to a price ceiling, we will need to adjust the product price to meet the
requirement and to accommodate for the pricing of competitors in the competition
for market shares. The price ceilings set by the SDRC may limit our
profitability, and in some instances, such as where the price ceiling is below
production costs, may cause us to stop manufacturing certain products which may
adversely affect our results of operations.
Because
we may not be able to obtain business insurance in the PRC, we may not be
protected from risks that are customarily covered by insurance in the United
States.
Business
insurance is not readily available in the PRC. To the extent that we
suffer a loss of a type which would normally be covered by insurance in the
United States, such as product liability and general liability insurance, we
would incur significant expenses in both defending any action and in paying any
claims that result from a settlement or judgment. We have not
obtained fire, casualty and theft insurance, and there is no insurance coverage
for our raw materials, goods and merchandise, furniture and buildings in
China. Any losses incurred by us will have to be borne by us without
any assistance, and we may not have sufficient capital to cover material damage
to, or the loss of, our production facility due to fire, severe weather, flood
or other cause, and such damage or loss would have a material adverse effect on
our financial condition, business and prospects.
We
may be subject to product liability claims, for which we have no
insurance.
We may
produce products which inadvertently have an adverse pharmaceutical effect on
the health of individuals. Existing laws and regulations in China do not
require us to maintain third party liability insurance to cover product
liability claims. However, if a product liability claim is brought against
us, it may, regardless of merit or eventual outcome, result in damage to our
reputation, breach of contracts with our customers, decreased demand for our
products, costly litigations, product recalls, loss of revenue, and our
inability to commercialize some products.
We
do not carry directors and officers’ liability insurance to cover any expenses
and losses due to lawsuits related to financial reporting errors. Our
indemnification obligations could adversely affect our business, financial
condition and results of operations.
We have
not obtained director and officer liability insurance to cover lawsuit expenses
and losses related to financial reporting errors. Our bylaws require
us to indemnify our current and former directors, officers, employees and agents
against most actions of a civil, criminal, administrative or investigative
nature. Generally, we are required to advance indemnification
expenses prior to any final adjudication of an individual’s
culpability. The expense of indemnifying our current and former
directors, officers and employees and agents in their defense or related
expenses as a result of any actions related to the internal investigation and
financial restatement may be significant. Therefore, our
indemnification obligations could result in the diversion of our financial
resources and may adversely affect our business, financial condition and results
of operations.
14
Potential
environmental liability could have a material adverse effect on our operations
and financial condition.
As a
manufacturer, we are subject to various Chinese environmental laws and
regulations on air emission, waste water discharge, solid wastes and
noise. We are in the process of applying for Pollution Discharge
Permit, other than that we believe that our operations are in substantial
compliance with current environmental laws and regulations. We can not assure
you that we may not be able to comply with these regulations at all times as the
Chinese environmental legal regime is evolving and becoming more
stringent. Therefore, if the Chinese government imposes more
stringent regulations in future, we may have to incur additional and potentially
substantial costs and expenses in order to comply with new regulations, which
may negatively affect our results of operations. Furthermore, no
assurance can be given that all potential environmental liabilities have been
identified or properly quantified or that any prior owner, operator, or tenant
has not created an environmental condition unknown to us. If we fail
to comply with any of the present or future environmental regulations in any
material aspects, we may suffer from negative publicity and be subject to claims
for damages that may require us to pay substantial fines or have our operations
suspended or even be forced to cease operations.
Risks
Relating to the Our Corporate Structure
Our
corporate structure, in particular the VIE Agreements, are subject to
significant risks, as set forth in the following risk factors.
The
PRC government may determine that the VIE Agreements are not in compliance with
applicable PRC laws, rules and regulations.
In the
PRC it is widely understood that foreign invested enterprises are forbidden or
restricted to engage in certain businesses or industries which are sensitive to
the economy. As we intend to centralize our management and operation
in the PRC without being restricted to conduct certain business activities which
are important for our current or future business but are restricted or might be
restricted in the future, we believe our VIE Agreements will be essential for
our business operation. In order for WFOE to manage and operate our
business through Bohai in the PRC, the VIE Agreements were entered into under
which almost all the business activities of Bohai are managed and operated by
WFOE and almost all economic benefits and risks arising from the business of
Bohai are transferred to WFOE.
There are
risks involved with the operation of Bohai under the VIE
Agreements. As advised by our PRC legal counsel, if the VIE
Agreements are considered to be in breach of any existing or future PRC laws or
regulations, the relevant regulatory authorities would have broad discretion in
dealing with such breach, including:
|
·
|
imposing
economic penalties;
|
|
·
|
discontinuing
or restricting the operations of WFOE or
Bohai;
|
|
·
|
imposing
conditions or requirements in respect of the VIE Agreements with which
WFOE may not be able to comply;
|
|
·
|
requiring
us to restructure the relevant ownership structure or
operations;
|
|
·
|
taking
other regulatory or enforcement actions that could adversely affect our
business; and
|
15
|
·
|
revoking
the business license and/or the licenses or certificates of WFOE, and/or
voiding the VIE Agreements.
|
Any of
these actions could have a material adverse impact on our business, financial
condition and results of operations.
We
depend upon the VIE Agreements in conducting our production, manufacturing and
distribution of traditional Chinese herbal medicines in the PRC, which may not
be as effective as direct ownership.
We
conduct our production, manufacturing and distribution of traditional Chinese
herbal medicines in the PRC and generate the revenues through the VIE
Agreements. The VIE Agreements may not be as effective in providing
us with control over Bohai as direct ownership. The VIE Agreements
are governed by PRC laws and provide for the resolution of disputes through
arbitration proceedings pursuant to PRC laws. Accordingly, the VIE
Agreements will be interpreted in accordance with PRC laws. If Bohai
or its shareholders fail to perform the obligations under the VIE Agreements, we
may have to rely on legal remedies under PRC laws, including seeking specific
performance or injunctive relief, and claiming damages, and there is a risk that
we may be unable to obtain these remedies. The legal environment in
China is not as developed as in other jurisdictions. As a result,
uncertainties in the PRC legal system could limit our ability to enforce the VIE
Agreements.
The
pricing arrangement under the VIE Agreements may be challenged by the PRC tax
authorities.
We could
face adverse tax consequences if the PRC tax authorities determine that the VIE
Agreements were not entered into based on arm’s length
negotiations. If the PRC tax authorities determine that the VIE
Agreements were not entered into on an arm’s length basis, they may adjust the
income and expenses of our company for PRC tax purposes which could result in
higher tax liability.
We
rely on the approval certificates and business license held by Bohai and any
deterioration of the relationship between WFOE and Bohai could materially and
adversely affect the overall business operation of our company.
Pursuant
to the VIE Agreements, our production, manufacturing and distribution of
traditional Chinese herbal medicines in China is undertaken on the basis of the
approvals, certificates and business license as well as other requisite licenses
held by Bohai. There is no assurance that Bohai will be able to renew
its licenses or certificates when their terms expire with substantially similar
terms as the ones they currently hold.
Further,
our relationship with Bohai is governed by the VIE Agreements, which are
intended to provide us, through our indirect ownership of WFOE, with effective
control over the business operations of Bohai. However, the VIE
Agreements may not be effective in providing control over the applications for
and maintenance of the licenses required for our business
operations. Bohai could violate the VIE Agreements, go bankrupt,
suffer from difficulties in its business or otherwise become unable to perform
its obligations under the VIE Agreements and, as a result, our operations,
reputation, business and stock price could be severely harmed.
16
If
WFOE exercises the purchase options over Bohai’s equity pursuant to the VIE
Agreements, the payment of purchase prices could materially and adversely affect
the financial position of our company.
Under the
VIE Agreements, WFOE holds an option to purchase all or a portion of the equity
of Bohai at a price, pro rata in case of not all, based on the capital paid in
by the Bohai shareholders (namely, $2.94 million or RMB 20 million
). In the case that applicable PRC laws and regulations require an
appraisal of the equity interest or provide other restriction on the purchase
price, the purchase price shall be the lowest price permitted under the
applicable PRC laws and regulations. As Bohai is already a contractually
controlled affiliate to our company, WFOE’s purchase of Bohai’s equity would not
bring immediate benefits to our company and the exercise of the option and
payment of the purchase prices could adversely affect the financial position of
our company.
Risks
Associated With Doing Business in China
There
are substantial risks associated with doing business in China, some of which are
addressed in the following risk factors.
The
Chinese government exerts substantial influence over the manner in which we must
conduct our business activities.
We are
dependent on our relationship with the local government in the province in which
we operate our business. The Chinese government has exercised and
continues to exercise substantial control over virtually every sector of the
Chinese economy through regulation and state ownership. Our ability
to operate in China may be harmed by changes in its laws and regulations,
including those relating to taxation, environmental regulations, land use
rights, property and other matters. The central or local governments
of in the PRC jurisdictions may impose new, stricter regulations or
interpretations of existing regulations that would require additional
expenditures and efforts on our part to ensure our compliance with such
regulations or interpretations. Accordingly, government actions in
the future, including any decision not to continue to support recent economic
reforms and to return to a more centrally planned economy or regional or local
variations in the implementation of economic policies, could have a significant
effect on economic conditions in China or particular regions thereof, and could
require us to divest ourselves of any interest we then hold in Chinese
properties.
Future
inflation in China may inhibit our ability to conduct business in China. In
recent years, the Chinese economy has experienced periods of rapid expansion and
high rates of inflation. Rapid economic growth can lead to growth in
the money supply and rising inflation. If prices for our products
rise at a rate that is insufficient to compensate for the rise in the costs of
supplies, it may have an adverse effect on profitability. These
factors have led to the adoption by Chinese government, from time to time, of
various corrective measures designed to restrict the availability of credit or
regulate growth and contain inflation. High inflation may in the
future cause Chinese government to impose controls on credit and/or prices, or
to take other action, which could inhibit economic activity in China, and
thereby harm the market for our products.
Our
operations and assets in China are subject to significant political and economic
uncertainties.
Changes
in PRC laws and regulations, or their interpretation, or the imposition of
confiscatory taxation, restrictions on currency conversion, imports and sources
of supply, devaluations of currency or the nationalization or other
expropriation of private enterprises could have a material adverse effect on our
business, results of operations and financial condition. Under its
current leadership, the Chinese government has been pursuing economic reform
policies that encourage private economic activities and greater economic
decentralization. There is no assurance, however, that the Chinese
government will continue to pursue these policies, or that it will not
significantly alter these policies from time to time without
notice.
17
We
derive all of our sales in China and a slowdown or other adverse developments in
the PRC economy may materially and adversely affect our customers, demand for
our products and our business.
All of
our sales are generated in China. We anticipate that sales of our
products in China will continue to represent all of our total sales in the near
future. Although the PRC economy has grown significantly in recent
years, we cannot assure you that such growth will continue. The
industry which we are involved in the PRC is relatively new and growing, but we
do not know how sensitive we are to a slowdown in economic growth or other
adverse changes in the PRC economy which may affect demand for our
products. In addition, the Chinese government also exercises
significant control over Chinese economic growth through the allocation of
resources, controlling payment of foreign currency-denominated obligations,
setting monetary policy and providing preferential treatment to particular
industries or companies. Efforts by the Chinese government to slow
the pace of growth of the Chinese economy could result in reduced demand for our
products. A slowdown in overall economic growth, an economic downturn
or recession or other adverse economic developments in the PRC may materially
reduce the demand for our products and materially and adversely affect our
business.
Currency
fluctuations and restrictions on currency exchange may adversely affect our
business, including limiting our ability to convert Chinese Renminbi into
foreign currencies and, if Chinese Renminbi were to decline in value, reducing
our revenue in U.S. dollar terms.
Our
reporting currency is the U.S. dollar and our operations in China use their
local currency as their functional currencies. Substantially all of our revenue
and expenses are in Chinese Renminbi. We are subject to the effects
of exchange rate fluctuations with respect to any of these
currencies. For example, the value of the Renminbi depends to a large
extent on Chinese government policies and China’s domestic and international
economic and political developments, as well as supply and demand in the local
market. Since 1994, the official exchange rate for the conversion of Renminbi to
the U.S. dollar had generally been stable and the Renminbi had appreciated
slightly against the U.S. dollar. However, on July 21, 2005, the
Chinese government changed its policy of pegging the value of Chinese Renminbi
to the U.S. dollar. Under the new policy, Chinese Renminbi may
fluctuate within a narrow and managed band against a basket of certain foreign
currencies. It is possible that the Chinese government could adopt a more
flexible currency policy, which could result in more significant fluctuation of
Chinese Renminbi against the U.S. dollar. We can offer no assurance
that Chinese Renminbi will be stable against the U.S. dollar or any other
foreign currency.
Our
financial statements are translated into U.S. dollars at the average exchange
rates in each applicable period. To the extent the U.S. dollar
strengthens against foreign currencies, the translation of these foreign
currencies denominated transactions results in reduced revenue, operating
expenses and net income for our international operations. Similarly,
to the extent the U.S. dollar weakens against foreign currencies, the
translation of these foreign currency denominated transactions results in
increased revenue, operating expenses and net income for our international
operations. We are also exposed to foreign exchange rate fluctuations
as we convert the financial statements of our foreign consolidated subsidiaries
into U.S. dollars in consolidation. If there is a change in foreign
currency exchange rates, the conversion of the foreign consolidated
subsidiaries’ financial statements into U.S. dollars will lead to a translation
gain or loss which is recorded as a component of other comprehensive
income. In addition, we have certain assets and liabilities that are
denominated in currencies other than the relevant entity’s functional
currency. Changes in the functional currency value of these assets
and liabilities create fluctuations that will lead to a transaction gain or
loss. We have not entered into agreements or purchased instruments to
hedge our exchange rate risks, although we may do so in the
future. The availability and effectiveness of any hedging transaction
may be limited and we may not be able to hedge our exchange rate
risks.
18
The
State Administration of Foreign Exchange (“SAFE”) restrictions on currency
exchange may limit our ability to receive and use our sales revenue effectively
and to pay dividends, and the restrictions may cause a delay in payment of
interest on the Notes.
All of
our sales revenue and expenses are denominated in the Chinese currency,
Renminbi. Under PRC law, the Renminbi is currently convertible under
the “current account,” which includes dividends and trade and service-related
foreign exchange transactions, but not under the “capital account,” which
includes foreign direct investment and loans. Currently, our PRC
operating subsidiary, Bohai, may purchase foreign currencies for settlement of
current account transactions, including payments of dividends to us, without the
approval of SAFE, by complying with certain procedural
requirements. However, the relevant PRC government authorities may
limit or eliminate our ability to purchase foreign currencies in the
future. Since a significant amount of our future revenue will be
denominated in Renminbi, any existing and future restrictions on currency
exchange may limit our ability to utilize revenue generated in Renminbi to fund
our business activities outside China that are denominated in foreign
currencies.
All of
our income is derived from the consulting fees we receive from Bohai through the
VIE Agreements. SAFE restrictions may delay the payment of dividends,
since we have to comply with certain procedural requirement and we may
experience difficulties in completing the administrative procedures necessary to
obtain and remit foreign currency for the payment of dividends from the profits
of WFOE, and it thus may delay our payment of interest to the Notes
holders.
Foreign
exchange transactions by PRC operating subsidiaries under the capital account
continue to be subject to significant foreign exchange controls and require the
approval of or need to register with PRC government authorities, including
SAFE. In particular, if Bohai, our PRC operating subsidiary, borrows
foreign currency through loans from us or other foreign lenders, these loans
must be registered with SAFE, and if we finance Bohai by means of additional
capital contributions, these capital contributions must be approved by certain
government authorities, including the Ministry of Commerce, or their respective
local counterparts. These limitations could affect Bohai’s ability to
obtain foreign exchange through debt or equity financing.
The PRC
government also may at its discretion restrict access in the future to foreign
currencies for current account transactions. If the foreign exchange
control system prevents us from obtaining foreign currency, we may be unable to
pay the interest and principal on the Notes, pay dividends or meet obligations
that may be incurred in the future that require payment in foreign
currency.
19
The
PRC State Administration of Foreign Exchange restrictions on the use of offshore
holding companies in mergers and acquisitions in China may create regulatory
uncertainties that could restrict or limit our ability to operate.
In
November 2005, SAFE issued a public notice, known as Circular 75, concerning
foreign exchange registrations that are required in order to use of offshore
holding companies in mergers and acquisitions in China. The public
notice provides that if an offshore company controlled by PRC residents intends
to acquire a PRC company, such acquisition will be subject to registration with
the relevant foreign exchange authorities. The public notice also
suggested that registration with the relevant foreign exchange authorities is
required for any sale or transfer by the PRC residents of shares in an offshore
holding company that owns an onshore company. PRC residents must each
submit a registration form to the local SAFE branch with respect to their
ownership interests in the offshore company, and must also file an amendment to
such registration if the offshore company experiences material events, such as
changes in the share capital, share transfer, mergers and acquisitions, spin-off
transactions or use of assets in China to guarantee offshore
obligations.
Internal
implementing guidelines issued by SAFE, which became public in June 2007 (known
as Notice 106), expanded the reach of Circular 75 by: (i) purporting to cover
the establishment or acquisition of control by PRC residents of offshore
entities which merely acquire “control” over domestic companies or assets, even
in the absence of legal ownership; (ii) adding requirements relating to the
source of the PRC resident’s funds used to establish or acquire the offshore
entity; (iii) covering the use of existing offshore entities for offshore
financings; (iv) purporting to cover situations in which an offshore special
purpose vehicle, or SPV, establishes a new subsidiary in China or acquires an
unrelated company or unrelated assets in China; and (v) making the domestic
affiliate of the SPV responsible for the accuracy of certain documents which
must be filed in connection with any such registration, notably, the business
plan which describes the overseas financing and the use of
proceeds. Amendments to registrations made under Circular 75 are
required in connection with any increase or decrease of capital, transfer of
shares, mergers and acquisitions, equity investment or creation of any security
interest in any assets located in China to guarantee offshore obligations, and
Notice 106 makes the offshore SPV jointly responsible for these
filings. In the case of an SPV which was established, and which
acquired a related domestic company or assets, before the implementation date of
Circular 75, as applied by SAFE in accordance with Notice 106, may result in
fines and other penalties under PRC laws for evasion of applicable foreign
exchange restrictions. Any such failure could also result in the
SPV’s affiliates being impeded or prevented from distributing their profits and
the proceeds from any reduction in capital, share transfer or liquidation to the
SPV, or from engaging in other transfers of funds into or out of
China.
The PRC
regulatory authorities may take the view that our acquisition of indirect
ownership and controlling interest in Bohai through VIE arrangements shall be
subject to SAFE approval and registration. Any adverse action taken against us
by PRC regulatory authorities could significantly and negatively impact our
operations and the trading market for our common stock.
PRC
regulations and potential registration requirements relating to acquisitions of
PRC companies by foreign entities may create regulatory uncertainties that could
restrict or limit our ability to operate. Similarly, our failure to
obtain the prior approval of PRC authorities for our January 2010 private
placement and the listing and trading of our common stock could have a material
adverse effect on our business, operating results, reputation and trading price
of our common stock.
On August
8, 2006, the PRC Ministry of Commerce (“MOC”), joined by the State-owned Assets
Supervision and Administration Commission of the State Council, the State
Administration of Taxation, the State Administration for Industry and Commerce,
the China Securities Regulatory Commission (“CSRC”) and SAFE, released a
substantially amended version of the Provisions for Foreign Investors to Merge
with or Acquire Domestic Enterprises (the “Revised M&A Regulations”), which
took effect September 8, 2006. These new rules significantly revised
China’s regulatory framework governing onshore-to-offshore restructurings and
foreign acquisitions of domestic enterprises. These new rules signify
greater PRC government attention to cross-border merger, acquisition and other
investment activities, by confirming MOC as a key regulator for issues related
to mergers and acquisitions in China and requiring MOC approval of a broad range
of merger, acquisition and investment transactions. Further, the new
rules establish reporting requirements for acquisition of control by foreigners
of companies in key industries, and reinforce the ability of the Chinese
government to monitor and prohibit foreign control transactions in key
industries.
20
Among
other things, the revised M&A Regulations include new provisions that
purport to require that an offshore SPV, formed for listing purposes and
controlled directly or indirectly by PRC companies or individuals must obtain
the approval of the CSRC prior to the listing and trading of such SPV’s
securities on an overseas stock exchange. On September 21, 2006, the
CSRC published on its official website procedures specifying documents and
materials required to be submitted to it by SPVs seeking CSRC approval of their
overseas listings. However, the application of this PRC regulation
remains unclear with no consensus currently existing among the leading PRC law
firms regarding the scope and applicability of the CSRC approval
requirement.
Our
principal stockholder, Glory Period, is 100% owned by Joshua Tan, a Singapore
citizen. As of the date of this prospectus, Glory Period holds 55% of
our outstanding common stock. Mr. Tan and Mr. Qu (the principal
founder of Bohai and our Chairman, President and Chief Executive Officer)
entered into the Call Option Agreement on December 7, 2009 by which Mr. Qu has
an option to acquire all the issued and outstanding shares of Glory Period
within three years for nominal consideration. Chance High, as the
wholly owned subsidiary of our company, formed WFOE on November 23, 2009 and
WFOE obtained effective and substantial control over Bohai further through
executing the VIE Agreements on December 7, 2009 by and among WFOE, Bohai and
the three shareholders of Bohai (including Mr. Qu). The PRC
regulatory authorities may take the view that entry into the VIE Agreements by
WFOE and Bohai resulting in Mr. Qu, a PRC resident becoming the majority owner
and effective controlling party of our company which acquired 100% indirect
ownership of Bohai. The PRC regulatory authorities may also take the
view that the relevant parties should fully disclose to SAFE or MOC of the
overall restructuring arrangements, the existence of the Share Exchange and
related VIE Agreements. If the PRC regulatory authorities take the
view that the Share Exchange and VIE arrangement constitutes a reverse ,merger
or round-trip investment under the M&A Regulations, we cannot assure you we
may be able to obtain the approval required from the national offices of
MOC.
If the
PRC regulatory authorities take the view that the Share Exchange and the VIE
Agreements constitutes a reverse merger acquisition or round-trip investment
without the approval of the national offices of MOC, they could invalidate the
Share Exchange and VIE Agreements. Additionally, the PRC regulatory
authorities may take the view that any public offering plan of us will require
the prior approval of CSRC. If we cannot obtain MOC or CSRC approval
in case we are required to do so, our business and financial performance will be
materially adversely affected. We may also face regulatory actions or
other sanctions from the MOC or other PRC regulatory agencies. These
regulatory agencies may impose fines and penalties on our operations in the PRC,
limit our operating privileges in the PRC, delay or restrict the repatriation of
the proceeds from the Private Placement into the PRC, or take other actions that
could have a material adverse effect on our business, financial condition,
results of operations, reputation and prospects, as well as the trading price of
our common stock.
Also, if
later the CSRC requires that we obtain its approval, we may be unable to obtain
a waiver of the CSRC approval requirements, if and when procedures are
established to obtain such a waiver. Any uncertainties and/or negative publicity
regarding this CSRC approval requirement could have a material adverse effect on
the trading price of our common stock. Furthermore, published news
reports in China recently indicated that the CSRC may have curtailed or
suspended overseas listings for Chinese private companies. These news reports
have created further uncertainty regarding the approach that the CSRC and other
PRC regulators may take with respect to transactions that we have engaged in our
may in the future engage in. Any adverse action taken against us by
PRC regulatory authorities could significantly and negatively impact our
operations and the trading market for our common stock.
21
Because
our assets are located outside of the United States and our sole director and
officer resides outside of the United States, it may be difficult for you to
enforce your rights based on the United States federal securities laws against
us and our sole officer and director in the United States or to enforce
judgments of United States courts against us or him in the PRC.
Our sole
director and officer, Mr. Qu, resides outside of the United States in
China. In addition, our operating subsidiary is located in the PRC
and all of its assets are located outside of the United States. China
does not have a treaty with United States providing for the reciprocal
recognition and enforcement of judgments of courts. It may therefore
be difficult for investors in the United States to enforce their legal rights
based on the civil liability provisions of the United States federal securities
laws against us in the courts of either the United States or the PRC and, even
if civil judgments are obtained in courts of the United States, to enforce such
judgments in the PRC courts. Further, it is unclear if extradition
treaties now in effect between the United States and the PRC would permit
effective enforcement against us or our officers and directors of criminal
penalties, under the United States federal securities laws or
otherwise.
We
may have limited legal recourse under PRC laws if disputes arise under our
contracts with third parties.
The
Chinese government has enacted some laws and regulations dealing with matters
such as corporate organization and governance, foreign investment, commerce,
taxation and trade. However, their experience in implementing,
interpreting and enforcing these laws and regulations is limited, and our
ability to enforce commercial claims or to resolve commercial disputes is
unpredictable. If our new business ventures are unsuccessful, or
other adverse circumstances arise from these transactions, we face the risk that
the parties to these ventures may seek ways to terminate the transactions, or,
may hinder or prevent us from accessing important information regarding the
financial and business operations of these acquired companies. The
resolution of these matters may be subject to the exercise of considerable
discretion by agencies of the Chinese government, and forces unrelated to the
legal merits of a particular matter or dispute may influence their
determination. Any rights we may have to specific performance, or to seek an
injunction under PRC laws, in either of these cases, are severely limited, and
without a means of recourse by virtue of the Chinese legal system, we may be
unable to prevent these situations from occurring. The occurrence of
any such events could have a material adverse effect on our business, financial
condition and results of operations. Although legislation in China
over the past 30 years has significantly improved the protection afforded to
various forms of foreign investment and contractual arrangements in China, these
laws, regulations and legal requirements are relatively new and their
interpretation and enforcement involve uncertainties, which could limit the
legal protection available to us, and foreign investors, including
you. The inability to enforce or obtain a remedy under any of our
future agreements could result in a significant loss of business, business
opportunities or capital and could have a material adverse impact on our
operations.
We
must comply with the Foreign Corrupt Practices Act.
We are
required to comply with the United States Foreign Corrupt Practices Act, which
prohibits U.S. companies from engaging in bribery or other prohibited payments
to foreign officials for the purpose of obtaining or retaining
business. Foreign companies, including some of our competitors, are
not subject to these prohibitions. Corruption, extortion, bribery,
pay-offs, theft and other fraudulent practices occur from time-to-time in
mainland China. If our competitors engage in these practices, they
may receive preferential treatment from personnel of some companies, giving our
competitors an advantage in securing business or from government officials who
might give them priority in obtaining new licenses, which would put us at a
disadvantage. Although we inform our personnel that such practices
are illegal, we have not established formal policies or procedures for
prohibiting or monitoring this conduct, and we can not assure you that our
employees or other agents will not engage in such conduct for which we might be
held responsible. If our employees or other agents are found to have
engaged in such practices, we could suffer severe penalties.
22
If
we make equity compensation grants to persons who are PRC citizens, they may be
required to register with SAFE. We may also face regulatory
uncertainties that could restrict our ability to adopt equity compensation plans
for our directors and employees and other parties under PRC laws.
On April
6, 2007, SAFE issued the “Operating Procedures for Administration of Domestic
Individuals Participating in the Employee Stock Ownership Plan or Stock Option
Plan of An Overseas Listed Company, also know as “Circular 78.” It is
not clear whether Circular 78 covers all forms of equity compensation plans or
only those which provide for the granting of stock options. For any plans which
are so covered and are adopted by a non-PRC listed company, such as our company,
after April 6, 2007, Circular 78 requires all participants who are PRC citizens
to register with and obtain approvals from SAFE prior to their participation in
the plan. In addition, Circular 78 also requires PRC citizens to
register with SAFE and make the necessary applications and filings if they
participated in an overseas listed company’s covered equity compensation plan
prior to April 6, 2007. We believe that the registration and approval
requirements contemplated in Circular 78 will be burdensome and time
consuming.
In the
future, we may adopt an equity incentive plan and make numerous stock option
grants under the plan to our officers, directors and employees, some of whom are
PRC citizens and may be required to register with SAFE. If it is
determined that any of our equity compensation plans are subject to Circular 78,
failure to comply with such provisions may subject us and participants of our
equity incentive plan who are PRC citizens to fines and legal sanctions and
prevent us from being able to grant equity compensation to our PRC employees. In
that case, our ability to compensate our employees and directors through equity
compensation would be hindered and our business operations may be adversely
affected.
Due
to various restrictions under PRC laws on the distribution of dividends by our
PRC operating companies, we may not be able to pay dividends to our
stockholders.
The
Wholly-Foreign Owned Enterprise Law (1986), as amended and the Wholly-Foreign
Owned Enterprise Law Implementing Rules (1990), as amended and the Company Law
of the PRC (2006) contain the principal regulations governing dividend
distributions by wholly foreign owned enterprises. Under these regulations,
wholly foreign owned enterprises, such as WFOE, may pay dividends only out of
their accumulated profits, if any, determined in accordance with PRC accounting
standards and regulations. Additionally, WFOE is required to set aside a certain
amount of their accumulated profits each year, if any, to fund certain reserve
funds. These reserves are not distributable as cash dividends except
in the event of liquidation and cannot be used for working capital
purposes.
Furthermore,
if our consolidated subsidiaries in China incur debt on their own in the future,
the instruments governing the debt may restrict its ability to pay dividends or
make other payments. If we or our consolidated subsidiaries are unable to
receive all of the revenues from our operations due to these contractual or
dividend arrangements, we may be unable to pay dividends on our common
stock.
23
We
may have difficulty establishing adequate management, governance, legal and
financial controls in the PRC.
The PRC
historically has been deficient in western style management, governance and
financial reporting concepts and practices, as well as in modern banking, and
other control systems. Our current management has little experience
with western style management, governance and financial reporting concepts and
practices, and we may have difficulty in hiring and retaining a sufficient
number of qualified employees to work in the PRC. As a result of
these factors, and especially given that we expect to be a publicly listed
company in U.S. and subject to regulation as such, we may experience difficulty
in establishing management, governance legal and financial controls, collecting
financial data and preparing financial statements, books of account and
corporate records and instituting business practices that meet western
standards. We may have difficulty establishing adequate management,
governance, legal and financial controls in the PRC. Therefore, we
may, in turn, experience difficulties in implementing and maintaining adequate
internal controls as required under Section 404 of the Sarbanes-Oxley Act of
2002 and other applicable laws, rules and regulations. This may
result in significant deficiencies or material weaknesses in our internal
controls which could impact the reliability of our financial statements and
prevent us from complying with SEC rules and regulations and the requirements of
the Sarbanes-Oxley Act of 2002. Any such deficiencies, weaknesses or
lack of compliance could have a materially adverse effect on our business and
the public announcement of such deficiencies could adversely impact our stock
price.
It
may be difficult to protect and enforce our intellectual property rights under
PRC laws.
Intellectual
property rights in China are still developing, and there are uncertainties
involved in the protection and the enforcement of such rights. We
will need to pay special attention to protecting our intellectual property and
trade secrets. Failure to do so could lead to the loss of a
competitive advantage that could not be compensated by our damages
award.
If
our land use rights are revoked, we would have no operational
capabilities.
Under
Chinese law land is owned by the state or rural collective economic
organizations. The state issues to tenants the rights to use
property. Use rights can be revoked and the tenants forced to vacate
at any time when redevelopment of the land is in the public
interest. The public interest rationale is interpreted quite broadly
and the process of land appropriation may be less than
transparent. Bohai, our operating subsidiary, relies on these land
use rights as the cornerstone of its operations, and the loss of such rights
would have a material adverse effect on our company. We currently do
not maintain a land use right certificate for a piece of land located in Xingfu
Twelve Village of Zhifu District with the area of 11,222 m2. In
the process of the planning of Yantai City, the usage of the aforesaid land use
right has been changed from “industrial use” to “commercial use” and therefore,
the process for the land use right certificate on five relevant parcels of land
including the land occupied by Bohai is suspended until the completion of the
planning. We can not assure you that we will eventually obtain the
land use right certificate for the foresaid land with reasonable
cost.
Risks
Related to Our Common Stock
Trading
in our common stock has been non-existent, so investors may not be able to sell
as many of their shares as they want at prevailing prices.
Our
common stock is listed for quotation on OTCBB under the symbol “BOHP.OB”, but
there has been no trading in our common stock. Trading in our common
stock may not commence for a variety of reasons, and even trading does commence,
it is expected to be limited. If limited trading in the common stock
continues, it may be difficult for investors to sell such shares in the public
market at any given time at prevailing prices. Also, the sale of a
large block of common stock, should it occur, could depress the market price of
the common stock to a greater degree than a company that typically has a higher
volume of trading of its securities.
24
The
registration statement of which this prospectus forms a part may not remain
effective, which could impact the liquidity of our common stock.
Under the
terms of our January 2010 Registration Rights Agreement, we are obligated to
include the shares of common stock underlying the Notes and Warrants in an
effective registration statement, an the registration statement of which this
prospectus forms a part is intended to satisfy these
obligations. From time to time, it will be necessary for us to file
post-effective amendments to the registration statement when subsequent events
so require. We intend to use our best efforts to keep the
registration statement current, but may not be able to do so. If the
registration statement is not current in the future, investors’ ability to sell
the shares of common stock underlying the Notes and Warrants will be limited,
which would have a material adverse effect on the liquidity of our common
stock.
There
is currently no trading in our common stock, and the limited public trading
market that may develop in the future may cause extreme volatility in our stock
price.
Although
our common stock is listed for quotation on the OTCBB, there has never been any
trading in our stock. Even if a market for our common stock does
develop, there is a risk that a meaningful, consistent and liquid trading market
may not develop. Moreover, stocks with limited trading markets have
historically experienced extreme price and volume fluctuations and have
particularly affected the market prices of many smaller companies like
us. Our common stock is thus expected to be subject to significant
volatility when and if trading commences. Sales of substantial
amounts of our common stock, or the perception that such sales might occur,
could adversely affect prevailing market prices of our common
stock.
An
active and visible trading market for our common stock may not
develop.
We cannot
predict whether an active market for our common stock will develop in the
future. In the absence of an active trading market:
|
·
|
Investors
may have difficulty buying and selling or obtaining market
quotations;
|
|
·
|
Market
visibility for our common stock may be limited;
and
|
|
·
|
A
lack of visibility for our common stock may have a depressive effect on
the market price for our common
stock.
|
The OTCBB
is an unorganized, inter-dealer, over-the-counter market that provides
significantly less liquidity than NASDAQ or the NYSE AMEX. The
trading price of the common stock is expected to be subject to significant
fluctuations in response to variations in quarterly operating results, changes
in analysts’ earnings estimates, announcements of innovations by us or our
competitors, general conditions in the industry in which we operate and other
factors. These fluctuations, as well as general economic and market
conditions, may have a material or adverse effect on the market price of our
common stock.
The
market price for our stock may be volatile.
The
market price for our stock may be volatile and subject to wide fluctuations in
response to factors including the following:
|
·
|
actual
or anticipated fluctuations in our quarterly operating
results;
|
25
|
·
|
changes
in financial estimates by securities research
analysts;
|
|
·
|
conditions
in pharmaceutical markets;
|
|
·
|
changes
in the economic performance or market valuations of other pharmaceutical
companies;
|
|
·
|
announcements
by us or our competitors of new products, acquisitions, strategic
partnerships, joint ventures or capital
commitments;
|
|
·
|
addition
or departure of key personnel;
|
|
·
|
fluctuations
of exchange rates between RMB and the U.S.
dollar;
|
|
·
|
intellectual
property or other litigation; and
|
|
·
|
general
economic or political conditions in
China.
|
In
addition, the securities market has from time to time experienced significant
price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also
materially and adversely affect the market price of our stock.
Shares
eligible for future sale may adversely affect the market price of our common
stock, as the future sale of a substantial amount of outstanding stock in the
public marketplace could reduce the price of our common stock.
Pursuant
to the terms of the Registration Rights Agreement and Securities Purchase
Agreement, we agreed to file the registration statement of which this prospectus
forms a part with the SEC to register the common stock underlying the Notes,
Warrants and Placement Agent Warrants for public resale. All of such
shares may be freely sold and transferred following conversion or exercise of
the Notes and Warrants if such registration statement remains
effective. Additionally, concurrently with the closing of the Private
Placement, we engaged in a Share Exchange, and following the Share Exchange, the
former shareholders of Chance High (other than Glory Period) may be eligible to
sell all or some of their shares of common stock by means of ordinary brokerage
transactions in the open market pursuant to such registration statement or SEC
Rule 144, subject to certain limitations. In general, pursuant to
Rule 144, a stockholder (or stockholders whose shares are aggregated) who has
satisfied an one-year holding period may, under certain circumstances, sell
within any three-month period a number of securities which does not exceed the
greater of 1% of the then outstanding shares of common stock or the average
weekly trading volume of the class during the four calendar weeks prior to such
sale. As of the closing of the Share Exchange, and not accounting for
the private placement, 1% of our issued and outstanding shares of common stock
equals approximately162,500 shares. Rule 144 also permits, under
certain circumstances, the sale of securities, without any limitations, by a
non-affiliate that has satisfied a one-year holding period. Any
substantial sale of common stock pursuant to any resale prospectus or Rule 144
may have an adverse effect on the market price of our common stock by creating
an excessive supply.
26
Our
controlling stockholder may exercise significant influence over us.
Our
controlling stockholder, Glory Period Limited, owns approximately 55% of our
outstanding common stock as of the closing of the Share Exchange. Tan
is the sole shareholder of Glory Period and Qu is the sole director of Glory
Period. Either Tan or Qu has a controlling influence in determining
the outcome of any corporate transaction or other matters submitted to our
stockholders for approval, including mergers, consolidations and the sale of all
or substantially all of our assets, election of directors, and other significant
corporate actions. Tan and Qu may also have the power to prevent or
cause a change in control. In addition, without the consent of Tan
and Qu, we could be prevented from entering into transactions that could be
beneficial to us. The interests of Tan and Qu may differ from the
interests of our other stockholders.
Compliance
with changing regulation of corporate governance and public disclosure, and our
management’s inexperience with such regulations, will result in additional
expenses and creates a risk of non-compliance.
Changing
laws, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act of 2002 and related SEC
regulations, have created uncertainty for public companies and significantly
increased the costs and risks associated with accessing the public markets and
public reporting. Our management team will need to invest significant
management time and financial resources to comply with both existing and
evolving standards for public companies, which will lead to increased general
and administrative expenses and a diversion of management time and attention
from revenue generating activities to compliance activities. In
addition, our management is located in the PRC has little experience with
compliance with U.S. laws (including securities laws). This
inexperience may cause us to fall out of compliance with applicable regulatory
requirements, which could lead to enforcement action against us and a negative
impact on our stock price.
If
we fail to maintain an effective system of internal controls, we may not be able
to accurately report our financial results or prevent fraud.
We are
subject to reporting obligations under the U.S. securities laws. The
SEC, as required by Section 404 of the Sarbanes-Oxley Act of 2002, adopted rules
requiring every public company to include a management report on such company’s
internal controls over financial reporting in its annual report, which contains
management’s assessment of the effectiveness of our internal controls over
financial reporting. In addition, an independent registered public
accounting firm must attest to and report on management’s assessment of the
effectiveness of our internal controls over financial
reporting. Our management may conclude that our internal
controls over our financial reporting are not effective. Moreover, even if our
management concludes that our internal controls over financial reporting are
effective, our independent registered public accounting firm may still decline
to attest to our management’s assessment or may issue a report that is qualified
if it is not satisfied with our controls or the level at which our controls are
documented, designed, operated or reviewed, or if it interprets the relevant
requirements differently from us. Our reporting obligations as a
public company will place a significant strain on our management, operational
and financial resources and systems for the foreseeable
future. Effective internal controls, particularly those related to
revenue recognition, are necessary for us to produce reliable financial reports
and are important to prevent fraud. As a result, our failure to
achieve and maintain effective internal controls over financial reporting could
result in the loss of investor confidence in the reliability of our financial
statements, which in turn could harm our business and negatively impact the
trading price of our stock. Furthermore, we anticipate that we will
incur considerable costs and use significant management time and other resources
in an effort to comply with Section 404 and other requirements of the
Sarbanes-Oxley Act.
27
Our
common stock may be considered a “penny stock,” and thereby be subject to
additional sale and trading regulations that may make it more difficult to
sell.
Our
common stock, which is currently and will be quoted for trading on OTCBB, may be
considered to be a “penny stock” if it does not qualify for one of the
exemptions from the definition of “penny stock” under Section 3a51-1 of the
Exchange Act, as amended. Our common stock may be a “penny stock” if
it meets one or more of the following conditions: (i) the stock trades at a
price less than $5 per share; (ii) it is NOT traded on a “recognized” national
exchange; (iii) it is not quoted on the Nasdaq Capital Market, or even if so,
has a price less than $5 per share; or (iv) is issued by a company that has been
in business less than three years with net tangible assets less than $5
million. The principal result or effect of being designated a “penny
stock” is that securities broker-dealers participating in sales of our common
stock will be subject to the “penny stock” regulations set forth in Rules 15-2
through 15g-9 promulgated under the Exchange Act. For example, Rule
15g-2 requires broker-dealers dealing in penny stocks to provide potential
investors with a document disclosing the risks of penny stocks and to obtain a
manually signed and dated written receipt of the document at least two business
days before effecting any transaction in a penny stock for the investor’s
account. Moreover, Rule 15g-9 requires broker-dealers in penny stocks
to approve the account of any investor for transactions in such stocks before
selling any penny stock to that investor. This procedure requires the
broker-dealer to: (i) obtain from the investor information concerning his or her
financial situation, investment experience and investment objectives; (ii)
reasonably determine, based on that information, that transactions in penny
stocks are suitable for the investor and that the investor has sufficient
knowledge and experience as to be reasonably capable of evaluating the risks of
penny stock transactions; (iii) provide the investor with a written statement
setting forth the basis on which the broker-dealer made the determination in
(ii) above; and (iv) receive a signed and dated copy of such statement from the
investor, confirming that it accurately reflects the investor’s financial
situation, investment experience and investment
objectives. Compliance with these requirements may make it more
difficult and time consuming for holders of our common stock to resell their
shares to third parties or to otherwise dispose of them in the market or
otherwise.
We
do not foresee paying cash dividends in the foreseeable future and, as a result,
our investors’ sole source of gain, if any, will depend on capital appreciation,
if any.
We do not
plan to declare or pay any cash dividends on our shares of common stock in the
foreseeable future and currently intend to retain any future earnings for
funding growth. As a result, investors should not rely on an investment in our
securities if they require the investment to produce dividend income. Capital
appreciation, if any, of our shares may be investors’ sole source of gain for
the foreseeable future. Moreover, investors may not be able to resell their
common stock at or above the price they paid for them.
28
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of
the statements contained in this prospectus that are not historical facts are
“forward-looking statements” which can be identified by the use of terminology
such as “estimates,” “projects,” “plans,” “believes,” “expects,” “anticipates,”
“intends,” or the negative or other variations, or by discussions of strategy
that involve risks and uncertainties. We urge you to be cautious of the
forward-looking statements, that such statements, which are contained in this
Registration Statement, reflect our current beliefs with respect to future
events and involve known and unknown risks, uncertainties and other factors
affecting our operations, market growth, services and products. No
assurances can be given regarding the achievement of future results, as actual
results may differ materially as a result of the risks we face, and actual
events may differ from the assumptions underlying the statements that have been
made regarding anticipated events. Factors that may cause actual
results, our performance or achievements, or industry results, to differ
materially from those contemplated by such forward-looking statements include
without limitation:
|
·
|
our
financial position, business strategy and other plans and objectives for
future operations;
|
|
·
|
the
ability of our management team to execute its plans to meet its
goals;
|
|
·
|
our
ability to attract and retain qualified management
personnel;
|
|
·
|
our
growth strategies;
|
|
·
|
anticipated
trends in our business;
|
|
·
|
our
ability to consummate or integrate
acquisitions;
|
|
·
|
our
liquidity and ability to finance our operations and acquisition and
development activities;
|
|
·
|
the
timing, cost and procedure for proposed
acquisitions;
|
|
·
|
the
impact of government regulation in China and
elsewhere;
|
|
·
|
estimates
regarding future net revenues or
profits;
|
|
·
|
planned
capital expenditures (including the amount and nature
thereof);
|
|
·
|
estimates,
plans and projections relating to acquired properties or
businesses;
|
|
·
|
the
possibility that our acquisitions may involve unexpected
costs;
|
|
·
|
the
impact of competition;
|
|
·
|
general
economic conditions, whether internationally, nationally or in the
regional and local market areas in which we are doing business, that may
be less favorable than expected;
and
|
29
|
·
|
other
economic, competitive, governmental, legislative, regulatory, geopolitical
and technological factors that may negatively impact our businesses,
operations and pricing.
|
Regarding
the Company’s acquisition strategy, please see “Business” “— Key
Characteristics” and “— Marketing Strategy.” All written and oral
forward-looking statements made in connection with this prospectus that are
attributable to us or persons acting on our behalf are expressly qualified in
their entirety by these cautionary statements. Given the uncertainties that
surround such statements, you are cautioned not to place undue reliance on such
forward-looking statements.
USE
OF PROCEEDS
This
prospectus relates to shares of our common stock that may be offered and sold
from time to time by the selling stockholders named herein. There
will be no proceeds to us from the sale of shares of common stock in this
offering.
We will
not receive any proceeds from the sale of shares by the selling stockholders
other than the exercise price of any Warrants and Placement Agent Warrants that
are exercised by the applicable selling stockholders who do not conduct cashless
exercises, the proceeds of which we expect to use for our general working
capital. If all of these Warrants and Placement Agent Warrants are
exercised for cash, then we will receive gross proceeds of
$15,840,000. No assurances can be given, however, that all or any
portion of such warrants will ever be exercised.
DETERMINATION
OF OFFERING PRICE
The
selling stockholders may sell these shares in the over-the-counter market or
otherwise, at market prices prevailing at the time of sale, at prices related to
the prevailing market price, or at negotiated prices. We will not
receive any proceeds from the sale of shares by the selling stockholders but we
may receive proceeds upon the exercise, if any, of the Warrants and Placement
Agent Warrants.
30
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS
AND
RESULTS OF OPERATIONS
The
following discussion and analysis of financial condition and results of
operations relates to the operations and financial condition reported in the
unaudited condensed consolidated financial statements of the Company for the
three months ended December 31, 2009 and 2008 and for the fiscal years ended
June 30, 2009 and 2008, and should be read in conjunction with the related
unaudited and audited financial statements and related notes included in this
prospectus. Those statements in the following discussion that are not
historical in nature should be considered to be forward looking statements that
are inherently uncertain. Actual results and the timing of the events may differ
materially from those contained in these forward looking statements due to a
number of factors, including those discussed in the “Cautionary Note on Forward
Looking Statements” set forth elsewhere in this Report.
Overview
We were
incorporated under the laws of the State of Nevada on January 9,
2008. Since January 5, 2010, our business consists of the production,
manufacturing and distribution of herbal pharmaceuticals in the PRC which are
based on traditional Chinese medicine. We are based in the city of
Yantai, Shandong Province, China.
Our
medicines are intended to address rheumatoid arthritis, viral infections,
gynecological diseases, cardio vascular issues and respiratory
diseases. We have obtained Drug Approval Numbers in China for 29
varieties of traditional Chinese herbal medicines in 2004 and we currently
produces 10 varieties of approved traditional Chinese herbal medicines in seven
delivery systems: tablets, granules, capsules, syrup, concentrated powder,
tincture and medicinal wine. Of these 10 products, 4 are prescription
drugs and 6 are over-the-counter products.
Prior to
January 5, 2010, we were a public “shell” company operating under the name “Link
Resources, Inc.” On January 5, 2010, we consummated a share exchange
transaction (the “Share Exchange”) pursuant to which we acquired Chance High,
the parent company of Yantai Bohai Pharmaceuticals Group Co. Ltd., our principal
operating subsidiary, which is a Chinese variable interest entity that we
(through a Chinese wholly-owned foreign enterprise subsidiary) control through
certain contractual arrangements.
31
Three Months Ended December 31, 2009 Compared to Three Months Ended December 31, 2008
Three
Months Ended
December
31,
|
||||||||
2009
|
2008
|
|||||||
Sales
|
$ | 17,118,645 | $ | 12,026,457 | ||||
Less:
Sales Tax
|
(272,342 | ) | (197,091 | ) | ||||
Net
sales
|
16,846,303 | 11,829,366 | ||||||
Cost
of sales
|
(2,662,427 | ) | (1,996,467 | ) | ||||
Gross
profit
|
14,183,876 | 9,832,899 | ||||||
Selling,
general and administrative expenses
|
(9,813,217 | ) | (7,494,180 | ) | ||||
Interest
expenses
|
(51,814 | ) | (50,293 | ) | ||||
Operating
income
|
4,318,845 | 2,288,426 | ||||||
Non-operating
income
|
40,322 | - | ||||||
Non-operating
costs
|
(23,738 | ) | (35 | ) | ||||
Income
before taxes
|
4,335,429 | 2,288,391 | ||||||
Income
taxes
|
(1,057,890 | ) | (203,764 | ) | ||||
Net
income
|
$ | 3,277,539 | $ | 2,084,627 |
Sales
Net sales
for the three months ended December 31, 2009 increased by approximately
$5,016,937 or 42.41 % to $16,846,303 as compared to $11,829,366 for
the three months ended December 31, 2008. Our sales growth was driven by
effective marketing strategies being implemented which we believe has led to an
extension of our client base.
Cost
of Sales
Our cost
of sales for the three months ended December 31, 2009 was $2,662,427 as compared
to $1,996,467 for the three months ended December 31, 2008, representing an
increase of 33.36 %. The increase was mainly attributable to the
increase in cost of raw material by $665,960 as a result of the increase of
sales.
Gross
Profit
We
achieved gross profit of $14,183,876 for the three months ended December 31,
2009, compared to $9,832,899 for the same quarter of the previous year,
representing a 44.25 % quarter to quarter increase. Our overall gross
profit margin as a percentage of revenue are 82.26% and 81.76% for the three
months ended December 31, 2009 and 2008, respectively.
Selling,
General and Administrative Expenses
Our
operating expenses, consisting of selling, general and administrative expenses,
increased by approximately $2,319,037, to $9,813,217, for the three months ended
December 31, 2009 from $7,494,180 for the same quarter of the previous
year. This increase is mainly attributable to a significant increase
in expenses on advertising and promotion due to an increase in the frequency of
television broadcasts, which amounted to $3,346,013 during the
period.
32
Interest
Expense
Interest
expense was $51,814 for the three months ended December 31, 2009, compared to
$50,293 for the three months ended December 31 , 2008. The increase
represents accrued interest from additional bank loans utilized during the
period. The loans were used for working capital and capital
expenditures for the expansion of production through acquisition of plants and
machinery to improve the efficiency of the production lines.
Income
tax
Our
provisions for income taxes for the three months ended December 31, 2009 and
2008 were $1,057,890 and $203,764, respectively, an increase of $854,126 or 419%
from period to period. The increase in tax provision was due to
significant increase of income before tax during the period.
Net
Income
We had a
net income of $3,277,539 for the three months ended December 31, 2009, as
compared to net income of $2,084,627 for the three months ended December 31,
2008. The increase in net income is primarily attributable to
increase of sales during the period.
Foreign
Currency Translation Gains
During
the three months ended December 31, 2009, the RMB steadily rose against the U.S.
dollar, and we recognized a foreign currency translation gain of
$34,291.
Six
Months Ended December 31, 2009 Compared to the Six Months Ended December 31,
2008
The
following table sets forth our statement of operations for the period
indicated:
Six
Months Ended
December
31,
|
||||||||
2009
|
2008
|
|||||||
Sales
|
$ | 31,299,817 | $ | 23,439,129 | ||||
Less:
Sales Tax
|
(499,500 | ) | (380,922 | ) | ||||
Net
sales
|
30,800,317 | 23,058,207 | ||||||
Cost
of sales
|
(4,879,940 | ) | (3,960,866 | ) | ||||
Gross
profit
|
25,920,377 | 19,097,341 | ||||||
Selling,
general and administrative expenses
|
(19,069,289 | ) | (14,069,386 | ) | ||||
Interest
expenses
|
(149,594 | ) | (101,029 | ) | ||||
Operating
income
|
6,701,494 | 4,926,926 | ||||||
Non-operating
income
|
20,125 | - | ||||||
Non-operating
costs
|
(29,003 | ) | (67 | ) | ||||
Income
before taxes
|
6,692,616 | 4,926,859 | ||||||
Income
taxes
|
(1,613,261 | ) | (804,085 | ) | ||||
Net
income
|
$ | 5,079,355 | $ | 4,122,774 |
33
Sales
Net sales
for the six months ended December 31, 2009 was $30,800,317, an increase of
approximately $7,742,110, or 33.58%, from $23,058,207 in the six months ended
December 31, 2008. This increase was primarily due to the significant
increase of our revenue on all the products as a result of the effective
implementation of marketing strategy in the calendar year ended December 31,
2009.
Cost
of Sales
Our cost
of sales for the six months ended December 31, 2009 was $4,879,940 as compared
to $3,960,866 for the six months ended December 31, 2008, representing an
increase of $919,074, or 23.20%. The increase was mainly attributable to the
increase of raw materials cost by $1,643,356 as a result of the increase of
sales.
Gross
Profit
For the
six months ended December 31, 2009 as compared to the six months ended December
31, 2008, we generated gross profit of $25,920,377 and $19,097,341,
respectively, reflecting an increase of approximately $6,823,036, or 35.73
%. The increase in our gross profit was mainly due to significantly
increase of sales income.
Selling,
General and Administrative Expenses
We
incurred general and administrative expenses of $19,069,289 for the six months
ended December 31, 2009, representing an increase of $4,999,903, or 35.54%,
compared to 14,069,386 for the six months ended December 31,
2008. This increase was mainly due to the increase of cost of
advertising and percentages of commissions to sales representative allocated in
our branch offices throughout China.
Interest
Expense
Interest
expense was $149,594 for the six months ended December 31, 2009, compared to
$101,029 for the six months ended December 31, 2008. The increase is largely due
to proceeds of bank loans during the year. The loans were used for working
capital and capital expenditures for the expansion of production through
acquisition of production plants and equipment to improve the efficiency of
production.
34
Income
tax
For the
six months ended December 31, 2009, income tax expense was $1,613,261, an
increase of $809,176, or 100.63%, from $804,085 for the six months ended
December 31, 2008. The increase was mainly due to income before tax
increase during the period.
Net
Income
We had
net income of $5,079,355, or 16.49% of net revenue, for the six months ended
December 31, 2009, as compared to net income $4,122,774, or 17.88% of net
revenue, for the six months ended December 31, 2008, representing an increase of
$956,581, or 23.20 %. The increase in our net income was the result
of the significant increase of our revenue generated in the calendar year ended
December 31, 2009.
Foreign
Currency Translation Gains
During
the fiscal period ended December 31, 2009, the RMB steadily rose against the
U.S. dollar, and we recognized a foreign currency translation gain of
$14,491.
Liquidity
and Capital Resources
We have
historically funded our operation primarily through paid-in capital, sales of
goods and short term loans from financial institutions in China. Net
cash provided by operating activities for the three months ended December 31,
2009 was $4,079,115 compared to used in 3,602,703 for the three months ended
December 31, 2008. During the three months ended December 31, 2009, net cash
provided by from operating activities by $4,079,115, and cash borrowed from
banks amounted to $2,200,500 and repayment of borrowing from previous period
amounted to $3,661,300 which resulted in a net cash inflow
$2,794,812. The Company may seek to raise additional capital through
sales of common stock, as well as seeking financing from third
parties.
Operating
activities
For the
three months ended December 31, 2009, cash provided by operating activities
totaled $4,079,115 compared to cash used in $3,602,703 for the three months
ended December 31, 2008. This was primarily attributable to cash used
in prepayment for advertising expense and repayment of accounts payable during
the six month ended December 31, 2008.
Investing
activities
For the
three months ended December 31, 2009, net cash outflow for investing activities
was approximately $176,497 compared to provided by $321,548 in the three months
ended December 31, 2008. This increase was primarily attributable to proceeds of
notes payable during the period in amounting to $400,000.
Financing
activities
Financing
activities provided net cash outflow of $1,460,000 during the three months ended
December 31, 2009 primarily as a result of repayment of significant borrowing
during the year. As of December 31, 2009, the proceeds from
short-term borrowings amounted to $2,200,500 and the repayment of borrowings
amounted to $3,661,300, which resulted in a net cash outflow by financing
activities of $1,460,800.
35
Off-Balance
Sheet Arrangements
We have
not entered into any financial guarantees or other commitments to guarantee the
payment obligations of any third parties. We have not entered into any
derivative contracts that are indexed to our shares and classified as
stockholder’s equity or that are not reflected in our condensed consolidated
financial statements. Furthermore, we do not have any retained or contingent
interest in assets transferred to an unconsolidated entity that serves as
credit, liquidity or market risk support to such entity. We do not have any
variable interest in any unconsolidated entity that provides financing,
liquidity, market risk, or credit support to us or engages in leasing, hedging,
or research and development services with us.
Inflation
In recent
years, the Chinese economy has experienced periods of rapid expansion and high
rates of inflation. During the past ten years, the rate of inflation
in China has been as high as 20.7% and as low as -2.2%. These factors
have led to the adoption by Chinese government, from time to time, of various
corrective measures designed to restrict the availability of credit or regulate
growth and contain inflation. While inflation has been more moderate
since 1995, high inflation may in the future cause Chinese government to impose
controls on credit and/or prices, or to take other action, which could inhibit
economic activity in China, and thereby harm the market for our
products.
Fiscal
Year Ended June 30, 2009 Compared to the Fiscal Year Ended June 30,
2008
The
following table sets forth our statement of operations for the period
indicated:
Year Ended
June 30, 2009
|
Year Ended
June 30, 2008
|
|||||||
Sales
|
$ | 50,170,014 | $ | 38,172,513 | ||||
Less:
Sales Tax
|
(821,400 | ) | (629,489 | ) | ||||
|
|
|||||||
Net
sales
|
49,348,614 | 37,543,024 | ||||||
Cost
of sales
|
(7,975,267 | ) | (5,950,680 | ) | ||||
Gross
profit
|
41,373,347 | 31,592,344 | ||||||
Selling,
general and administrative expenses
|
(31,347,139 | ) | (22,608,164 | ) | ||||
Interest
expenses
|
(184,404 | ) | (234,101 | ) | ||||
Operating
income
|
9,841,804 | 8,750,079 | ||||||
Non-operating
income
|
49,447 | 8 | ||||||
Non-operating
costs
|
(36,366 | ) | (835 | ) | ||||
Income
before taxes
|
9,854,885 | 8,749,252 | ||||||
Income
taxes
|
(1,906,985 | ) | (2,303,712 | ) | ||||
Net
income
|
$ | 7,947,900 | $ | 6,445,540 |
36
Gross
Profit
For the
fiscal year ended June 30, 2009 as compared to the fiscal year ended June 30,
2008, we generated gross profit of $41,373,347 and $31,592,344 respectively,
reflecting an increase of approximately $9,781,003, or 30.96%. The increase in
our gross profit was mainly due to significantly increase of sales
income.
Selling,
General and Administrative Expenses
We
incurred general and administrative expenses of $31,347,139 for the fiscal year
ended June 30, 2009, representing an increase of $8,738,957, or 38.65%, compared
to 22,608,164 for the fiscal year ended June 30, 2008. This increase was mainly
due to the increase of cost of advertising and percentages of commissions to
sales representative allocated in branch office through out China.
Interest
Expense
Interest
expense was $184,404 for the fiscal year ended June 30, 2009, compared to
$234,101 for the fiscal year ended June 30, 2008. The decrease is largely due to
repayment of bank loans utilized in the year 2007 during the period. The loans
were used for working capital and capital expenditures for the expansion of
production through acquisition of production plants and equipment to improve the
efficiency of production.
Income
tax
For the
fiscal year ended June 30, 2009, income tax expense was $1,906,985, and a
decrease of $396,727, or 17.22%, from $2,303,712 for the fiscal year ended June
30, 2008. The decrease was mainly due to the decrease of enterprise income tax
in PRC from 33% to 25% since January 1, 2008.
Net
Income
We had
net income of $7,993,228, or 16.11% of net revenue for the fiscal year ended
June 30, 2009 as compared to net income $6,451,772 or 17.17% of net revenue for
the fiscal year ended June 30, 2008, representing an increase of $1,541,456, or
23.89%. The increase in our net income was the result of the
significant increase of our revenue generated in the fiscal year of
2009.
37
Foreign
Currency Translation Gains
During
the fiscal year ended June 30, 2009, the RMB steadily rose against the U.S.
dollar, and we recognized a foreign currency translation gain of
$106,233.
Liquidity
and Capital Resources
We have
historically funded our operation primarily through paid-in capital, sales of
goods and short term loans from financial institutions. Net cash used
in operating activities for the year ended June 30, 2009 was $1,513,062 compared
to provided by $2,359,072 for the year ended September 20, 2008. During the year
ended June 30, 2009, cash borrowed from banks amounted to $5,860,000 and
repayment of borrowing from previous years amounted to $1,896,700, which
resulted in a net cash outflow in financing activities of
$3,963,300. Management is planning to raise additional capital
through sales of common stock, as well as seeking financing from third
parties.
Operating
activities
For the
fiscal year ended June 30, 2009, cash used in operating activities totaled
$1,513,062 compared to cash provided by $2,359,072 for the fiscal year ended
June 30, 2008. This was primarily attributable to significant increase of cash
used in prepayment for advertising expense and repayment of accounts
payable.
Investing
activities
For the
fiscal year ended June 30, 2009, net cash outflow for investing activities was
approximately $788,993 compared to $26,647 in the fiscal year ended June 30,
2008. This increase was primarily attributable to significant increase of
capital investment in acquisition of property, plant and equipment during the
year. During the fiscal year ended June 30, 2009, we spent $227,690, $59,459,
$295,610 and $220,884 on acquisitions of plant and equipment, purchase of office
equipment, purchase of motor vehicle and construction in progress,
respectively.
Financing
activities
Financing
activities provided net cash inflow of $3,963,300 during the fiscal year ended
June 30, 2009 primarily as a result of process of significant borrowing during
the year. As of June 30, 2009, the proceeds from short-term borrowings amounted
to $5,860,000 and the repayment of borrowings amounted to $1,896,000, which
resulted in a net cash inflow by financing activities of
$3,963,300.
Off-Balance
Sheet Arrangements
We have
not entered into any financial guarantees or other commitments to guarantee the
payment obligations of any third parties. We have not entered into any
derivative contracts that are indexed to our shares and classified as
shareholder’s equity or that are not reflected in our condensed consolidated
financial statements. Furthermore, we do not have any retained or contingent
interest in assets transferred to an unconsolidated entity that serves as
credit, liquidity or market risk support to such entity. We do not have any
variable interest in any unconsolidated entity that provides financing,
liquidity, market risk, or credit support to us or engages in leasing, hedging,
or research and development services with us.
38
Inflation
In recent
years, the Chinese economy has experienced periods of rapid expansion and high
rates of inflation. During the past ten years, the rate of inflation
in China has been as high as 20.7% and as low as -2.2%. These factors
have led to the adoption by Chinese government, from time to time, of various
corrective measures designed to restrict the availability of credit or regulate
growth and contain inflation. While inflation has been more moderate
since 1995, high inflation may in the future cause Chinese government to impose
controls on credit and/or prices, or to take other action, which could inhibit
economic activity in China, and thereby harm the market for our
products.
39
BUSINESS
Our
Business
We are
engaged in the production, manufacturing and distribution of herbal
pharmaceuticals based on traditional Chinese medicine, or TCM, in the
PRC. We are based in the city of Yantai, Shandong Province, China,
and our operations are exclusively in China.
Our
medicines address rheumatoid arthritis, viral infections, gynecological
diseases, cardio vascular issues and respiratory diseases. We
obtained Drug Approval Numbers for 29 varieties of traditional Chinese herbal
medicines in 2004 and it currently produces 10 varieties of approved traditional
Chinese herbal medicines in seven delivery systems: tablets, granules, capsules,
syrup, concentrated powder, tincture and medicinal wine. Of these 10
products, 4 are prescription drugs and 6 are OTC products.
We
believe our rapid growth in recent years has been supported by the continuing
expansion of the market for TCM in the PRC. This market is forecasted
to reach $24 billion by 2010 according to the Information Office of the State
Council of the People’s Republic of China, “Status Quo of Drug
Supervision.”
In a
significant development, on December 1, 2009, two of our lead products, Tongbi
Capsules and Tablets and Lung Nourishing Cream, became eligible for
reimbursement under China’s National Medical Insurance Program. In
fiscal year ended June 30, 2009, these two products accounted for more than 50%
of our revenues.
The
Chinese government has previously awarded us exclusive rights to manufacture
Tongbi Capsules and we share manufacturing rights with one or more manufacturers
for Shangtongning Tablets and Anti-flu Granules. We held the
Certificates of Protected Variety of Traditional Chinese Medicine (Grade Two)
(the “Certificate of Protection”) issued by State Food and Drug Administration
of China (“SFDA”) for Tongbi Capsules and Shangtongning Tablets which give us
exclusive or near-exclusive rights to manufacture and distribute these two
medicines. The protection periods for both Tongbi Capsules and Shangtongning
Tablets expired in September 2009 and we are seeking to extend the protection
periods. We have submitted the application of Tongbi Capsules to extend such
protection period on March 12, 2009 and SFDA has recently started its review
process. We expect such approval may be granted by end of June this year. We
have decided not to submit extension application of Shangtongning Tablets,
because the SFDA will not approve Certificate of Protection for Shangtongning
Tablets or any other products that are currently produced by more than three
manufacturers in China according to applicable Chinese SFDA
regulations.
As of
February 15, 2010, we had approximately 596 employees, including 304 sales
representatives, operating from 20 offices throughout China. More
than 50% of our workforce is engaged in sales and distribution
activities.
Our
strategy is to leverage the “protected” status of a number of our pharmaceutical
products that grant it exclusive or near-exclusive manufacturing and
distribution rights in China to aggressively increase market penetration
throughout the world’s most populous nation. By utilizing our
distribution platform, in addition to utilizing mass media and other marketing
methods to build awareness of our brand, we will seek significantly grow
revenues and earnings.
40
We are
placing particular marketing focus on our Lung Nourishing Cream over the next
several years. The Lung Nourishing Cream is one of our most popular
products and contains what we believe is a novel formulation for the treatment
of asthma and other common respiratory ailments with an emphasis on the
improvement of overall lung function and health. While other
manufacturers of TCM in China produce medicines that address lung and
respiratory health, our Lung Nourishing Cream has been recognized for its
efficacy but is an unfamiliar brand to an estimated two-thirds of the
population. We believe this represents an exceptional market
opportunity.
Our
business strategy will seek to capitalize on new government programs established
in early 2009 to extend health insurance coverage to previously uncovered
Chinese citizens. The PRC government’s new health care policies are
also designed to encourage the use of TCM and its approach to wellness and
treatment of disease. As a result, the government continues to expand
the number of TCMs eligible for reimbursement under national medical insurance
programs. This has resulted in medical professionals working in the
state-run medical facilities to increasingly prescribe and recommend TCM
products of the type we manufacture and market. The state-run
facilities provide the majority of medical care in China. Two of our
lead products, Lung Nourishing Cream and Tongbi Capsules and Tablets, are
authorized to be eligible for insurance coverage, with others expected to
follow. Currently public health officials in China are developing
general consumer awareness of increasing problems and concerns with respiratory
and lung health caused by pervasive national air pollution. This
nationwide epidemic is an unfortunate by-product of the robust development of
China’s expansive manufacturing and industrial activities. Increased
air pollution is a cause and contributory factor to a range of acute respiratory
illnesses including chronic conditions such as asthma. As a result,
we intend to significantly increase our advertising for our Lung Nourishing
Cream.
Overview
of Traditional Chinese Medicine
In China,
Traditional Chinese Medicine is not an alternative form of therapy but is used
in the state-run hospitals alongside modern medicine. For its
practitioners and advocates, TCM is a complete medical system that is used to
treat disease in all its forms. TCM is also believed to promote long
term wellness and vigor. Many modern-day drugs have been developed from herbal
sources. These include drugs designed to treat asthma and hay fever
such as ephedrine; hepatitis remedies from fruits and licorice roots and a
number of anticancer agents from trees and shrubs.
For the
Chinese, however, health is more than just the absence of
disease. Chinese herbal medicine is not only intended to cure but to
enhance the capacity for enjoyment, fulfillment and
happiness. Accordingly, there are herbal drugs that are used to
invigorate, nourish blood, calm tension and regulate menstruation.
The roots
of TCM date back thousands of years and include a number of therapeutic
approaches. These include herbal medications, acupuncture, dietary
manipulation, massage and others. Very early works of Chinese medical
literature date back as much as 2,500 years while other classics appeared
approximately 2,000 years ago during the Han Dynasty. Medicine in
China continued to develop throughout the Middle Ages when emperors commissioned
the creation of various scholarly works that compiled and documented hundreds of
medicines derived from herbs, animal sources and minerals. In
addition, these works described their therapeutic uses. In the 1950s,
TCM was further modernized and reformed by the PRC government.
The
emphasis on wellness and the avoidance of disease is considered by some to be a
key distinction between TCM and western medical practice which has been seen as
more heavily oriented toward the treatment of disease and less toward
prevention. While TCM has remained a substantial part of medical
treatment in China and throughout East Asia, recent decades have seen increasing
acceptance throughout the United States, Europe and elsewhere. This
growth is, in part, driven by increasingly educated and empowered consumers of
medical care who seek organic, natural and alternative approaches to western
medical treatments and prescription drugs. Doctors are also
accelerating the process of acceptance. In the face of mounting
clinical research data demonstrating the effectiveness and safety of TCM and
herbal treatments, medical doctors trained in the western tradition in Europe,
the United States and elsewhere are integrating TCM and alternative treatments
in their everyday practice. Additionally, a growing number of
physicians specifically trained in TCM, acupuncture and other modalities are
opening offices in communities in the U.S. and around the
world.
41
We
believe that the sales of TCM in China reflect the central and still growing
role these therapies play in medical care in that nation. According
to Helmut Kaiser Consultancy, in 2005, total sales revenue for Chinese herbal
medicine manufactured in China was $13.6 billion which accounted for 25.8% of
all medicine manufactured in China. This segment had total profit of
$1.76 billion which accounted for 29% of the total profit of the Chinese drug
industry. In 2006, there were approximately 1,400 Chinese herbal
medicine manufacturers with an annual growth rate of 15%, much higher than the
comparable period GDP growth. According to Helmut Kaiser Consultancy,
as a result of the increasing wealth of China and an aging population, it is
estimated that by 2010, China will be the fifth largest market for herbal
medicines in the world exceeding more than $24 billion in sales.
China
currently has more than 10,000 distributors supplying drugs and medical devices
to hospitals and pharmacies. At present, most Chinese seeking medical
care go directly to the hospitals where more than 80% of the medicines used
throughout China are prescribed. Only recently have chain drug stores
begun to appear allowing drugs to be obtained in many areas without a visit to a
hospital.
Products
Overview
We
obtained Drug Approval Numbers for 29 varieties of traditional Chinese herbal
medicines in 2004 and currently produces 10 TCM pharmaceutical products, all
derived from herbal and organic sources. These include both
prescription and non-prescription over-the-counter (OTC)
medicines. The first five-year valid terms of such Drug
Approval Numbers have expired. We submitted the applications for
re-registration on June 29, 2007 which were accepted by SFDA. We have
been advised that the approval processes for these drugs has been recently
commenced by the Shandong Branch of SFDA. During the renewal period,
we are permitted to continue manufacturing these drugs as if the renewals had
been approved.
The
following is a list of approved pharmaceutical products that we are producing
with their intended uses:
Lung Nourishing
Cream. Lung Nourishing Cream is designed to moisten the lung
and relieve coughs and can be used to treat weak lung and chest tightness, poor
chronic cough, shortness of spontaneous breath and chronic
bronchitis.
Tongbi
Capsules. This product is designed to promote blood
circulation and relieve swelling and pain, and can be used to treat cold
resistance, liver and kidney deficiency, arthralgia syndrome and rheumatoid
arthritis.
Tongbi
Tablets. Tongbi Tablets are designed to regulate and fortify
the blood promote blood circulation and relieve swelling pain and can be used to
treat alpine resistance, liver and kidney deficiency, including rheumatoid
arthritis, and rheumatoid arthritis.
42
Shangtongning
Tablets. This product is designed to alleviate pain and can be
used to treat bruises.
Zhuangyuan shenhailong Medicinal
Wine. This liquid product is designed to promote kidney
function and can be used to treat the weakness waist and knee fatigue, insomnia
and forgetfulness.
Danqi Tablet. This
product is designed to improve blood circulation and can be used to treat blood
stasis, cardio-thoracic pain, dizziness and headache, and menstrual
pain.
Fukangning
Tablet. This product is designed to improve blood circulation
and can be used to treat blood stasis, cardio-thoracic pain, dizziness, headache
and menstrual pain.
Bazhen Yimu
Cream. This product is designed for menstruation conditioning
and can be used to treat dizziness, palpitation, fatigue, weakness and other
menstrual symptoms and can also be used to ease menstrual flow.
Huoxue Shujin
Ting. This product is designed to promote blood circulation
and relieve blood congestion, and can be used to treat pain in the waist and
leg, numbness in the feet and hands and arthritis.
Anti-flu
Granules. This product is designed to detoxify the body, and
can be used to treat cold caused by exogenous wind-heat with symptoms such as
fever, headache, stuffy nose, sneezing, pharyngodynia, generalized weakness and
soreness.
In
addition to the 10 medicines currently in production, we hold the rights to
produce 19 other herb-based pharmaceutical formulations. We
anticipate that we will commence the manufacturing and distribution for these
additional products if and when appropriate business conditions
develop.
Product
Types
Bohai has
five production lines for the manufacturing of medicines in five forms,
including tablets, granules, capsules, syrup, and medicinal wine. In
our fiscal year June 30, 2009, we produced:
|
·
|
1.35
billion tablets and capsules;
|
|
·
|
30
million bags granules (370 million
granules);
|
|
·
|
15
million bottles/units of concentrated
decoctions;
|
|
·
|
10
million bottles/units of syrup;
|
|
·
|
1
million bottles/units of tinctures;
and
|
|
·
|
1
million bottles/units medical wine
|
Three of
our pharmaceutical products have been granted “protected” status by the PRC
government, a marketplace classification used by the government to regulate both
production and distribution of traditional and herbal
medicines. These “protected” medicines are not patented in the
traditional commercial sense but are essentially proprietary. The
protection refers, in part, to standardizations of formulae which require that
medicines of the same name have the same type and proportion of
ingredients. The “protected” designation grants us exclusive
manufacturing and distribution rights within China over certain protected
products or with up to six manufacturers in other cases.
43
We have
the exclusive rights to manufacture Tongbi Capsules and we share manufacturing
rights with one or more manufacturers for Shangtongning Tablets and Anti-flu
Granules. The exclusive rights usually have a term of seven years and
can be extended for another seven year period after the initial seven year
period elapses. The protection periods for both Tongbi Capsules and
Shangtongning Tablets expired in September 2009 and we have filed an application
for extending the protection period on March 12, 2009 for Tongbi Capsules. We
have decided not to submit extension application of Shangtongning Tablets,
because the SFDA shall not approve Certificate of Protection for Shangtongning
Tablets or any other products that are currently produced by more than three
manufacturers in China according to applicable Chinese SFDA
regulations.
During
2010, we expect to increase marketing and advertising of Tongbi Capsules and
Tablets, which are formulated to treat various forms of
arthritis. Sales of our Tongbi medicines are expected to grow in
2010. In addition to the Tongbi medicines and the Lung Nourishing
Cream, other substantial contributors to our revenues include its Shangtongning
Tablets which are also expected to grow in 2010. Sales of our OTC
product Bazhen Yimu Cream, used to strengthen the immune system, the enhancement
of physical strength and conditioning, are also projected to grow in
2010.
We price
our medicines well under government-mandated caps and at a premium to most
competitors because we believe that the purity, potency and effectiveness of our
ingredients are superior to similar products from other companies. In
other words, we believe that patients can use less of a Bohai pharmaceutical
product to achieve the same effectiveness.
Overview
of the Chinese Market
The
People’s Republic of China is undergoing the world’s most important and powerful
economic transformation. This transformation includes the confluence
of its ancient culture with modern trends in business, technology and
finance. As a result, Chinese operating companies are capitalizing on
unmatched growth opportunities in this evolving and growing
marketplace. Although average income is approximately one-tenth that
of developed western nations, business growth and market reform-driven policies
have given the country’s 1.3 billion citizens more purchasing power than
ever.
Total
consumer spending in China reached $1.7 trillion in 2007, according to the most
recent figures available, compared with $12 trillion in the U.S. In
new research on Chinese consumers, management consulting firm McKinsey
classifies two million households out of a population of 1.3 billion as
“wealthy,” based on fairly modest annual earnings of more than
$30,000. An enormous middle class is rising, however, numbering some
70 million urban households, but these still earn $5,000-$10,000 a
year.
China’s
National Bureau of Statistics, based on a random survey of 65,000 urban
households in China, found that the average (annual) disposable income of urban
residents in the first half of 2009 was U.S.$1,300, an increase of 9.8% compared
to the same period last year. When price factors are deducted, this is
equivalent to a real increase of 11.2%. The average consumption
expenditure amount of urban residents in the first half of 2009 was
U.S.$876, an increase of 8.9% compared to the same period last year. When price
factors are deducted, this is equal to a real increase of 10.3%.
TCM
Industry Drivers
We
believe that demographic, governmental and related factors in the China will be
favorable to growth and expansion of our business.
44
Growing Prosperity of the Chinese
People. The increased spending power of China’s population
continues to be reflected in the increased consumption of health products and
medical services between 2007 and 2010. According to Euromonitor
data, spending by Chinese people on these goods and services will increase from
$100 billion in 2007 to $145 billion in 2010.
Population
and Aging
|
·
|
The
total population of China was 1.32 billion at the end of 2007, according
to official government estimates.
|
|
·
|
Due
to improved healthcare, the elderly population of China is
growing.
|
|
·
|
The
health/medical costs associated with care for elderly in China are
approximately five (5x) times that of younger
people.
|
|
·
|
China
had 170 million elderly people in 2007 but will have an expected 230
million elderly by 2015 according to “Consumer Lifestyles in China:
Consumer Trends, China’s Grey Population,” by Euromonitor,
2009.
|
|
·
|
The
proportion of the China’s population aged 65 and over will rise from just
10% of the overall population in 1995 to 22% by 2030, according to the
World Bank. The process of aging in China is occurring much
more rapidly than in western countries such as
Germany.
|
|
·
|
From
1995 to 2030 it is estimated that the ratio of working-age people to
pensioners will decrease from 9.7:1 to 4.2:1. China’s national
estimates vary slightly from World Bank figures, but still show in
increase in the proportion of the population over 65 years from 7% in 2000
to 9.4% in 2007, according to China Country Profile 2009, The Economist
Intelligence Unit Ltd.
|
Government Policies in Health Care
and TCM. In April of 2009 the PRC government implemented a new
national medical and health plan. Among other features, this new plan
extended national medical insurance coverage to China’s rural areas, where the
bulk of the population resides. This expanded coverage will
eventually encompass virtually all of China’s 1.3 billion citizens, greatly
expanding the market for TCM pharmaceuticals, as well as other health care
products and services. This has led to massive potential for
increased sales growth for Bohai and other providers of TCM pharmaceutical
products.
According
to Espicom Business Intelligence, in the next three years, the PRC government’s
health care investment will rise to $125 billion, compared with $96 billion for
2008. Direct health care subsidies of urban and rural residents will
amount to $57 billion. China’s health care investment is expected to
witness a growth of 19.7% and the overall growth rate will reach more than
25%.
Government Support of Traditional
Chinese Medicine. Among its public health initiatives, the
Chinese government officially supports use of TCM to enhance wellness and to
treat chronic and acute diseases. The government has also commenced a program to
evaluate TCM and herbal-based pharmaceuticals for coverage and reimbursement
under national medical insurance. In 2002, TCM was declared a
“national strategic industry” in the government’s “Development Outline of
Traditional Chinese Medicine Modernization (2002 – 2010).”
45
Decreased
Competition. Prior to 2009, there were approximately 6,000
Chinese pharmaceutical manufacturers. That number is being
significantly reduced through both marketplace attrition and direct government
involvement, decreasing competition and increasing potential sales opportunities
for the surviving companies. Other companies are expected to fail
through lack of innovative and aggressive management. As an example,
approximately one third of Chinese pharmaceutical companies do not have their
own sales organization and distribution network.
Growth
Strategy
Our
strategic initiatives for the foreseeable future are designed to aggressively
capitalize on the health and wellness needs of increasingly wealthy and
empowered consumer class in China. In particular, we are seeking to
capitalize on the government policies that extended medical insurance in 2009 to
hundreds of millions of Chinese citizens living in rural areas, representing a
vast untapped market of potential consumers who previously lacked access to
national medical insurance. As part of its reforms to expand and
improve public health and medical care, the PRC government is promoting the use
of herbal-based TCM and expanding insurance coverage to 100% of an increasing
number of medicines.
Our
strategic initiatives include the following:
Grow Hospital
Presence. We have targeted 600 hospitals in 100 locations
throughout China for direct marketing of Bohai products. As part of
this initiative, our sales team will expand its marketing activities to educate
hospital personnel about the our product lines and train hospital employees in
the preventative and curative qualities of these products. The
initial focus will capitalize on the best known and most popular of our
products, such as Tongbi capsules and Shangtongning tablets, using these as
door-openers for our other medicines.
The
average cost to “open” each hospital to our products is $1,500 with the
following provinces targeted:
Cities
|
Number
of Hospitals
|
|
Zhejiang
|
100
|
|
Jiangsu
|
80
|
|
Anhui
|
150
|
|
Shandong
|
200
|
|
Sichuan
|
20
|
|
Hubei
|
100
|
Build Awareness of the Lung
Nourishing Cream. We plan to allocate a significant portion of
the proceeds from our January 2010 private placement for
brand-building. We will primarily target consumers through television
and print advertising to expand awareness of the uses and effectiveness of our
Lung Nourishing Cream. The advertising will incorporate messaging
targeting smokers and workers with occupational diseases as well as city
dwellers exposed to smog. It is expected that the consumer television
advertising program will initially be focused in the following
areas:
46
TV
Station Location
|
Shandong
|
Anhui
|
Hubei
|
Sichuan
|
Chongqing
|
Shanxi
|
Jiangsu
|
Liaoning
|
Expand to Rural
Areas. We expect to execute a comprehensive marketing campaign
targeting 100 rural counties as a result of the national government’s emphasis
on expansion of healthcare and health insurance into the country’s rural
areas. We plan on starting its rural marketing in Shandong, Anhui,
Liaoning and Hubei. Our sales team will market its products to
pharmacies, hospitals, physicians, herbal medicine experts, media outlets and
other opinion leaders in these rural areas. The main purpose is to be
listed in the New Rural Cooperative Medical Directory which is farmer-friendly
and assists these rural dwellers with reimbursement of medical
expenses.
Generally,
the cost of this professional relationship-building with each rural county is
$3,000 with a listing fee in the New Rural Cooperative Medical Directory costing
in excess of $1,000,000. We planned to hire 80 sales people for this
effort and to equip each with a minivan to enable in-person
contacts. Each employee will be responsible for 5
counties. 30 sales people for this effort have been hired as of the
date of this prospectus. All of these sales and marketing initiatives
will involve both OTC and prescribed products.
Build Product Line and Product
Awareness. Brand awareness marketing will include the
promotion and introduction to new markets of the current popular Bohai products
such as Tongbi Tablets, Lung Nourishing Cream and Champion Sea Dragon Wine
Medicine. As part of its increase in sales and marketing staff, we
plan to have special trainers and presenters who can conduct promotional events
and seminars to increase awareness of our products.
Competitive
Advantages
We
believe there are several key factors that will continue to differentiate us
from our competition in the PRC:
|
·
|
“Protected” Status of Bohai
Products. One of our 10 products currently enjoys
protected status by the PRC government. We have submitted an
application for extending the protection period for another one of our
products. This status regulates competition, granting us exclusive or
near-exclusive rights to manufacture and sell the protected
products.
|
47
|
·
|
Insurance Coverage for Lead
Bohai Products. Two of our lead products, Lung
Nourishing Cream and Tongbi Capsules and Tablets, are listed in the
Catalogue Eligible for Medicine Reimbursement as of December 1,
2009. This means that these medicines are eligible for
reimbursement under the national health
insurance.
|
|
·
|
Relatively
low research and development (including acquisition) costs of TCM,
compared with western pharmaceutical
companies.
|
|
·
|
Highly
trained sales force of about 304 people as of February
2010.
|
Raw
Materials and Suppliers
The
principal raw materials used for the production of our distributed products are
honey, laiyang pear paste, Sichuan fritillaria, pangolin, and Chinese
angelica. Raw materials, as well as packaging materials, are sourced
from various independent suppliers in the PRC. We have no long term
agreements with our suppliers, and purchase raw materials on a purchase order
basis. We try to maintain relationships with at least two vendors for
each major raw material in order to ensure a reliable supply of raw materials at
reasonable prices. We believe there is ample supply in the market for
the foreseeable future of the ingredients for our products. Our
principal suppliers include Anhui Dechang Pharmaceutical Tablet Co., Ltd.,
Shandong Yantai Medical Materials Purchasing and Supply Station, Zibo Taibao
Forgery-proof Product Co., Ltd., and Zhejiang Yuhuan Kangning Medicine Packaging
CO., Ltd. In fiscal 2009, one supplier accounted for over 10% of our
purchases of raw materials. Approximately 30% of the raw material is
purchased from Anhui Dechang Pharmaceutical Tablet Co., Ltd., Shandong Yantai
Medical Materials Purchasing and Supply Station and Shandong Cangli Medicine
Co., Ltd.
Research
and Development
We
currently have limited resources to devote to and limited capabilities to
conduct the development of new products. We have only one full-time
employee who is engaged in research and development, so we mainly dependent on a
third-party, Yantai Tianzheng Medicine Research and Development Co., Ltd., to
perform research and development for us. We currently have two
products, namely Forsythia Capsule and Fern Injection, under research and
development in association with Yantai Tianzheng Medicine Research and
Development Co., Ltd.
However,
we, like other TCM manufacturers, enjoy relatively low research and development
expenses as most TCM medicines are based on standardized
formula. Research and development expenses are generally estimated at
5% of revenue for TCM manufacturers. The research and development
process includes toxicological tests, pharmalogical and qualitative research,
preparation for production and other miscellaneous costs. We intend
to introduce one new product by 2014 which is currently identified as a Shujin
Pain Relief soft capsule. The total cost to develop this product is
not expected to exceed $150,000. We may also seek to acquire new
products through acquisitions of other TCM companies in the future.
Manufacturing
Although
TCM is thousands of years old, we believe that our product manufacturing and
procedures are the most modern and up-to-date available. We employ
rigorous standards for product quality control and safety. Our
manufacturing is conducted in the city of Yantai in Shandong Province in a
state-of-the-art 18,000 square-meter facility that meets or exceeds the latest
Good Manufacturing and Quality Management Practice standards (referred to in
China as “GMP”).
48
GMP
standards are the government’s benchmark for pharmaceutical manufacturers in
China and must be met for the manufacturer to be eligible to market domestically
or enter world markets. On March 31, 2009, we completed a GMP review
which included examination of 225 items including development technology,
production, quality assurance, quality control, material handling and
engineering. As a result of that review, we were been re-certified
for a new five-year period.
Through
stringent application of GMP standards, the PRC government has reduced the
number of marginal medicine manufacturers by one-third, from 6,000 to
4,000. It is expected that TCM and pharmaceutical companies such as
ours that have received full GMP approval by the government will enjoy the
competitive benefits of their strict adherence to quality control, safety,
health and manufacturing standards.
Our
advanced and mechanized facilities utilize controlled, clean-room procedures
with sophisticated water filtration and materials processing
systems. In our annual operations, we process 800 tons of herbal
plants to extract, isolate and purify the compounds used in its medicines and
health supplements. The
manufacturing staff consists of 205 production employees and 21 quality control
inspectors as of February 2010.
Marketing,
Sales and Distribution
Bohai’s
products are sold either by prescription through hospitals or Over The Counter
(OTC) through local pharmacies and retail drug store chains. Sales and
distribution are managed and executed by about 304 sales representatives located
in 20 offices throughout China as of February 2010. These employees
are trained in all details of each product and are encouraged to develop strong
ties with physicians, hospitals and pharmacies in their local
areas.
Our
distribution and marketing initiatives for the next several years will be
focused on achieving the following goals:
Expand hospital
presence. We intend to further develop business in 600
hospitals in provinces we already serve including Shandong, Zhejiang, Jiangsu,
Anhui, Sichuan and Hubei. We believe that we will generate additional
revenue from the newly developed hospitals in those provinces.
Expand distribution to the rural
market. We believe that the Chinese government’s expansion in
2009 of national medical insurance coverage to the rural population provides us
with new and largely untapped markets. Some of our products, namely
Lung Nourishing Cream, Tongbi Capsules, Tongbi Tablets and Bazhen Yimu Cream
have been listed in government’s New National Medical Insurance Catalogue in
Shandong and Anhui Province as of November 30, 2009, and we expect to gain a
competitive advantage in these newly accessible rural markets.
During
2010, we plan to develop relationships with 100 new county-level hospitals in
rural areas of Shandong, Anhui, Liaoning and Hubei to establish its primary
marketing and distribution network in these rural areas.
Expand prescription medicine sales
organization. A key element of our growth strategy is
increased outreach to physicians. These outreach programs will focus
on the five current pharmaceutical products of ours that are available by
prescription only and will typically take place at state-run hospitals where
virtually all Chinese citizens obtain their medical care. Our
educational training programs will be designed to inform doctors of the range of
our pharmaceutical products including diseases or health/wellness concerns
targeted and proper usage of the medicines. Management will allocate
a portion of the proceeds derived from our January 2010 private placement to
expand existing physician-education programs.
49
Expand OTC team to drive market
share. Our management intends to accelerate and expand sales
of our OTC medicines through promotion and advertising targeting
consumers. The marketing programs will principally utilize
television, print advertising and news releases.
Competition
China’s
domestic pharmaceutical industry is highly competitive, with hundreds of
companies vying to reach consumers through more than 100,000 pharmacies.
In some categories in which we compete there are many other companies
offering the same competitive products. The market continues to attract
new entrants because the per capita medicine consumption in China is still low,
compared to developed countries, and that shows promise for substantial
growth.
Competitive
factors primarily include price and quality. We believe that we are able to
effectively compete in our market segment in China based upon the quality of our
product, given our new GMP certified manufacturing facility and our reputation
in the market place.
Many of
our current and potential competitors have significantly longer operating
histories and significantly greater managerial, financial, marketing, technical
and other competitive resources, as well as greater name recognition, than we
do. These competitors may be able to respond more quickly to new or changing
opportunities and customer requirements and may be able to undertake more
extensive promotional activities, offer more attractive terms to customers or
adopt more aggressive pricing policies. We cannot assure you that we will be
able to compete effectively with current or future competitors or that the
competitive pressures we face will not harm our business.
Intellectual
Property
We market
our products under the trademark “Xian Ge” which is registered with the PRC
Trademark Bureau under the State Administration for Industry and
Commerce. Currently, another company is licensed to utilize our
registered trademark “Xian Ge”. We have applied for a patent for a medicine with
its production method for the treatment of Lung-qi Deficiency Cough and Chronic
Bronchitis. The application was accepted by the State Intellectual
Property Office of the PRC on September 20, 2007 and is currently under review
process. We anticipate the approval may be granted by the end
calendar 2010.
Government
Regulation
We are
subject to many general regulations governing business entities and their
behavior in China and in any other jurisdiction in which we have operations. In
particular, we are subject to laws and regulations covering food, dietary
supplements and pharmaceutical products. Such regulations typically
deal with licensing, approvals and permits. Any change in product
licensing may make our products more or less available on the
market. Such changes may have a positive or negative impact on the
sale of our products and may directly impact the associated costs in compliance
and our operational and financial viability.
Our only
sales market is presently in China. We are subject to the
Pharmaceutical Administrative Law, which governs the licensing, manufacturing,
marketing and distribution of pharmaceutical products in China and sets
penalties for violations of the law. We are also subject to the Food
Sanitation Law, which provides for the food sanitation standards to be
followed.
50
Under
SFDA guidelines for licensing of pharmaceutical products, all pharmaceutical
manufacturers must obtain and maintain GMP Certificate. We hold a GMP
Certificate (No. Lu K0587) issued by Shandong Branch of SFDA on June 18, 2009.
Because our manufacturing facility has obtained the National GMP
Certificate, we are authorized to produce products in seven modes which are
tablets, capsules, granules, syrup, concentrated decoctions, tincture and
medical wine. Such certificate expires on June, 14,
2014.
We hold a
Permit for the Production of Medicine (Lu Zb20050330) issued by Shandong Branch
of SFDA on January 1, 2006 which allows us to engage in the production of
tablets, capsules, granules, syrup, concentrated decoctions, tincture (for oral
use) and medical wine. Such permit expires on December 31, 2010 and
we are planning to submit renewal application in compliance with the
requirements of the Shandong Branch of SFDA.
The
Permit for the Production of Medicine and GMP certificates are each valid for a
term of five years and must be renewed before their expiration.
We
obtained a Drug Approval Number for each of our products in 2004. The first five
year valid terms of such Drug Approval Numbers have expired. We
submitted the applications for re-registration on June 29, 2007 which were
accepted by SFDA. We have been advised that the approval processes
for these drugs have been recently commenced by the Shandong Branch of
SFDA. During the renewal period, we are permitted to continue
manufacturing these drugs as if the renewals had been approved.
The
governmental approval process in China’s newly developed health product is as
follows: a product sample is sent to a clinical testing agent designated by the
Ministry of Health, which conducts extensive clinical testing and examinations
to verify if the product has the specified functions as stated by the company
producing the product. A report will be issued by the clinical
testing agent confirming or negating such functions. It generally takes
approximately six months to one year for the report to be
issued. This report then has to be submitted to a provincial Health
Management Commission for approval. A letter of approval issued by such
commission will then be submitted to the Ministry of Health for the issuance of
a certificate that authorizes the sales and marketing of the product in China.
The whole process generally takes one and a half to two years.
Because
our subsidiary Yantai Shencaojishi Pharmaceuticals Co., Ltd. is a wholly foreign
owned enterprise, we are subject to the law on foreign investment enterprises in
China, and the foreign company provisions of the Company Law of China, which
governs the conduct of our subsidiary and its officers and directors.
Additionally, we are also subject to varying degrees of regulations and permit
system by the Chinese government.
Currently
we have not developed a market in U.S. so we believe we are not subject to any
of regulations by the U.S. Food and Drug Administration.
Environment
Regulation
We
believe we are in compliance with the Environmental Protection Law of the PRC,
as well as applicable local regulations, except that as of the date of this
Memorandum we are in the process of applying for the Pollution Discharge Permit.
Zhifu District Branch of Yantai Environment Protection Bureau issued a
written document on September 10, 2009, and stated that we have never been
subject to sanction due to violation of relevant environmental protection laws
since the incorporation. In addition to compliance with PRC laws and
local regulations, we consistently undertake active efforts to ensure the
environmental sustainability of our operations. Because the manufacturing
of herb and plant-based products does not generally cause significant damage or
pollution to the environment, the cost of complying with applicable
environmental laws is not material. In the event we fail to comply with
applicable laws, we may be subject to penalties.
51
Properties
Our
corporate office is located at No. 9 Daxin Road, Zhifu District, Yantai,
Shandong Province, China. Under the current PRC laws, land is owned
by the state, and parcels of land in rural areas which is known as collective
land is owned by the rural collective economic organization. “Land use rights”
are granted to an individual or entity after payment of a land use right fee is
made to the applicable state or rural collective economic organization. Land use
rights allow the holder of the right to use the land for a specified long-term
period. We have a land use right, expiring in 2047, for a total of
approximately 30,637 square meters of land. We currently have not
obtained a land use right certificate for a piece of land located in Xingfu
Twelve Village of Zhifu District with the area of 11,222 square meters. In the
process of the planning of Yantai City, the usage of the aforesaid land use
right has been changed from “industrial use” to “commercial use” and therefore,
the approval process for the land use right certificates on five relevant
parcels of land including the land occupied by us is suspended until the
completion of the planning. We can not assure you that we will
eventually obtain the land use right certificate for the foresaid
land.
Employees
Substantially
all of our employees are located in China. As of February 15, 2010, we have 596
employees, including 304 sales representatives. There are no
collective bargaining contracts covering any of our employees. We believe our
relationship with our employees is satisfactory.
We are
required to contribute a portion of our employees’ total salaries to the Chinese
government’s social insurance funds, including medical insurance, unemployment
insurance and job injuries insurance, and a housing assistance fund, in
accordance with relevant regulations. In the last three years, we
contributed approximately $62,930, $80,839 and $85,024 for the fiscal years
ended June 30, 2006, 2007 and 2008, respectively. We expect the amount of
contribution to the government’s social insurance funds to increase in the
future as we expand its workforce and operations.
January
2010 Share Exchange and Private Placement Transaction
We were
originally incorporated under the laws of the State of Nevada under the name
Link Resources Inc. on January 9, 2008. Our principal office was in
Calgary, Alberta, Canada. Prior to January 5, 2010, we were a public
“shell” company in the exploration stage since our formation and had not yet
realized any revenues. We entered into a Mineral Lease Agreement on
April 1, 2008 for two mining claims in Pershing County, Nevada, in an area known
as the Goldbanks East Prospect. We terminated the lease on July 7,
2009.
Share
Exchange with Chance High
Pursuant
to the Share Exchange Agreement entered into on January 5, 2010, we acquired
Chance High and its indirect, controlled subsidiary Bohai, a Chinese company
engaged the production, manufacturing and distribution in China of herbal
medicines, including capsules and other products, based on Traditional Chinese
Medicine. On January 5, 2010, pursuant to the terms of the Share
Exchange Agreement, we acquired all of the Chance High Shares of Chance High
from the Chance High Shareholders, and the Chance High Shareholders transferred
and contributed all of their Chance High Shares to us. In exchange,
we issued to Chance High Shareholders an aggregate of 13,162,500 newly issued
shares of our common stock. Certain of the Chance High Shareholders
are selling stockholders hereunder.
52
In
addition, pursuant to the terms of the Share Exchange Agreement, Zaradic, our
former sole officer and director, cancelled a total of 1,500,000 shares of
common stock owned by him. As a further condition of the Share
Exchange, effective as of January 5, 2010, Zaradic resigned from all of his
positions with our company and Qu, the former principal stockholder and
Executive Director of Bohai, was appointed as our President, Chief
Executive Officer, Interim Chief Financial Officer, Treasurer and Secretary and
also, effective January 16, 2010, as our sole director.
Private
Placement and Related Agreements
Securities Purchase
Agreement. On January 5, 2010, we entered into the Securities
Purchase with the Investors and Euro Pacific, as representative of the
Investors, relating to a private placement by us of 6,000,000 units consisting
of Notes and Warrants. The consummation of the private placement
resulted in gross proceeds to us of $12,000,000 and net proceeds of
approximately $9,700,000. Each unit consisted of a $2 principal
amount, two year convertible Note and a three year Warrant to purchase one share
of our common stock at $2.40 per share, subject to certain
conditions. Euro Pacific acted as the lead placement agent and
Chardan Capital Markets, LLC acted as co-placement agent of the private
placement.
Pursuant to the Securities Purchase
Agreement, we have agreed that we shall:
(a) Within
six (6) months of the closing of the private placement, appoint individuals
constituting a majority of “independent” directors (as defined under the Nasdaq
Marketplace rules) to the our board of directors, with one such director being
designated by Euro Pacific, and with at least two of such directors being fluent
in English. As of the date of this prospectus, we have yet to fulfill
this agreement but are seeking to do so.
(b) Within
six (6) months of the closing of the private placement, enter into a 24 month
agreement with a new Chief Financial Officer who is reasonably satisfactory to
Euro Pacific and who is proficient in: (i) U.S. generally accepted accounting
principals; (ii) transactions similar to the ones contemplated by Securities
Purchase Agreement; and (iii) U.S. public company listings and the related
filing and compliance requirements. As of the date of this
prospectus, we have yet to fulfill this agreement but are seeking to do
so.
(c) Within
three (3) months of the closing of the private placement, enter into a 12 month
agreement with an investor and public relations firm that is reasonably
satisfactory to Euro Pacific. As of the date of this prospectus, we
have fulfilled this agreement.
Registration Rights
Agreement. In connection with the private placement, we
entered into the Registration Rights Agreement with the Investors which sets
forth the rights of the Investors to have the shares of common stock underlying
the Notes and Warrants issued in the private placement registered with the SEC
for public resale. The filing of the registration statement of which
this prospectus is a part is intended to satisfy certain of our obligations the
Registration Rights Agreement.
Pursuant
to the Registration Rights Agreement, we agreed to file a registration statement
on Form S-1 (“Registration Statement”) by March 5, 2010 (which agreement was
fulfilled) and use our commercially reasonable best efforts to have the
Registration Statement declared effective by the SEC within 160 days after the
closing of the private placement to register 100% of the common stock
underlying: (i) the Notes, (ii) the Warrants and the Private Placement Warrants,
and (iii) any capital stock of the Company issued or issuable, with respect to
the registered shares of common stock as a result of any stock split, stock
dividend, recapitalization, exchange or similar event or otherwise, without
regard to any limitations on exercises of the Warrants.
53
The
Registration Rights Agreement provides that if we fail to file, obtain and
maintain effectiveness of Registration Statement due to “filing failure” or
“maintenance failure” (each as defined in the Registration Rights Agreement), we
shall pay to Investors, distributed pro rata, equal to one percent (1%) of the
aggregate purchase price paid for the Notes and Warrants (the “Registration
Delay Payments”), provided that in no event shall the aggregate amount of
Registration Delay Payments exceed, in the aggregate, six percent (6%) of such
aggregate purchase price, or $720,000.
Securities Escrow
Agreement. Also in connection with the private placement, we
entered into the Securities Escrow Agreement with Euro Pacific, as
representative of the Investors, our principal stockholder, Glory Period, and
the Escrow Agent. Pursuant to the Securities Escrow Agreement, Glory
Period has pledged and deposited a stock certificate representing 1 million
shares of our common stock (the “Escrow Shares”) into escrow in order to provide
security to the Investors in the event of an occurrence of an event of default
under the Notes. Upon the earlier to occur of the full repayment of
all amounts due to the Investors under the Notes or the conversion of fifty
percent of the principal face value of Notes into shares of common stock, the
Investors’ rights in and to the Escrow Shares shall terminate. Glory
Period is controlled by Qu through certain contractual relationships described
elsewhere in this prospectus.
Closing Escrow Agreement.
Pursuant to the Closing Escrow Agreement that we entered into in
connection with the private placement on December 10, 2009, we placed a total of
$240,000 of proceeds from the private placement (the “Holdback Amount”) with the
Escrow Agent. The Holdback Amount represents an amount sufficient to
satisfy the payment to the Investors of one quarterly interest payment due on
the aggregate principal amount of all Notes issued in the private
placement. If, subject to certain conditions and after applicable
notice and cure periods, an event of default is declared by Euro Pacific with
respect to our failure to make a quarterly interest payment to Investors, the
Escrow Agent shall disburse such portion of the Holdback Amount to the
Investors, and we shall be obligated to deposit additional amounts equal to the
Holdback Amount with Escrow Agent. At such time as seventy-five
percent of the aggregate shares of common stock underlying the Notes have been
issued upon conversion of the Notes, all remaining funds of the Holdback Amount
shall promptly be disbursed to us.
Certain Rights of Euro
Pacific. From and after the closing of the private placement,
we have agreed with Euro Pacific that if we decide to engage any placement
agent, underwriter or investment bank on a fee basis in connection with any
private placement of our securities or our affiliates and executive officers (a
“Subsequent Offering”) for a period of twelve (12) months from the date of the
closing of the private placement, we shall give prompt written notice of such an
event to Euro Pacific, and Euro Pacific shall be entitled to a 5 day right of
first refusal, beginning on the day Euro Pacific receives such written notice
from us of such Subsequent Offering, to act as agent or manager for such private
placement. In addition, Euro Pacific shall be entitled 10.0% of the
gross proceeds received by us with respect to any equity or equity-linked
financing transactions consummated within twelve (12) months from the closing of
the private placement with any investor introduced to is by Euro
Pacific.
54
MANAGEMENT
The
following table sets forth the name, age, and position of our sole officer and
director as of the date of this prospectus. Executive officers are
elected annually by our Board of Directors. Each executive officer
holds his office until he resigns, is removed by the Board, or his successor is
elected and qualified. Directors are elected annually by our stockholders at the
annual meeting. Each director holds his office until his successor is
elected and qualified or his earlier resignation or removal.
Name
|
Age
|
Position
|
||
Hongwei
Qu
|
|
35
|
|
President,
Chief Executive Officer, Interim Chief Financial Officer, Treasurer and
Secretary and Chairman of the Board of
Directors
|
Hongwei Qu. Mr. Qu
became our President, Chief Executive Officer, Interim Chief Financial Officer,
Treasurer and Secretary as of January 5, 2010, and, became the sole director and
Chairman of the our board of directors effective as of January 16, 2010 upon
filing of Schedule 14(f) with the SEC on January 6, 2010 in compliance with
Section 14(f) of the Exchange Act. From 2001 to May 2007, Mr. Qu was
the founder and principal officer of Yantai Hangwei Medical Trading Co., a PRC
company engaged in the wholesale of drugs and medical products and retail of
medical devices. In May 2007, Mr. Qu took principal responsibilities for the
acquisition of Bohai. From May 2007 until present, Mr. Qu has served
as the General Manger and Executive Director of Boha. . Mr. Qu has significant
experience in the medical and pharmaceutical sectors in China. Mr. Qu
graduated from Shandong Economic University with a bachelor degree.
Audit,
Nominating, Compensation Committees and Director Independence
Mr. Qu is
currently our sole director. Our board of directors therefore does
not have standing audit, nominating or compensation committees as of the date
hereof and the entire board is performing the functions normally associated with
an audit, nominating and compensation committee. As part of obligations under
the Securities Purchase Agreement in connection with our January 2010 private
placement, we are required to appoint a board of directors consisting of a
majority of “independent” directors (as defined under the Nasdaq Marketplace
rules) and one director designated by Euro Pacific, with at least two of such
directors being fluent in English within six months of the closing of the
private placement. Upon such appointment, we will seek to form audit
and other board committees in a manner consistent with Nasdaq listed
companies.
Communication
with our Director
Stockholders
or other interested parties may communicate with our director by sending mail to
Mr. Hongwei Qu, c/o Yantai Bohai Pharmaceuticals Group Co. Ltd., No.9 Daxin
Road, Zhifu District, Yantai, Shandong Province, China 264000.
Board
of Directors’ Meetings
During
our prior fiscal year ending May 31, 2009, we did not hold any meetings of the
board of directors, although our board of directors did act by unanimous written
consent.
55
EXECUTIVE
COMPENSATION
The
following table sets forth all cash compensation paid by Bohai, for the fiscal
years ended June 30, 2009 and 2008. The table below sets forth the positions and
compensations for each officer and director of Bohai. All the
officers were paid in RMB and the amounts reported in this table have been
converted from Renminbi to U.S. dollars based on the June 30, 2009 conversion
rate of RMB 6.8319 to $1.
COMPENSATION SUMMARY TABLE
|
|||||||||||||||||||||||||||||||||
Name and
Principal
Position
|
Fiscal Year
|
Salary
($)
|
Bonus
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-Equity
Incentive Plan
Compensation
($)
|
Change in
Pension Value
and
Nonqualified
Deferred
Compensation
Earnings
($)
|
All Other
Compensation
($)
|
Total
($)
|
||||||||||||||||||||||||
Hongwei
Qu,
|
2008(1)
|
$ | 14,480.5 | $ | 5,321.79 | — | — | — | — | — | $ | 19,802.25 | |||||||||||||||||||||
President
and Chief Executive Officer
|
2009(2)
|
$ | 14,644.5 | $ | 4,910.78 | $ | 19,555.28 |
Option/SAR
Grants in Last Fiscal Year
We have
not granted any stock options to our executive officers or directors from
inception through the date hereof.
Director
Compensation
We do not
pay our directors any fees or other compensation for acting as directors. We
have not paid any fees or other compensation to any of our directors for acting
as directors to date.
Employment
Contracts
We
presently do not have any employment agreements or other compensation
arrangements with Mr. Qu.
56
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Reorganization
Related Transactions
Chance
High owns 100% of the issued and outstanding capital stock of WFOE, a wholly
foreign owned enterprise incorporated under the laws of the PRC. On
December 7, 2009, WFOE entered into the VIE Agreements with Bohai, a company
incorporated under the laws of the PRC, and its three shareholders (the
principal shareholder being Mr. Qu, Bohai’s Executive Director), in which WFOE
effectively assumed management of the business activities of Bohai and has the
right to appoint all executives and senior management and the members of the
board of directors of Bohai. The VIE Agreements are comprised of a
series of agreements, including a Consulting Services Agreement, Operating
Agreement, Proxy Agreement, Equity Pledge Agreement, and Option Agreement,
through which WFOE has the right to advise, consult, manage and operate Bohai
for an annual fee in the amount of Bohai’s yearly net profits after
tax. Additionally, Bohai’s shareholders have pledged their rights,
titles and equity interest in Bohai as security for WFOE to collect consulting
and services fees provided to Bohai through an Equity Pledge Agreement. In order
to further reinforce WFOE’s rights to control and operate Bohai, Bohai’s
shareholders have granted WFOE the exclusive right and option to acquire all of
their equity interests in Bohai through an Option Agreement.
Through
WFOE, Chance High operates and controls Bohai through the VIE Agreements. WFOE
used the contractual arrangements to acquire control of Bohai, instead of using
a complete acquisition of Bohai’s assets or equity to make Bohai a wholly-owned
subsidiary of WFOE because: (i) PRC laws governing share exchanges with foreign
entities, which became effective on September 8, 2006, make the consequences of
such acquisitions uncertain and (ii) other than by share exchange transactions,
PRC laws require Bohai to be acquired for cash and WFOE was not able to raise
sufficient funds to pay the full appraised value for Bohai’s assets or shares as
required under PRC laws.
Slow Walk Arrangements
On
December 7, 2009, Mr. Qu, who is a PRC citizen, entered into the Call Option
Agreement with Joshua Tan, a Singapore passport holder and the sole shareholder
of Glory Period. Under the Call Option Agreement, Mr. Qu shall have
right and option to acquire up to 100% shares of Glory Period for nominal
consideration within the next 3 years. The Call Option Agreement also
provides that Mr. Tan shall not dispose any of the shares of Glory Period
without Mr. Qu’s consent.
Guarantee for the loans with banks by
Mr. Qu
Mr. Qu,
our President, Chief Executive Officer and Chairman, is providing a guaranty for
Bohai’s loans with Pudong Development Bank Qingdao Branch in a total amount of
$2.2 million, or RMB 15 million.
Loans
to Mr. Qu
As of
September 30, 2009, Bohai extended a loan of $1,465,000 to Mr. Qu. The loan was
unsecured, interest bearing at 3.93% per annum and has no fixed term of
repayment. The loan was repaid on December 10, 2009.
57
Other
Other
than employment and the foregoing arrangements, none of the following persons
has any direct or indirect material interest in any transaction to which we are
a party since our incorporation or in any proposed transaction to which we are
proposed to be a party: (i) any of Bohai’s directors or officers; (ii) any
person who beneficially owns, directly or indirectly, shares carrying more than
10% of the voting rights attached to our common stock; or any relative or spouse
of any of the foregoing persons, or any relative of such spouse, who has the
same house as such person or who is a director or officer of any parent or
subsidiary of our company.
58
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth certain information regarding our common stock
beneficially owned as of the date of this prospectus for: (i) each stockholder
known to be the beneficial owner of 5% or more of our outstanding common
stock, (ii) each executive officer and director, and (iii) all executive
officers and directors as a group, on a pro forma basis, assuming none of the Notes
have been converted into common stock and none of the Warrants and Agent
Warrants were exercised as of such date. The information contained
in the following table is provided for disclosure purposes only as there can be
no assurance that the actual ownership will be as set forth therein based on the
assumptions used.
Name of Beneficial Owner
|
Shares of Common
Stock Owned
|
Percent of Class
Beneficially Owned (1)
|
|||||
Glory
Period Limited (2)(3)(4)
|
8,942,471 |
55.0%
|
|||||
Hongwei
Qu (4)
|
8,942,471 |
55.0%
|
|||||
Cawston Enterprises, Ltd. (5) | 812,500 |
5.0%
|
|||||
All
Executive Officers and Directors as a group
|
8,942,471 |
55.0%
|
(1)
|
Based
on 16,250,000 shares of common stock issued and outstanding as of the date
of this prospectus.
|
(2)
|
Joshua
Tan is the sole shareholder of Glory Period, but pursuant to a Call Option
Agreement, he has no right to sell any shares without prior written
consent by Hongwei Qu.
|
(3)
|
Hongwei
Qu is the executive director of Glory
Period.
|
(4)
|
On
December 7, 2009, Mr. Qu, who is a PRC citizen, entered into the Call
Option Agreement with Mr. Tan, a Singapore passport holder and the sole
shareholder of Glory Period. Under the Call Option Agreement,
Mr. Qu shall have right and option to acquire up to 100% shares of Glory
Period for nominal consideration within the next 3 years. The
Call Option Agreement also provides that Mr. Tan shall not dispose any of
the shares of Glory Period without Mr. Qu’s
consent.
|
(5)
|
Cawston Enterprises, Ltd. acted as PRC financial advisor to Bohai in
connection with the Share Exchange and concurrent private placement
transaction, for which Cawston received shares of our common stock as
compensation. Joshua Tan is the principal of Cawston Enterprises, Ltd.
|
59
DESCRIPTION
OF SECURITIES
Our
common stock was registered under the Securities Exchange Act of 1934, as
amended, pursuant to a Form 8-A (File Number 000-53401) that was filed with the
SEC on September 4, 2008.
Our
authorized capital consists of 150,000,000 shares of common stock and 10,000,000
shares of preferred stock, par value $01 per share. There are no
outstanding shares of preferred stock as of the date of this
prospectus. A majority of our then stockholders approved an amendment
to our Articles of Incorporation to increase our authorized shares of common
stock from 75,000,000 to 150,000,000, which amendment was filed with the
Secretary of State of Nevada on December 17, 2009.
As of the
date of this prospectus, we have 16,250,000 shares of common stock issued and
outstanding.
Description of Common
Stock. Our common stock is entitled to one vote per share on
all matters submitted to a vote of the stockholders, including the election of
directors. Except as otherwise required by law, the holders of common
stock will possess all voting power. Generally, all matters to be
voted on by stockholders must be approved by a majority (or, in the case of
election of directors, by a plurality) of the votes entitled to be cast by all
shares of common stock that are present in person or represented by
proxy. Holders of our common stock representing a majority of the
voting power of our capital stock issued, outstanding and entitled to vote,
represented in person or by proxy, are necessary to constitute a quorum at any
meeting of stockholders. Our Articles of Incorporation, as amended,
do not provide for cumulative voting in the election of
directors. Holders of common stock have no pre-emptive rights, no
conversion rights and there are no redemption provisions applicable to the
common stock.
Holders
of our common stock are entitled to share in all dividends that the board of
directors, in its discretion, declares from legally available funds. In the
event of a liquidation, dissolution or winding up, each outstanding share
entitles its holder to participate pro rata in all assets that remain after
payment of liabilities and after providing for each class of stock, if any,
having preference over the common stock.
Notes Issued in Connection with the
Private Placement. In connection with our January 2010 private
placement, we offered and sold $12,000,000 worth of Notes convertible into
6,000,000 shares of common stock.
The Notes
are unsecured, payable on January 5, 2012 and carry an interest rate of 8% per
annum payable quarterly in arrears. We have placed in escrow with the
Escrow Agent an amount of the proceeds of the private placement equal to one
quarter worth of interest payments on the Notes to secure prompt interest
payments, or $240,000. Until such time as 75% of the Notes are
converted into shares of common stock, if such escrow is depleted in order to
make interest payments, we will replenish such escrow amount.
At the
option of each holder, the Notes may be converted into common stock at a price
of $2 per share, which conversion price is subject to customary weighted average
and stock based anti-dilution protection.
The Notes
contains standard events of default, including: (i) failure to file the
Registration Statement with the SEC within the prescribed period; (ii) failure
to have the Registration Statement deemed effective by the SEC within the
prescribed period; (iii) failure to maintain the effectiveness of the
Registration Statement thereafter; (iv) nonpayment of principal or interest; (v)
termination of registration or suspension of reporting obligations under the
Securities Exchange Act of 1934, as amended, suspension from trading on the
OTCBB (or an exchange), or failure to file reports with the SEC on a timely
basis as required by the Securities Exchange Act of 1934, as amended; (vi)
material breach of representations, warranties and other obligations under the
transaction documents associated with the Securities Purchase Agreement; (vii)
enforcement proceedings; (viii) cross default and cross acceleration; (ix)
insolvency, winding up and other market standard analogous events; (x)
moratorium and nationalization; (xi) proceedings against us or our consolidated
subsidiaries with potential loss/damage of U.S.$5 million or more; and (xii)
illegality of Notes under any applicable law.
60
The Notes
also contain customary affirmative and negative covenants, including negative
covenants which restrict our ability to do the following without the consent of
Euro Pacific, as representative of the Investors: (i) incur, or permit to exist,
any indebtedness for borrowed money in excess of (A) US$10,000,000
during the twelve (12) month period beginning on January 5, 2010, or (B)
US$15,000,000 during period beginning on January 5, 2010 and ending on January
5, 2012 (the maturity date of the Notes), except in the ordinary course of our
business; (ii) lend or advance money, credit or property to or invest in (by
capital contribution, loan, purchase or otherwise) any person or entity in
excess of US$2,000,000 except: (A) investments
in United States Government obligations, certificates of deposit of any banking
institution with combined capital and surplus of at least $200,000,000; (B)
accounts receivable arising out of sales in the ordinary course of business; and
(C) inter-company loans between and among us and our subsidiaries; (iii) pay
dividends or make any other distribution on shares of our capital stock; (iv)
create, assume or permit to exist, any lien on any of our property or assets now
owned or hereafter acquired, subject to existing liens and certain exceptions;
(v) assume guarantees, subject to certain exceptions; (vi) engage in
“sale-leaseback” transactions, subject to certain exceptions; (vii) make capital
expenditures in excess of US$5,000,000 in any fiscal year, subject to certain
exceptions; and (viii) materially alter our business.
Warrants. We
issued Warrants to purchase 6,000,000 shares of common stock in conjunction with
the private placement. Each Warrant entitles the holder to purchase
one share of common stock. The Warrants shall be exercisable in whole
or in part, at an initial exercise price per share of $2.40, which exercise
price is subject to customary weighted average and stock based anti-dilution
protection. The Warrants may be exercised at any time upon the
election of the holder, beginning on the date of issuance and ending of the
third anniversary of the closing of the private placement, or January 5,
2013. The Warrants are not redeemable.
In the
event of our liquidation, dissolution or winding up, the holders of Warrants
will not be entitled to participate in the distribution of our
assets. In addition, holders of Warrants do not have voting,
pre-emptive, subscription or other rights of stockholders in respect of the
Warrants, nor shall such holders be entitled to receive dividends.
Placement Agent
Warrants. In connection with the private placement, on January
5, 2010, we issued to affiliates of Euro Pacific and to Chardan Capital Markets,
LLC (“Chardan”) three-year Placement Agent Warrants to purchase 600,000 shares
of common stock at an exercise price of $2.40 per share. The
Placement Agent Warrants are substantially identical to the Warrants issued to
the Investors in the Private Placement, except that such warrants may not be
exercised until June 5, 2010. The holders of the Placement Agent
Warrants are selling stockholders hereunder.
Transfer
Agent and Registrar
The
transfer agent for our common stock is Island Stock Transfer. Our
transfer agent’s address is 100 2nd Avenue South, Suite 705 S, St.Petersburg,
FL, 33701.
61
SELLING
STOCKHOLDERS
We are
registering for the resale shares of our common stock held by the selling
stockholders identified below. We are registering the shares to
permit the selling stockholders and their pledges, donees, transferees and other
successors-in-interest that receive their shares from a selling stockholder as a
gift, partnership distribution or other non-sale related transfer after the date
of this prospectus to resell the shares when and as they deem
appropriate.
The
following table presents information as of March 2, 2010 and sets
forth:
|
·
|
the
name of the selling stockholders;
|
|
·
|
the
number of shares of our common stock that may be offered for resale for
the account of the selling stockholder under this
prospectus;
|
|
·
|
the
number and percentage of shares of our common stock that the selling
stockholder beneficially owned prior to the offering for resale of the
shares under this prospectus; and
|
|
·
|
the
number and percentage of shares of our common stock to be beneficially
owned by the selling stockholder after the offering of the resale shares
(assuming all of the offered resale shares are sold by the selling
stockholders).
|
The
19,632,529 shares of our common stock registered for public resale pursuant to
this prospectus and listed under the column “Shares of Common Stock Included in
Prospectus” on the table set forth below consist of:
|
(i)
|
7,032,529
shares that were: (i) issued on January 5, 2010 in connection with the
Share Exchange or (ii) held by holders of “restricted” shares under
applicable law, in each case as described in the footnotes to the table
below;
|
|
(ii)
|
12,000,000
shares issuable upon conversion or exercise of Notes and Warrants that
were issued in our January 2010 private placement;
and
|
|
(iii)
|
600,000
shares issuable upon exercise of the Placement Agent
Warrants.
|
Euro
Pacific Capital, Inc. (“Euro Pacific”) and Chardan Capital Markets, LLC
(“Chardan”) were engaged by us to provide placement agent services in connection
with our Janaury 2010 private placement. In exchange for providing
these services, Euro Pacific and Chardan received an aggregate $1,200,000 in
cash commissions and an aggregate of three-year Placement Agent Warrants to
purchase 600,000 shares of common stock at exercise price of $2.40 per share, of
which 31,500 placement agent warrants were issued to Chardan and 568,500
placement agent warrants were issued to affiliates of Euro
Pacific. The Placement Agent Warrants are substantially identical to
the Warrants issued to the Investors in the private placement, except that such
warrants may not be exercised until June 5, 2010. Euro Pacific and
Chardan received these securities to be resold in the ordinary course of
business and at the time of the issuance of the securities to be resold, had no
agreements or understandings, directly or indirectly, with any person to
distribute the securities.
62
The below
table assumes that all of the currently outstanding Warrants and Notes will be
exercised and converted for common stock and all of the securities will be sold
in this offering. However, any or all of the securities listed below
may be retained by any of the selling stockholders, and therefore, no accurate
forecast can be made as to the number of securities that will be held by the
selling stockholders upon termination of this offering. The selling
stockholders are not making any representation that any shares covered by this
prospectus will be offered for sale. We believe that, based on information
provided to us by each of the selling stockholders, the selling stockholders
listed in the table have sole voting and investment powers with respect to the
securities indicated. As indicated below, certain selling
stockholders are broker-dealers or affiliates of broker-dealers.
Name of Selling Stockholders
|
Shares of
Common
Stock
Included In
Prospectus
|
Shares
Beneficially
Owned Prior
To Offering (1)
|
Percentage
of Shares
Before
Offering (1)
|
Shares
Beneficially
Owned After
Offering (2)
|
Percentage of
Shares After
Offering (2)
|
|||||||||||||||
IRA
FBO Robert Stephen Adams Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Selwyn
Adelson (3)
|
60,000 | 60,000 | * | 0 | 0 | % | ||||||||||||||
Syed
Hasnat Ahmed & Mirian F Ahmed JT TEN (3)
|
110,000 | 110,000 | * | 0 | 0 | % | ||||||||||||||
Am-Per
Enterprises Inc. (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
David
Arita Tod Dtd 05/10/2009 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
William
C Arthur By Pass Trust Dated 10/18/1990 UAD 10/18/90 (3)
|
43,200 | 43,200 | * | 0 | 0 | % | ||||||||||||||
James
V. Bacon Trust Dtd 09/14/1995 UAD 03/26/09 (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
IRA
FBO Jeffrey P Baker Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Michael
Baldwin (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Balfour
Hollow LLC (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
Sarah J. Basler Living Trust UAD 07/02/98 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Richard
E Benamy (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Middlesex
Ortho Surgeons 401k FBO Lawrence Berson (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Jeff
Blackburn (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Ronald
Bovasso & Linda Bovasso JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Bradley
Anesthesiology PC Proft Sharing Plan & Tst (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Ten
Brink Trust Dated 10/02/1986 UAD 10/02/86 (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
White
Pine Productions Defined Benefit Pension Plan (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
SEP
FBO James Brown, Pershing LLC as Custodian (3)
|
90,000 | 90,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Pat Browne Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Scott
Burns (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Robert
Carlson & Michelle Carlson JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Brad
K Carr & Roxane Carr JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Lowell
Cerise (3)
|
75,000 | 75,000 | * | 0 | 0 | % | ||||||||||||||
SRC
Corporation Defined Benefit Pension Plan (3)
|
50,000 | 50,000 | * | 0 | 0 | % |
63
Donald
T Clemetson (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Roland
Cram Tod Dtd 06/03/2009 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Integrity
Funds LP (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
2000 Jorge &Elena Echeverria Family Trust UAD 11/09/00
(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Hy Echt Pershing LLC As Custodian (3)
|
60,000 | 60,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Ralph Dale Edson Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Jonathan
Edwards & Virginia C Adams JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
Arthur Eklund & Janet Eklund 1998 Inter Vivos Trust
(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Steven
Jay Epstein (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Donald Fagen Pershing LLC as Custodian (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
Sep
FBO Vic Ferrer Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Walter
Friesen (3)
|
150,000 | 150,000 | * | 0 | 0 | % | ||||||||||||||
The
Alexander Galuz and Yana Galuz Jt Living Tst UAD 08/24/05
(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Andrew
Garnock (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Richard
Glaser MDDBPP and Trust (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
Goldschlager Family Trust UAD 06/24/04 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Richard
Griff & Jackie Griff JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Richard
D Helppie Jr Trust UAD 04/02/92 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Howard
J Hickingbotham Jr & Sandra B Hickingbotham JT TEN(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
Robert K Heimann Living Trust UAD 07/24/01 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Hoke
Living Trust UAD 04/19/02 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Ulrich
Honighausen & Amanda Honighausen JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Herschel
Hunter Trust UAD 11/30/88 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Bert Huntsinger Pershing LLC as Custodian (3)
|
199,000 | 199,000 | 1.2 | % | 0 | 0 | % | |||||||||||||
Ingram
Living Trust Dated 11/02/2005 UAD 11/02/05 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Ajay
Kalra (3)
|
80,000 | 80,000 | * | 0 | 0 | % | ||||||||||||||
Karges
Revocable Intervivos Trust UAD 04/29/85 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Jon Murray Karkow Pershing LLC as
Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Patrick
Kirk & Gloria Kirk JTWROS (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Darrel
Lee Kloeckner (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Norman
S Kramer & Linda L Kramer JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % |
64
IRA
FBO Thomas A Ladner Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Scott
and Lori Langmack Family Trust UAD 06/22/02 (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Sep
FBO Carter Laren Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
David
W Larson & Jennifer L Larson JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Scott
R. Lennes IRA LLC (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Gregg Linhoff Pershing LLC as Custodian (3)
|
110,000 | 110,000 | * | 0 | 0 | % | ||||||||||||||
Sep
FBO George Madaraz Pershing LLC as Custodian (3)
|
70,000 | 70,000 | * | 0 | 0 | % | ||||||||||||||
Sep
FBO Gerald E Manwill Pershing LLC as Custodian (3)
|
75,000 | 75,000 | * | 0 | 0 | % | ||||||||||||||
David
Marble (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Northern
Star Growth Trust Dtd 10/20/1998 UAD 10/20/98 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Mitchell
Martin & Deborah Martin JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Brent
May PS Plan FBO F Brent May, Francis Brent TTWW; Dr. May
DMD
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Stephen
P Mccarron PSP-Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Joseph McCarthy Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Rod
Mcintyre Trust UA Dated 5/1/01 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Jerry Mcwilliams Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
The
Meister Non-Exempt Marital Trust UAD 11/17/83 (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Carlos
Alfonso Merino Rev Living Trust UAD 12/04/96 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Mark Mitchell Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Mark
R Mitchell M.D., a Medical Corporation (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
MMH Group,
LLC (3)
|
95,800 | 95,800 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Gerald Mona Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Kevin
Moore (3)
|
75,000 | 75,000 | * | 0 | 0 | % | ||||||||||||||
Deepak
Munjal (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Kenneth Henry Nass Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Tim Nass Pershing LLC as Custodian (3)
|
62,000 | 62,000 | * | 0 | 0 | % | ||||||||||||||
Mary
Neiberg (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Kevin
P O'neill & Suzanne Odell Oneill JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Joseph
A & Pamela M Panella Living Trust 1 UAD 05/11/04 (3)
|
50,000 | 50,000 | * | 0 | 0 | % |
65
Brent
Paulger and Sharissa Paulger JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Tina
C Peterson & Hendrikus M Schraven JT TEN (3)
|
200,000 | 200,000 | * | 0 | 0 | % | ||||||||||||||
E.A.
Pickering Painting Inc. (3)
|
60,000 | 60,000 | * | 0 | 0 | % | ||||||||||||||
POM
Investments LLC (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Bruce
Walker Ravenel III (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
M.
Carl Rice Self Employed Retirement Plan #1 (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
John
Russell Riedmueller & Nicole Cameron Riedmueller Ten Com
(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
John
A Rupp Trust UAD 03/25/94 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Steven
V Sann Tod Dtd 10/16/2009 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Robert
C Sayson & Alice K Sayson JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Peter
Schortmann and Susan Schortmann JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Kimberly
S Schwenke (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Christianna
Seidel Separate Property Trust UAD 11/05/99 (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
James
A Sheahan & Melody K Sheahan JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Donald Francis Shoff Pershing LLC as Custodian
(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
John
D Smead (3)
|
75,000 | 75,000 | * | 0 | 0 | % | ||||||||||||||
Spielman
and Elkin Revocable Trust UAD 06/14/19(3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Diane Spolum Pershing LLC as Custodian (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
Spongbob
Ventures II LLC (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Amy
J Stefanik Revocable Trust UAD 02/06/01 (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Lynn Rollins Stull Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Charles Sullivan Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Gerard Surerus Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO James A Tamborello Pershing LLC as Custodian (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Abdolhosayn
Taslimi and Shidan Taslimi JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Mehran
M Taslimi (3)
|
500,000 | 500,000 | * | 0 | 0 | % | ||||||||||||||
Ruha
Taslimi and Shidan Taslimi JT TEN (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Shidan
Taslimi (3)
|
500,000 | 500,000 | 3.1 | % | 0 | 0 | % | |||||||||||||
Susanne
A Taslimi (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Trillion
Growth China LP (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
Robert
Vecchione (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Matthew A Walton Pershing LLC as Custodian (3)
|
110,000 | 110,000 | * | 0 | 0 | % |
66
Timothy
M Weaver (3)
|
250,000 | 250,000 | 1.54 | % | 0 | 0 | % | |||||||||||||
Gramercy
87 LLC (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Dipaolo
Worthington Family Trust Dtd 1/31/2008 UAD 01/31/08 (3)
|
100,000 | 100,000 | * | 0 | 0 | % | ||||||||||||||
Lambert
Wu & Liying Chu JT TEN (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Wymond
Investments, LLC (3)
|
500,000 | 500,000 | 3.1 | % | 0 | 0 | % | |||||||||||||
Layne
Yoshida (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
IRA
FBO Paul Harper Zink Pershing LLC as Custodian (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Jayhawk
Private Equity II, L.P. (3)
|
500,000 | 500,000 | 3.1 | % | 0 | 0 | % | |||||||||||||
North
Military Ltd. (3)
|
200,000 | 200,000 | 1.2 | % | 0 | 0 | % | |||||||||||||
Chadds
Ford Ltd. (3)
|
50,000 | 50,000 | * | 0 | 0 | % | ||||||||||||||
Chardan
SPAC Asset Management (3)(4)
|
150,000 | 150,000 | * | 0 | 0 | % | ||||||||||||||
Cawston
Enterprises, Ltd. (5)
|
812,500 | 812,500 | 5.0 | % | 0 | 0 | % | |||||||||||||
Regeneration
Capital Group, LLC (6)
|
561,875 | 561,875 | 3.46 | % | 0 | 0 | % | |||||||||||||
Perry
A Lerner (6)
|
87,500 | 87,500 | * | 0 | 0 | % | ||||||||||||||
SAI
LLC (6)
|
87,500 | 87,500 | * | 0 | 0 | % | ||||||||||||||
Emanuel
Addington Living Trust (6)
|
62,500 | 62,500 | * | 0 | 0 | % | ||||||||||||||
Joseph
Douek (6)
|
87,500 | 87,500 | * | 0 | 0 | % | ||||||||||||||
IRA
For The Benefit of Barry Fox (6)
|
87,500 | 87,500 | * | 0 | 0 | % | ||||||||||||||
La
Mancha Capital, LLC (6)
|
120,000 | 120,000 | * | 0 | 0 | % | ||||||||||||||
Altbachco,
LLC (6)
|
129,375 | 129,375 | * | 0 | 0 | % | ||||||||||||||
Richard
Kaufman (6)
|
120,000 | 120,000 | * | 0 | 0 | % | ||||||||||||||
Trilogy
Capital Partners, Inc. (6)
|
31,250 | 31,250 | * | 0 | 0 | % | ||||||||||||||
David
Jan Mitchell (6)
|
25,000 | 25,000 | * | 0 | 0 | % | ||||||||||||||
JHVM
Investments LLC (6)
|
25,000 | 25,000 | * | 0 | 0 | % | ||||||||||||||
Genesis
Capital Advisors, LLC (6)
|
125,000 | 125,000 | * | 0 | 0 | % | ||||||||||||||
Michael
Rosenblum (6)
|
31,250 | 31,250 | * | 0 | 0 | % | ||||||||||||||
Norman
Kunin (6)
|
15,625 | 15,625 | * | 0 | 0 | % | ||||||||||||||
Dene
LLC (6)
|
31,250 | 31,250 | * | 0 | 0 | % | ||||||||||||||
Michael
Levitt (6)
|
9,375 | 9,375 | * | 0 | 0 | % | ||||||||||||||
Barry
Cervantes (7)
|
12,500 | 12,500 | * | 0 | 0 | % | ||||||||||||||
Steven
Straub (7)
|
12,500 | 12,500 | * | 0 | 0 | % | ||||||||||||||
SODA
Ventures LLC (7)
|
125,000 | 125,000 | * | 0 | 0 | % | ||||||||||||||
Regeneration
Capital Group, LLC (7)
|
50,000 | 50,000 | ||||||||||||||||||
Gerald
Altbach (8)
|
162,500 | 162,500 | 1.0 | % | 0 | 0 | % |
67
Wang
Shulian (9)
|
650,228 | 650,228 | 4.0 | % | 0 | 0 | % | |||||||||||||
Liu
Shaocui (9)
|
487,013 | 487,013 | 3.0 | % | 0 | 0 | % | |||||||||||||
Jia
Peicai (9)
|
161,899 | 161.899 | * | 0 | 0 | % | ||||||||||||||
Zhang
Jingxin (9)
|
161,899 | 161,899 | * | 0 | 0 | % | ||||||||||||||
Liang
Jianxin (9)
|
161,899 | 161,899 | * | 0 | 0 | % | ||||||||||||||
Yu
Bohai (9)
|
325,114 | 325,114 | 2.0 | % | 0 | 0 | % | |||||||||||||
An
Zhongnan (9)
|
161,899 | 161,899 | * | 0 | 0 | % | ||||||||||||||
Xu
Xiaosheng (9)
|
161,899 | 161,899 | * | 0 | 0 | % | ||||||||||||||
Dong
Qin (9)
|
81,213 | 81,213 | * | 0 | 0 | % | ||||||||||||||
Li
Yanzhi (9)
|
406,195 | 406,195 | 2.5 | % | 0 | 0 | % | |||||||||||||
Fu
Wei (9)
|
487,013 | 487,013 | 3.0 | % | 0 | 0 | % | |||||||||||||
Wang
Zhizhen (9)
|
487,013 | 487,013 | 3.0 | % | 0 | 0 | % | |||||||||||||
Portswealth
Holdings Ltd. (9)
|
486,745 | 486,745 | 3.0 | % | 0 | 0 | % | |||||||||||||
Thomas
Z. Tan (10)
|
150,000 | 150,000 | * | 0 | 0 | % | ||||||||||||||
Peter
D. Schiff (10)
|
209,250 | 209,250 | 1.29 | % | 0 | 0 | % | |||||||||||||
William
G. McBean (10)
|
209,250 | 209,250 | 1.29 | % | 0 | 0 | % | |||||||||||||
Chardan
Capital Markets, LLC (11)
|
31,500 | 31,500 | * | 0 | 0 | % |
*
Represents less than 1% of total outstanding common stock.
(1) Beneficial
ownership is determined in accordance with Rule 13d-3 of the Exchange Act. In
computing the number of shares beneficially owned by a person and the percentage
ownership of that person, securities that are currently convertible or
exercisable into shares of our common stock, or convertible or exercisable into
shares of our common stock within 60 days of the date hereof are deemed
outstanding. Such shares, however, are not deemed outstanding for the purpose of
computing the percentage ownership of any other person. Except as indicated in
the footnotes to the following table, each stockholder named in the table has
sole voting and investment power with respect to the shares set forth opposite
such stockholder’s name. The percentage of beneficial ownership is based on
16,250,000 shares of common stock outstanding as of March 2, 2010.
(2) Assumes
that all securities registered will be sold.
(3) We
issued an aggregate of 6,000,000 of units for gross proceeds of $12 million on
January 5, 2010. Each unit consisted of an unsecured $2 principal
amount Notes payable 24 months from January 5, 2010 with an interest rate of 8%
per annum payable quarterly in arrears, and a three year Warrant to purchase one
share of our common stock. The amount of shares referenced for the
selling stockholder includes: (i) shares of common stock beneficially owned by
the selling stockholder which are issuable upon conversion of Note at an
exercise price at $2.00 per share, which shares represent 50% of the registrable
securities held by the selling stockholder; and (ii) shares of common stock
beneficially owned by the selling stockholder which are issuable upon exercise
of the Warrant at an exercise price at $2.40 per share, which shares represent
50% of the registrable securities held by the selling stockholder.
68
(4) Selling
stockholder is an affiliate of Chardan, a FINRA member and SEC registered
broker-dealer that acted as co-placement agent in our January 5, 2010 private
placement.
(5) Cawston
Enterprises Ltd. acted as PRC financial advisor to Bohai in connection with the
Share Exchange and concurrent private placement transaction, for which Cawston
received shares of our common stock as compensation.
(6) The
shares held by the selling stockholder are part of an aggregate of 1,637,500
shares of common stock issued to Regeneration Capital Group, LLC and its
affiliates (“Regeneration”). Regeneration and its affiliates: (i)
were investors in our company prior to the consummation of the January 5, 2010
Share Exchange and/or (ii) acted as U.S. financial advisor to Bohai in
connection with the Share Exchange and concurrent private placement transaction,
for which Regeneration received shares of our common stock as
compensation.
(7) The
shares held by the selling stockholder are part of an aggregate 200,000 shares
of common stock issued upon conversion of short term bridge loans totaling
$400,000 which were obtained from four investors in June 2009.
(8) Selling
stockholder acted as a consultant to us prior to our January 5, 2010 share
exchange and private placement.
(9) Selling
stockholder was a minority shareholder of Chance High Limited and received the
registrable securities as part of the Share Exchange transaction which closed on
January 5, 2010.
(10) Selling
stockholder is an affiliate of Euro Pacific, a FINRA member and SEC registered
broker-dealer that acted as the lead placement agent in our January 5, 2010
private placement. Securities represent shares of common stock
underlying the Placement Agent Warrant issued to the selling
stockholder.
(11) Chardan
is a FINRA member and SEC registered broker-dealer that acted as co-placement
agent in our January 5, 2010 private placement. Registrable
securities represents shares of common stock underlying the Placement Agent
Warrant issued to the selling stockholder.
69
PLAN
OF DISTRIBUTION
The
selling stockholders and any of their respective pledgees, donees, assignees and
other successors-in-interest may, from time to time, sell any or all of their
shares of common stock on any stock exchange, market or trading facility on
which the shares are traded or in private transactions. These sales may be at
fixed or negotiated prices. The selling stockholders may use any one or more of
the following methods when selling shares:
|
·
|
ordinary
brokerage transactions and transactions in which the broker-dealer
solicits the purchaser;
|
|
·
|
block
trades in which the broker-dealer will attempt to sell the shares as agent
but may position and resell a portion of the block as
principal;
|
|
·
|
facilitate
the transaction;
|
|
·
|
purchases
by a broker-dealer as principal and resale by the broker-dealer for its
account;
|
|
·
|
an
exchange distribution in accordance with the rules of the applicable
exchange;
|
|
·
|
privately-negotiated
transactions;
|
|
·
|
broker-dealers
may agree with the selling stockholders to sell a specified number of such
shares at a stipulated price per
share;
|
|
·
|
through
the writing of options on the
shares;
|
|
·
|
a
combination of any such methods of sale;
and
|
|
·
|
any
other method permitted pursuant to applicable
law.
|
The
selling stockholders may also sell shares under Rule 144 of the Securities Act
of 1933, as amended (the “Securities Act”), if available, rather than under this
prospectus. The selling stockholders shall have the sole and absolute discretion
not to accept any purchase offer or make any sale of shares if it deems the
purchase price to be unsatisfactory at any particular time.
The
selling stockholders or their respective pledgees, donees, transferees or other
successors in interest, may also sell the shares directly to market makers
acting as principals and/or broker-dealers acting as agents for themselves or
their customers. Such broker-dealers may receive compensation in the form of
discounts, concessions or commissions from the selling stockholders and/or the
purchasers of shares for whom such broker-dealers may act as agents or to whom
they sell as principal or both, which compensation as to a particular
broker-dealer might be in excess of customary commissions. Market makers and
block purchasers purchasing the shares will do so for their own account and at
their own risk. It is possible that a selling stockholder will attempt to sell
shares of common stock in block transactions to market makers or other
purchasers at a price per share which may be below the then existing market
price. We cannot assure that all or any of the shares offered in this prospectus
will be issued to, or sold by, the selling stockholders. The selling
stockholders and any brokers, dealers or agents, upon effecting the sale of any
of the shares offered in this prospectus, may be deemed to be “underwriters” as
that term is defined under the Securities Act, the Exchange Act and the rules
and regulations of such acts. In such event, any commissions received by such
broker-dealers or agents and any profit on the resale of the shares purchased by
them may be deemed to be underwriting commissions or discounts under the
Securities Act.
70
We are
required to pay all fees and expenses incident to the registration of the
shares, including fees and disbursements of counsel to the selling stockholders,
but excluding brokerage commissions or underwriter discounts.
The
selling stockholders, alternatively, may sell all or any part of the shares
offered in this prospectus through an underwriter. The selling
stockholders have not entered into any agreement with a prospective underwriter
and there is no assurance that any such agreement will be entered
into.
The
selling stockholders may pledge their shares to their brokers under the margin
provisions of customer agreements. If a selling stockholder defaults on a margin
loan, the broker may, from time to time, offer and sell the pledged shares. The
selling stockholders and any other persons participating in the sale or
distribution of the shares will be subject to applicable provisions of the
Exchange Act, and the rules and regulations under such act, including, without
limitation, Regulation M. These provisions may restrict certain activities of,
and limit the timing of purchases and sales of any of the shares by, the selling
stockholders or any other such person. In the event that any of the selling
stockholders are deemed an affiliated purchaser or distribution participant
within the meaning of Regulation M, then the selling stockholders will not be
permitted to engage in short sales of common stock. Furthermore, under
Regulation M, persons engaged in a distribution of securities are prohibited
from simultaneously engaging in market making and certain other activities with
respect to such securities for a specified period of time prior to the
commencement of such distributions, subject to specified exceptions or
exemptions. In addition, if a short sale is deemed to be a stabilizing activity,
then the selling stockholders will not be permitted to engage in a short sale of
our common stock. All of these limitations may affect the marketability of the
shares.
If a
selling stockholder notifies us that it has a material arrangement with a
broker-dealer for the resale of the common stock, then we would be required to
amend the registration statement of which this prospectus is a part, and file a
prospectus supplement to describe the agreements between the selling stockholder
and the broker-dealer.
71
MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Market
Information
Our
common stock is listed for quotation on the OTCBB under the symbol “BOPH.” From
January 9, 2008 until February 8, 2010, our common stock was listed for
quotation on the OTCBB under the symbol “LINK”.
As of the
date hereof, shares of our common stock have not traded and actual price
information is not readily available. There have been no trades in
the common stock since listing on the OTC Bulletin Board. The absence
of any transactions in the common stock indicates there is no established
trading market for our common stock.
Holders
As of
March 2, 2010, there were 16,250,000 shares of our common stock outstanding held
by approximately 42 stockholders of record. The number of our
stockholders of record excludes any estimate by us of the number of beneficial
owners of shares held in street name, the accuracy of which cannot be
guaranteed.
Dividend
Policy
We have
not paid any cash dividends on our common stock to date, and we have no
intention of paying cash dividends in the foreseeable future. Whether we will
declare and pay dividends in the future will be determined by our board of
directors at their discretion, subject to certain limitations imposed under
Delaware corporate law. In addition, our ability to pay dividends may be
affected by the foreign exchange controls in China. The timing, amount and form
of dividends, if any, will depend on, among other things, our results of
operations, financial condition, cash requirements and other factors deemed
relevant by our board of directors.
LEGAL
MATTERS
The
validity of our common stock offered hereby has been passed upon by Ellenoff
Grossman & Schole LLP, New York, New York.
EXPERTS
The
consolidated balance sheet of the Company and its subsidiary for the
fiscal years ended June 30, 2008 and 2009, and the related consolidated
statements of operations, changes in stockholders’ equity and cash flows
appearing in this registration statement have been so included in reliance on
the Report of Parker Randall CF (H.K.) CPA Limited, an independent registered
public accounting firm, appearing elsewhere in this prospectus, given on the
authority of such firm as experts in accounting and auditing.
72
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON
ACCOUNTING AND FINANCIAL DISCLOSURE
Effective
January 29, 2010, upon the approval of our board of directors, we dismissed John
Kinross-Kennedy as our independent registered public accountant.
During
the prior fiscal years ended May 31, 2009 and 2008, John
Kinross-Kennedy’s reports on the financial statements of our company contained
no adverse opinion or disclaimer of opinion and were not qualified or modified
as to uncertainty, audit scope or accounting principle.
During
the fiscal years ended May 31, 2009 and 2008 and subsequent period through
January 29, 2010, there were no disagreements (as defined in Item 304(a)(1)(iv)
of Regulation S-K) between us and John Kinross-Kennedy on any matter of
accounting principles or practices, financial statement disclosure or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of
John Kinross-Kennedy, would have caused him to make reference thereto in his
report on financial statements for such years.
During
the fiscal years ended May 31, 2009 and 2008 and subsequent period through
January 29, 2010, there were no reportable events as defined in Regulation S-K
Item 304(a)(1)(v).
On
January 29, 2010, upon the approval of our board of directors, Parker Randall CF
(H.K.) CPA Limited (the “Parker Randall”) was appointed as our independent
registered public accounting firm. During our prior fiscal years
ended May 31, 2009 and 2008 and subsequent period through January 31,2010, we
did not consult with Parker Randall regarding any of the matters or events set
forth in Item 304(a)(2)(i) and Item 304(a)(2)(ii) of Regulation
S-K.
WHERE
YOU CAN FIND MORE INFORMATION
This
prospectus is part of a Registration Statement on Form S-1 we have filed with
the SEC. We have not included in this prospectus all of the information
contained in the Registration Statement and you should refer to our Registration
Statement and its exhibits for further information.
We file
annual, quarterly, and special reports, proxy statements, and other information
with the SEC. You may read and copy any document we file at the SEC’s public
reference room at 100 F Street, N.E., Washington, D.C. 20549. Copies
of these materials may also be obtained from the SEC at prescribed rates by
writing to the Public Reference Section of the SEC, 100 F. Street, N.E.,
Washington, D.C. 20549. You may obtain information about the operation of the
SEC public reference room in Washington, D.C. by calling the SEC at
1-800-SEC-0330. Our filings are also available to the public from commercial
document retrieval services and at the website maintained by the SEC at
http://www.sec.gov.
73
BOHAI
PHARMACEUTICALS GROUP, INC.
AND
ITS SUBSIDIARIES
INDEX
TO FINANCIAL STATEMENTS
Page
|
|
Interim
Financial Statements (unaudited):
|
|
Consolidated
and Condensed Balance Sheet as of December 31, 2009
|
F-1
|
Consolidated
and Condensed Statement of Income for Three Months Ended and Six Months
Ended December 31, 2009
|
F-3
|
Consolidated
and Condensed Cash Flow Statement for Three Months Ended and Six Months
Ended December 31, 2009
|
F-4
|
Notes
to Interim Financial Statements
|
F-5
|
Audited
Financial Statements:
|
|
Report
of Independent Registered Public Accounting Firm
|
F-21
|
Consolidated
Balance Sheets as of June 30, 2009 and 2008
|
F-22
|
Consolidated
Statement of Income for the years ended June 2009 and 2008
|
F-23
|
Consolidated
Statement of Stockholders’ Equity for the years ended June 2009 and
2008
|
F-24
|
Consolidated
Statement of Cash Flows as of June 30, 2009 and 2008
|
F-25
|
Notes
to the Consolidated and Audited Financial Statements
|
F-26
|
F-1
BOHAI
PHARMACEUTICALS GROUP, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
AS
OF DECEMBER 31, 2009
(UNAUDITED)
(Stated
in US Dollars)
As
of
|
As
of
|
|||||||||
December 31,
|
June 30,
|
|||||||||
Notes
|
2009
|
2009
|
||||||||
(Unaudited)
|
(Audited)
|
|||||||||
ASSETS
|
||||||||||
Current
assets
|
||||||||||
Cash
and cash equivalents
|
7,892,908 | 2,493,510 | ||||||||
Accounts
receivable
|
11,781,363 | 11,096,866 | ||||||||
Other
receivables and prepayments
|
4
|
13,174,158 | 14,458,800 | |||||||
Inventories
|
5
|
772,504 | 307,834 | |||||||
Total
current assets
|
33,620,933 | 28,357,010 | ||||||||
Non-current
assets
|
||||||||||
Property,
plant and equipment, net
|
7
|
8,021,881 | 8,149,279 | |||||||
Intangible
assets
|
6
|
17,322,336 | 17,298,720 | |||||||
Total
non-current assets
|
25,344,217 | 25,447,999 | ||||||||
TOTAL
ASSETS
|
58,965,150 | 53,805,009 | ||||||||
LIABILITES
AND STOCKHOLDERS’ EQUITY
|
||||||||||
Current
liabilities
|
||||||||||
Short-term
borrowings
|
8
|
4,393,665 | 5,860,000 | |||||||
Notes
payable
|
9
|
400,000 | 400,000 | |||||||
Accounts
payable
|
755,058 | 971,208 | ||||||||
Other
accrued liabilities
|
10
|
13,270,358 | 12,339,355 | |||||||
Income
taxes payable
|
1,077,801 | 677,666 | ||||||||
Total
current liabilities
|
19,896,882 | 20,248,229 | ||||||||
STOCKHOLDERS’
EQUITY
|
||||||||||
Common
stock, $0.001 par value, 150,000,000 shares authorized, 3,450,000 shares
issued and outstanding
|
15
|
3,450 |
|
3,450 | ||||||
Additional
paid-in capital
|
15
|
2,974,520 |
|
2,974,520 | ||||||
Capital
reserve
|
5,836,000 | 5,836,000 | ||||||||
Accumulated
other comprehensive income
|
539,492 | 490,931 | ||||||||
Statutory
reserves
|
16
|
2,748,446 | 2,201,811 | |||||||
Retained
earnings
|
26,966,360 | 22,050,068 | ||||||||
Total
stockholders’ equity
|
39,068,268 | 33,556,780 | ||||||||
|
|
|||||||||
TOTAL
LIABILITIES AND STOCKOLDERS’ EQUITY
|
58,965,150 | 53,805,009 |
See
accompanying notes to the financial statements
F-2
BOHAI
PHARMACEUTICALS GROUP, INC.
CONDENSED
CONSOLIDATED STATEMENT OF INCOME
FOR
THE THREE MONTHS ENEDED AND SIX MONTHS ENDED DECEMBER 31, 2009
(UNAUDITED)
(Stated
in US Dollars)
Three
months
|
Three
months
|
Six
months
|
Six
months
|
|||||||||||||||||
ended
|
ended
|
ended
|
ended
|
|||||||||||||||||
December
31,
|
December
31,
|
December
31,
|
December
31,
|
|||||||||||||||||
Notes
|
2009
|
2008
|
2009
|
2008
|
||||||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||||||
$
|
$
|
$
|
$
|
|||||||||||||||||
Sales
|
17,118,645 | 12,026,457 | 31,299,817 | 23,439,129 | ||||||||||||||||
Less:
Sales Tax
|
(272,342 | ) | (197,091 | ) | (499,500 | ) | (380,922 | ) | ||||||||||||
Net
sales
|
16,846,303 | 11,829,366 | 30,800,317 | 23,058,207 | ||||||||||||||||
Cost
of sales
|
(2,662,427 | ) | (1,996,467 | ) | (4,879,940 | ) | (3,960,866 | ) | ||||||||||||
Gross
profit
|
14,183,876 | 9,832,899 | 25,920,377 | 19,097,341 | ||||||||||||||||
Selling,
general and administrative expenses
|
11
|
(9,813,217 | ) | (7,494,180 | ) | (19,069,289 | ) | (14,069,386 | ) | |||||||||||
Interest
expenses
|
12
|
(51,814 | ) | (50,293 | ) | (149,594 | ) | (101,029 | ) | |||||||||||
Operating
income
|
4,318,845 | 2,288,426 | 6,701,494 | 4,926,926 | ||||||||||||||||
Non-operating
income
|
40,322 | - | 20,125 | - | ||||||||||||||||
Non-operating
costs
|
(23,738 | ) | (35 | ) | (29,003 | ) | (67 | ) | ||||||||||||
Income
before taxes
|
4,335,429 | 2,288,391 | 6,692,616 | 4,926,859 | ||||||||||||||||
Income
taxes
|
13
|
(1,057,890 | ) | (203,764 | ) | (1,613,261 | ) | (804,085 | ) | |||||||||||
Net
income
|
3,277,539 | 2,084,627 | 5,079,355 | 4,122,774 |
See
accompanying notes to the financial statements
F-3
BOHAI
PHARMACEUTICALS GROUP CO., LTD.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR
THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31, 2009
(UNAUDITED)
(Stated
in US Dollars)
Three
months
|
Six
months
|
Six
months
|
||||||||||||||
Three
months ended
|
ended
|
ended
|
ended
|
|||||||||||||
December
31,
|
December
31,
|
December
31,
|
December
31,
|
|||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||
$
|
$
|
$
|
$
|
|||||||||||||
Cash
flows from operating activities
|
||||||||||||||||
Net
income
|
3,277,539 | 2,084,627 | 5,079,355 | 4,998,294 | ||||||||||||
Adjustments
to reconcile net income to net cash provided by operating
activities
|
||||||||||||||||
Depreciation
|
258,145 | 213,912 | 341,868 | 284,387 | ||||||||||||
Loss
on disposals of property, plant and equipment
|
(2,947 | ) | - | 3,655 | - | |||||||||||
Changes
in assets and liabilities
|
||||||||||||||||
(Increase)/decrease
in accounts receivable
|
(816,265 | ) | 37,780 | (684,497 | ) | (227,100 | ) | |||||||||
Decrease/(increase)
other receivables and prepayments
|
748,460 | (1,069,253 | ) | 1,257,905 | (1,797,462 | ) | ||||||||||
(Increase)/decrease
in inventories
|
(333,876 | ) | 352,088 | (464,670 | ) | 342,352 | ||||||||||
(Decrease)/increase)
in accounts payable
|
(92,506 | ) | (1,409,969 | ) | (216,150 | ) | (1,660,070 | ) | ||||||||
Increase/(decrease)
in accrued liabilities
|
518,579 | (3,416,156 | ) | 930,686 | (3,958,945 | ) | ||||||||||
(Decrease)/increase
in income taxes payable
|
521,986 | (395,732 | ) | 400,135 | (394,092 | ) | ||||||||||
Net
cash provided by/ (used in) operating activities
|
4,079,115 | (3,602,703 | ) | 6,648,287 | (2,412,636 | ) | ||||||||||
Cash
flows from investing activities
|
||||||||||||||||
Contributed
capital
|
5,970 | - | 5,970 | - | ||||||||||||
Proceeds
of note payable
|
400,000 | - | 400,000 | - | ||||||||||||
Proceeds
from disposals of property, plant and equipment
|
2,925 | - | 2,925 | - | ||||||||||||
Purchases
of property, plant and equipment
|
(232,398 | ) | (321,548 | ) | (238,431 | ) | -321,548 | |||||||||
Net
cash provided by/(used in) investing activities
|
176,497 | (321,548 | ) | 170,464 | (321,548 | ) | ||||||||||
Cash
flows from financing activities
|
||||||||||||||||
Proceeds
of borrowings
|
2,200,500 | 3,080,700 | 3,073,365 | 3,080,700 | ||||||||||||
Repayment
of borrowings
|
(3,661,300 | ) | (586,800 | ) | (4,541,500 | ) | (586,800 | ) | ||||||||
Net
cash (used in)/provided by financing activities
|
(1,460,800 | ) | 2,493,900 | (1,468,135 | ) | 2,493,900 | ||||||||||
Net
increase/(decrease) in cash and cash equivalents
|
2,794,812 | (1,430,351 | ) | 5,350,616 | (240,284 | ) | ||||||||||
Effect
of foreign currency translation on cash and cash
equivalents
|
34,291 | 113,985 | 48,782 | 204,086 | ||||||||||||
Cash
and cash equivalents at beginning of period
|
5,132,387 | 2,109,218 | 2,493,510 | 829,050 | ||||||||||||
Cash
and cash equivalents at end of period
|
7,892,908 | 792,852 | 7,892,908 | 792,852 |
See
accompanying notes to the financial statements
F-4
BOHAI
PHARMACEUTICALS GROUP, INC.
FOR
THE SIX MONTHS ENDED DECEMBER 31, 2009
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(Stated
in US Dollars)
1.
|
ORGANIZATION
AND PRINCIPAL ACTIVITIES
|
Bohai
Pharmaceuticals Group, Inc. (formerly known as Link Resources, Inc.) was
incorporated under the laws of the State of Nevada on January 9,
2008. Until January 5, 2010, its principal office was located in
Calgary, Alberta, Canada. The Company was a public “shell” company in
the exploration stage since its formation and had not yet realized any revenues
from its planned operations. The Company entered into a Mineral Lease
Agreement on April 1, 2008 for two mining claims in Pershing County, Nevada, in
an area known as the Goldbanks East Prospect. The Company terminated
the lease on July 7, 2009.
Pursuant
to a Share Exchange Agreement, dated January 5, 2010 (the “Share Exchange
Agreement” and the transactions contemplated thereby, the “Share Exchange”), the
Company acquired Chance High International Limited, a British Virgin Islands
company (“Chance High”) from Chance High’s shareholders (the “Chance High
Shareholders”) and, as a result, acquired Chance High’s indirect, controlled
subsidiary, Yantai Bohai Pharmaceuticals Group Co., Ltd. (“Bohai”), a Chinese
company engaged the production, manufacturing and distribution in the People’s
Republic of China (“China” or the “PRC”) of herbal medicines, including capsules
and other products, based on traditional Chinese medicine. The
closing of the Share Exchange (the “Closing”) took place on January 5, 2010 (the
“Closing Date”).
On the
Closing Date, pursuant to the terms of the Share Exchange Agreement, the Company
acquired all of the outstanding equity securities (the “Chance High Shares”) of
Chance High from the Chance High Shareholders, and the Chance High Shareholders
transferred and contributed all of their Chance High Shares to the
Company. In exchange, the Company issued to Chance High Shareholders
an aggregate of 13,162,500 newly issued shares of common stock, par value $0.001
per share (the “Common Stock”). In addition, pursuant to the terms of
the Share Exchange Agreement, Anthony Zaradic, the former President and Chief
Executive Officer of the Company, cancelled a total of 1,500,000 shares of
Common Stock.
Chance
High owns 100% of the issued and outstanding capital stock of the Yantai
Shencaojishi Pharmaceuticals Co., Ltd. (“WOFE”). On December 7, 2009,
the WOFE entered into a series of variable interest entity contractual
agreements (the “VIE Agreements”) with Bohai and its three shareholders,
including Mr. Hongwei Qu, currently the Company’s Chairman, Chief Executive
Officer and President (“Qu”), pursuant to which WOFE effectively assumed
management of the business activities of Bohai and has the right to appoint all
executives and senior management and the members of the board of directors of
Bohai. Chance High, WOFE and Bohai are referred to herein
collectively as the “Group”.
The VIE
Agreements are comprised of a series of agreements, including a Consulting
Services Agreement, Operating Agreement and Proxy Agreement, through which WOFE
has the right to advise, consult, manage and operate Bohai for an annual fee in
the amount of Bohai’s yearly net profits after tax. Additionally,
Bohai’s shareholders pledged their rights, titles and equity interest in Bohai
as security for WOFE to collect consulting and services fees provided to Bohai
through an Equity Pledge Agreement. In order to further reinforce
WOFE’s rights to control and operate Bohai, Bohai’s shareholders granted WOFE an
exclusive right and option to acquire all of their equity interests in Bohai
through an Option Agreement. As all of the companies in the Group are
under common control, this has been accounted for as a reorganization of
entities and the financial statements have been prepared as if the
reorganization had occurred retroactively. The Company has
consolidated Bohai’s operating results, assets and liabilities within its
financial statements.
F-5
2.
|
BASIS
OF PRESENTATION
|
The Group
maintains its general ledger and journals with the accrual method accounting for
financial reporting purposes. Accounting policies adopted by the
Group conform to generally accepted accounting principles in the United States
of America (“US GAAP”) and have been consistently applied in the presentation of
financial statements, which are compiled on the accrual basis of
accounting.
This
basis of accounting differs in certain material respects from that used for the
preparation of the books of account of the Group, which are prepared in
accordance with the accounting principles and the relevant financial regulations
applicable to enterprises with limited liabilities established in the PRC (“PRC
GAAP”), the accounting standards used in the places of their
domicile. The accompanying financial statements reflect necessary
adjustments not recorded in the books of account of the Group to present them in
conformity with US GAAP.
The
interim financial statements as of and for the six months ended December 31,
2009 reflect all adjustments which, in the opinion of management, are necessary
to present fairly the financial position, results of operations and cash flows
for the period presented in accordance with the accounting principles generally
accepted in the United States of America. All adjustments are of a
normal recurring nature.
3.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
|
(a)
|
Basis
of Presentation and consolidation
|
The
condensed consolidated financial statements are prepared on the basis with
assumption the Share Exchange was undergone at the beginning of July 1,
2008. The historical condensed consolidated financial statements of
the Group will be those of Bohai Pharmaceuticals Group, Inc. and of the
consolidated entities from the July 1, 2008, the deemed date of Share Exchange,
and subsequent. The consolidated financial statements for the Company
for the six months ended December 31, 2009 and 2008, include the financial
statements of Chance High, and its wholly owned subsidiary, WOFE, and Bohai, the
Company’s principal operating subsidiary, which is a Chinese variable interest
entity that WOFE controls through certain contractual
arrangements. Intercompany transactions and balances are eliminated
in consolidation.
F-6
As of
December 31, 2009, the particulars of the Company’s subsidiaries are as
follows:
Name
of
Company
|
Place
of
incorporation
|
Date
of
incorporation
|
Attributable
equity
interest
|
Issued
capital
|
|||||
Chance
High International Limited
|
British
Virgin Islands
|
July
02, 2009
|
100%
|
USD50,000
|
|||||
|
|||||||||
Yantai
Shencaojishi Pharmaceuticals Co., Ltd.
|
People’s
Republic of China
|
November
25, 2009
|
100%
|
|
USD9,500,000
|
||||
Yantai
Bohai Pharmaceuticals Group Co., Ltd.
|
People’s
Republic of China
|
July
8, 2004
|
*
|
USD2,918,000 (RMB20,000,000)
|
* The
Group has indirect controlling interest of Bohai under the VIE Agreements
entered on December 7, 2009, which are described in Note 1 above.
(b)
|
Economic
and Political Risks
|
The
Group’s operations are conducted solely in the PRC. There are
significant risks associated with doing business in the PRC, among others,
political, economic, legal and foreign currency exchange risks. The
Group’s results may be adversely affected by changes in the political and social
conditions in the PRC, and by changes in governmental policies with respect to
laws and regulations, anti-inflationary measures, currency conversion,
remittances abroad, and rates and methods of taxation, among other
things.
(c)
|
Use
of Estimates
|
In
preparing of the financial statements in conformity with US GAAP, management
makes estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosures of contingent assets and liabilities at the dates of
the financial statements, as well as the reported amounts of revenues and
expenses during the reporting periods. These accounts and estimates
include, but are not limited to, the valuation of accounts receivable,
inventories, deferred income taxes and the estimation on useful lives of plant
and machinery. Actual results could differ from those
estimates.
(d)
|
Cash
and Cash Equivalents
|
The Group
considers all highly liquid investments purchased with original maturities of
three months or less to be cash equivalents. The Group maintains bank
accounts only in the PRC. The Company does not maintain any bank
accounts in the United States of America. As of December 31, 2009 and
June 30, 2009, there were cash and cash equivalents of $7,892,908 and $2,493,510
respectively.
(e)
|
Accounts
Receivable
|
Accounts
receivable consists of amounts due from customers. The Group extends unsecured
credit to its customers in the ordinary course of business but mitigates the
associated risks by performing credit checks and actively pursuing past due
accounts. An allowance for doubtful accounts is established and
determined based on management’s assessment of known requirements, aging of
receivables, payment history, the customer’s current credit worthiness and the
economic environment.
F-7
(f)
|
Inventories
|
Inventories
are valued at the lower of cost or market with cost is determined on the
weighted average method. Finished goods inventories consist of raw materials,
direct labour and overhead associated with the manufacturing process. In
assessing the ultimate realization of inventories, the management makes
judgments as to future demand requirements compared to current or committed
inventory levels. The Group’s reserve requirements generally
increase/decrease due to management projected demand requirements, market
conditions and product life cycle changes. As of December 31, 2009 and June 30,
2009, the Group did not make any allowance for slow-moving or defective
inventories.
(g)
|
Fair
value of Financial Instruments
|
The
carrying values of the Group’s financial instruments, including cash and cash
equivalents, accounts receivables, other receivables and prepayments, short-term
borrowings, accounts payables, and other accrued liabilities their fair values
due to the short-term maturity of such instruments.
(h)
|
Intangible
Assets
|
Intangible
assets as “Pharmaceutical Formulas”, which acquired and with indefinite useful
live are measured initially at cost and not subject to amortization shall be
tested for impairment annually or more frequently if there is indication of
impairment. If the carrying amount exceeds fair value, an impairment loss should
be recognized. Subsequently reversal of a recognized impairment loss is
prohibited.
(i)
|
Property,
plant and equipment
|
Property,
plant and equipment, other than construction in progress, are stated at cost
less depreciation and amortization and accumulated impairment
loss. Cost represents the purchase price of the asset and other costs
incurred to bring the asset into its existing use. Maintenance,
repairs and betterments, including replacement of minor items, are charged to
expense; major additions to physical properties are capitalized.
Depreciation
of property, plant and equipment is calculated to written off the cost, less
their estimated residual value, if any, using the straight-line method over
their estimated useful lives. The principal annual rates are as
follows:-
Leasehold
land and buildings
|
30
to 40 years
|
Motor
vehicles
|
10
years
|
Plant
and machinery
|
10
years
|
Office
equipment
|
5
years
|
Upon sale
or disposition, the applicable amounts of asset cost and accumulated
depreciation are removed from the accounts and the net amount less proceeds from
disposal is charged or credited to income.
Construction
in progress mainly represents expenditures in respect of the Group’s corporate
campus and machinery under construction, which the campus was completed and at
which production began in 2009. Assets under construction are not
depreciated until the construction is completed and the assets are ready for
their intended use.
F-8
(j)
|
Accounting
for the Impairment of Long-Lived
Assets
|
The Group
adopted Statement of Financial Accounting Standards No. 144, “Accounting for the
Impairment or Disposal of Long-Live Assets” (“SFAS 144”), which addresses
financial accounting and reporting for the impairment or disposal of long-lived
assets. The Group periodically evaluates the carrying value of
long-lived assets to be held and used in accordance with SFAS 144. SFAS 144
requires impairment losses to be recorded on long-lived assets used in
operations when indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets are less than the assets’
carrying amounts. In that event, a loss is recognized based on the amount by
which the carrying amount exceeds the fair market value of the long-lived
assets. Loss on long-lived assets to be disposed of is determined in a similar
manner, except that fair market values are reduced for the cost of disposal.
Based on its review, the Group believes that, as of December 31, 2009 and June
30, 2009, there were no significant impairments of its long-lived
assets.
(k)
|
Foreign
Currency Translation
|
The Group
maintains its financial statements in the functional currency. The
functional currency of the Group is the Chinese Renminbi
(RMB). Monetary assets and liabilities denominated in currencies
other than the functional currency are translated into the functional currency
at rates of exchange prevailing at the balance sheet
dates. Transactions denominated in currencies other than the
functional currency are translated into the functional currency at the exchanges
rates prevailing at the dates of the transaction. Exchange gains or
losses arising from foreign currency transactions are included in the
determination of net income for the respective periods.
For
financial reporting purposes, the financial statements of the Group which are
prepared using the functional currency have been translated into United States
dollars. Assets and liabilities are translated at the exchange rates at the
balance sheet dates and revenue and expenses are translated at the average
exchange rates and stockholders’ equity is translated at historical exchange
rates. Any translation adjustments resulting are not included in determining net
income but are included in foreign exchange adjustment to other comprehensive
income, a component of stockholders’ equity.
12.31.2009 | 12.31.2008 | 9.30.2009 | 9.30.2008 | 6.30.2009 | 6.30.2008 | |||||||||||||||||||
Year
end US$: RMB exchange rate
|
6.81663 | 6.83527 | 6.82594 | 6.83720 | 6.85401 | 6.85420 | ||||||||||||||||||
Average
periodic US$: RMB exchange rate
|
6.82082 | 6.83107 | 6.82594 | 7.26269 | 6.83857 | 6.85307 |
RMB is
not freely convertible into foreign currency and all foreign exchange
transactions must take place through authorized institutions. No
representation is made that the RMB amounts could have been, or could be,
converted into US$ at the rates used in translation.
(l)
|
Revenue
Recognition
|
Revenue
represents the invoiced value of goods sold recognized upon the delivery of
goods to customers. Revenue is recognized when all of the following criteria are
met:
|
·
|
Persuasive
evidence of an arrangement exists;
|
|
·
|
Delivery
has occurred or services have been
rendered;
|
|
·
|
The
seller’s price to the buyer is fixed or determinable;
and
|
|
·
|
Collectability
is reasonably assured. Payments have been
established.
|
F-9
(m)
|
Cost
of Revenue
|
Regarding
the trading of medicine, the respective cost of revenue consists primarily of
material cost, labour cost, overhead associated with the manufacturing process
and related expenses which are directly attributable to the
trading.
(n)
|
Research
and Development Costs
|
Research
and development costs are charged as expense when incurred and included in
operating expenses.
(o)
|
Income
Taxes
|
Income
taxes are accounted for under the asset and liability
method. Deferred tax assets and liabilities are recognized for the
future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit
carry-forwards. Deferred tax assets are reduced by a valuation
allowance to the extent management concludes it is more likely than not that the
assets will not be realized. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in the statements of income and comprehensive
income in the periods that includes the enactment date.
(p)
|
Comprehensive
Income
|
Comprehensive
income is defined to include all changes in equity except those resulting from
investments by owners and distributions to owners. Among other
disclosures, all items that are required to be recognized under current
accounting standards as components of comprehensive income are required to be
reported in a financial statement that is presented with the same prominence as
other financial statements. The Group’s current components of other
comprehensive income are the foreign currency translation
adjustment.
(q)
|
Commitments
and Contingencies
|
Liabilities
for loss contingencies arising from claims, assessments, litigation, fines and
penalties and other sources are recorded when it is probable that a liability
has been incurred and the amount of the assessment can be reasonably
estimated.
(r)
|
Earning
per Shares
|
The Group
reports basic earnings per share in accordance with SFAS 128, “Earnings Per
Share”. Basic earnings/(loss) per share is computed by dividing net
income/(loss) by weighted average number of shares of common stock outstanding
during the period. Diluted earnings per share is computed by dividing net income
by the weighted average number of shares of common stock, common stock
equivalents and potentially dilutive securities outstanding during the period.
At December 31, 2009, the Group had no common stock equivalents that could
potentially dilute future earnings per share.
F-10
(s)
|
Recent
Accounting Pronouncements
|
In March
2008, the FASB issued SFAS No. 161, DISCLOSURES ABOUT DERIVATIVE INSTRUMENTS AND
HEDGING ACTIVITIES (an amendment to SFAS No. 133). This statement is effective
for financial statements issued for fiscal year and interim periods beginning
after November 15, 2008 and requires enhanced disclosures with respect to
derivative and hedging activities. The Group will comply with the disclosure
requirements of this statement if it utilizes derivative instruments or engages
in hedging activities upon its effectiveness.
In April
2008, the FASB issued FASB Staff Position No. 142-3, DETERMINATION OF THE USEFUL
LIFE OF INTANGIBLE ASSETS (“FSP No. 142-3”) to improve the consistency between
the useful life of a recognized intangible asset (under SFAS No. 142) and the
period of expected cash flows used to measure the fair value of the intangible
asset (under SFAS No. 141(R)). FSP No. 142-3 amends the factors to be considered
when developing renewal or extension assumptions that are used to estimate an
intangible asset’s useful life under SFAS No. 142. The guidance in the new staff
position is to be applied prospectively to intangible assets acquired after
December 31, 2008. In addition, FSP No.142-3 increases the disclosure
requirements related to renewal or extension assumptions. The Company does not
believe implementation of FSP No. 142-3 have a material impact on its financial
statements.
In May
2008, the FASB issued statement No. 162, THE HIERARCHY OF GENERALLY ACCEPTED
ACCOUNTING PRINCIPLES. This statement identifies the sources of accounting
principles and the framework for selecting the principles to be used in the
preparation of financial statements of nongovernmental entities that are
presented in conformity with generally accepted accounting principles (GAAP) in
the United States (the GAAP hierarchy). This statement is effective 60 days
following the SEC’s approval of the Public Company Accounting Oversight Board
amendments to AU Section 411, “the Meaning of Present Fairly in Conformity With
Generally Accepted Accounting Principles”.
In May
2008, the FASB issued FSP Accounting Principles Board (“APB”) 14-1 “Accounting
for Convertible Debt instruments That May Be Settled in Cash upon Conversion
(Including Partial Cash Settlement)” (“FSP APB 14-1”). FSP APB 14-1 requires the
issuer of certain convertible debt instruments that may be settled in cash (or
other assets) on conversion to separately account for the liability (debt) and
equity (conversion option) components of the instrument in a manner that
reflects the issuer’s non-convertible debt borrowing rate. FSP APB 14-1 is
effective for fiscal years beginning after December 15, 2008 on a retroactive
basis. As we do not have convertible debt at this time, we currently believe the
adoption of FSP APB 14-1 will have no effect on our combined results of
operations and financial condition.
In May
2008, the FASB issued Statement No. 163, ACCOUNTING FOR FINANCE GUARANTEE
INSURANCE CONTRACTS - AN INTERPRETATION OF FASB STATEMENT NO. 60. The premium
revenue recognition approach for a financial guarantee insurance contract links
premium revenue recognition to the amount of insurance protection and the period
in which it is provided. For purposes of this statement, the amount of insurance
protection provided is assumed to be a function of the insured principal amount
outstanding, since the premium received requires the insurance enterprise to
stand ready to protect holders of an insured financial obligation from loss due
to default over the period of the insured financial obligation. This Statement
is effective for financial statements issued for fiscal years beginning after
December 15, 2008.
In June
2008, the FASB issued FASB Staff Position Emerging Issues Task Force (EITF) No.
03-6-1, DETERMINING WHETHER INSTRUMENTS GRANTED IN SHARE-BASED PAYMENT
TRANSACTIONS ARE PARTICIPATING SECURITIES (“FSP EITF No. 03-6-1”). Under FSP
EITF No. 03-6-1, unvested share-based payment awards that contain rights to
receive nonforfeitable dividends (whether paid or unpaid) are participating
securities, and should be included in the two-class method of computing EPS. FSP
EITF No. 03-6-1 is effective for fiscal years beginning after December 15, 2008,
and interim periods within those years, and is not expected to have a
significant impact on the Company’s financial statements.
F-11
In April
2009, the FASB issued FSP 157-4, DETERMINING FAIR VALUE WHEN THE VOLUME AND
LEVEL OF ACTIVITY FOR THE ASSET OR LIABILITY HAVE SIGNIFICANTLY DECREASED AND
IDENTIFYING TRANSACTIONS THAT ARE NOT ORDERLY (“FSP 157-4”). FSP 157-4 provides
additional guidance for estimating fair value in accordance with SFAS 157 when
the volume and level of activity for the asset or liability have significantly
decreased. FSP 157-4 also includes guidance on identifying circumstances that
indicate a transaction is not orderly. FSP 157-4 is effective for interim and
annual reporting periods ending after June 15, 2009, with early adoption
permitted for periods ending after March 15, 2009. FSP 157-4 does not require
disclosures for earlier periods presented for comparative purposes at initial
adoption. In periods after initial adoption, FSP 157-4 requires comparative
disclosures only for periods ending after initial adoption. The adoption of the
provisions of FSP 157-4 is not anticipated to materially impact on the Company’s
results of operations or the fair values of its assets and
liabilities.
In May
2009, the FASB issued SFAS No. 165, SUBSEQUENT EVENTS (“SFAS 165”). SFAS 165
establishes general standards for accounting for and disclosure of events that
occur after the balance sheet date but before financial statements are issued or
available to be issued and was effective for interim and annual periods ending
after June 15, 2009. The adoption of SFAS No. 165 did not have an impact on the
Company’s results of operations or financial condition. The Company evaluated
all subsequent events that occurred from January 1, 2010 through January 30,
2010, inclusive, and does not found any material subsequent events are required
to disclose.
In June
2009, the FASB issued SFAS No. 166 ACCOUNTING FOR TRANSFERS OF FINANCIAL ASSETS
(“SFAS 166). This statement is intended to improve the relevance,
representational faithfulness, and comparability of the information that a
reporting entity provides in its financial reports about a transfer of financial
assets; the effects of a transfer on its financial position, financial
performance, and cash flows; and a transferor’s continuing involvement in
transferred financial assets. This Statement must be applied as of the beginning
of each reporting entity’s first annual reporting period that begins after
November 15, 2009, and is required to be adopted by the Company in the first
quarter of fiscal year 2011. Earlier application is prohibited. This Statement
must be applied to transfers occurring on or after the effective date. The
Company does not expect the adoption of SFAS 166 to have a material impact on
the Company’s financial position, results of operations and cash
flows.
In June
2009, the FASB issued SFAS No.167, “Amendments to FASB Interpretation No.46(R)”,
which is codified as ASC 810. ASC 810 amends FASB Interpretation No.46(R),
“Variable Interest Entities” for determining whether an entity is a variable
interest entity (“VIE”) and requires an enterprise to perform an analysis to
determine whether the enterprise’s variable interest or interests give it a
controlling financial interest in a VIE. Under ASC 810, an enterprise has a
controlling financial interest when it has a) the power to direct the activities
of a VIE that most significantly impact the entity’s economic performance and b)
the obligation to absorb losses of the entity or the right to receive benefits
from the entity that could potentially be significant to the VIE. ASC 810 also
requires an enterprise to assess whether it has an implicit financial
responsibility to ensure that a VIE operates as designed when determining
whether it has power to direct the activities of the VIE that most significantly
impact the entity’s economic performance. ASC 810 also requires ongoing
assessments of whether an enterprise is the primary beneficiary of a VIE,
requires enhanced disclosures and eliminates the scope exclusion for qualifying
special-purpose entities. ASC 810 shall be effective as of the beginning of each
reporting entity’s first annual reporting period that begins after November 15,
2009, for interim periods within that first annual reporting period, and for
interim and annual reporting periods thereafter. Earlier application is
prohibited. ASC 810 is effective for the Company in the first quarter of fiscal
2011. The Company is currently evaluating the effect of ASC 810 on its financial
statements and results of operation and is currently not yet in a position to
determine such effects.
F-12
In August
2009, the FASB issued Accounting Standards Update (“ASU”) No. 2009-05,
“Measuring Liabilities at Fair Value”, which is codified as ASC 820, “Fair Value
Measurements and Disclosures”. This Update provides amendments to ASC 820-10,
Fair Value Measurements and Disclosures –Overall, for the fair value measurement
of liabilities. This Update provides clarification that in circumstances in
which a quoted price in an active market for the identical liability is not
available, a reporting entity is required to measure fair value using a
valuation technique that uses the quoted price of the identical liability when
traded as an asset, quoted prices for similar liabilities or similar liabilities
when traded as assets, or that is consistent with the principles of ASC 820. The
amendments in this Update also clarify that when estimating the fair value of a
liability, a reporting entity is not required to include a separate input or
adjustment to other inputs relating to the existence of a restriction that
prevents transfer of the liability. The amendments in this Update also clarify
that both a quoted price in an active market for the identical liability at the
measurement date and the quoted price for the identical liability when traded as
an asset in an active market when no adjustments to the quoted price of the
assets are required are Level 1 fair value measurements. ASC 820 is effective
for the first reporting period (including interim periods) beginning after
August 28, 2009. The adoption of this Update did not have a significant impact
to the Company’s financial statements.
In
December 2009, the FASB issued ASU No. 2009-17, “Improvements to Financial
Reporting by Enterprises Involved with Variable Interest Entities (“ASU
2009-17”)”. ASU 2009-17 amends the variable-interest entity guidance in FASB ASC
810-10-05-8 to clarify the accounting treatment for legal entities in which
equity investors do not have sufficient equity at risk for the entity to finance
its activities without financial support. ASU 2009-17 shall be effective as of
the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009. ASU 2009-17 is effective for the Company in the
first quarter of fiscal 2011. The Company is currently evaluating the effect of
ASU 2009-17 on its financial statements and results of operation and is
currently not yet in a position to determine such effects.
None of
the above new pronouncements has current application to the Company, but may be
applicable to the Company’s future financial reporting.
4.
|
OTHER
RECEIVABLES AND PREPAYMENTS
|
Other
receivables and prepayments consist of the following :
As
of
December
31,
2009
|
As
of
June
30,
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Prepayment
for advertising and promotion
|
$ | 1,111,986 | $ | 1,736,025 | ||||
Amount
due from a equity holder
|
- | 1,465,000 | ||||||
Loan
to a third party
|
2,200,500 | 1,465,000 | ||||||
Loans
interest receivable
|
- | 18,459 | ||||||
Other
receivables
|
9,861,672 | 9,774,316 | ||||||
$ | 13,174,158 | $ | 14,458,800 |
F-13
The
amount due from a equity holder is unsecured, interest bearing at 3.93% per
annum and has no fixed term of repayment.
Loan to a
third party is unsecured, interest bearing at 5.31% per annum and repayable on
June 8, 2010.
5.
|
INVENTORIES
|
Inventories
consist of the following :
As
of
|
As
of
|
|||||||
December
31,
|
June
30,
|
|||||||
2009
|
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Raw
materials
|
$ | 432,587 | $ | 250,405 | ||||
Finished
goods
|
339,917 | 57,429 | ||||||
Total
inventories
|
$ | 772,504 | $ | 307,834 |
6.
|
INTANGIBLE
ASSETS
|
Intangible
assets consist of the following:
As
of
|
As
of
|
|||||||
December
31,
|
June
30,
|
|||||||
2009
|
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Pharmaceuticals
formulas, at cost
|
$ | 17,322,336 | $ | 17,298,720 |
7.
|
PROPERTY,
PLANT AND EQUIPMENT, NET
|
The
following is a summary of property, plant and equipment:
F-14
As
of December
31,
2009
|
As
of June 30,
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Cost
|
||||||||
Leasehold
land and buildings
|
$ | 7,611,830 | $ | 7,447,211 | ||||
Plant
and equipment
|
1,389,514 | 1,156,557 | ||||||
Office
equipment
|
82,425 | 74,700 | ||||||
Motor
vehicles
|
235,446 | 389,075 | ||||||
Total
|
9,319,215 | 9,067,543 | ||||||
Accumulated
depreciation
|
||||||||
Leasehold
land and buildings
|
508,487 | 414,133 | ||||||
Plant
and equipment
|
646,671 | 617,279 | ||||||
Office
equipment
|
15,970 | 10,681 | ||||||
Motor
vehicles
|
126,206 | 112,768 | ||||||
Total
|
1,297,334 | 1,154,861 | ||||||
Construction
in progress
|
- | 236,597 | ||||||
Net
|
||||||||
Leasehold
land and buildings
|
7,103,343 | 7,033,078 | ||||||
Plant
and equipment
|
742,843 | 539,278 | ||||||
Office
equipment
|
66,455 | 64,019 | ||||||
Motor
vehicles
|
109,240 | 276,307 | ||||||
Property,
plant and equipment, net
|
8,021,881 | 8,149,279 |
Depreciation
expenses for the six months ended December 31, 2009 was $341,868 and for the
year ended June 30, 2009 was $302,762 respectively.
As of
December 31, 2009 and June 30, 2009, Bohai had pledged plant and machinery
having a carrying amount of $552,710 and $562,331 to secure a bank loan to
Bohai.
8.
|
SHORT-TERM
BORROWINGS
|
Bohai
obtained several short-term loan facilities from financial institution in the
PRC. Short-term borrowings as of December 31, 2009 are consist of the
following :
F-15
Loan from
financial
institution
|
Loan period
|
Annual Interest
rate
|
Secured by
|
Amount
(unaudited)
|
|||||||
Yantai
City Commercial Bank
|
From
Jan 20, 2009 to Jan 20, 2010
|
6.9030%
|
Yantai
Hai Pu Can End Making Co. Ltd
|
$ | 1,320,300 | ||||||
Yantai
Laishan Rural Credit Union
|
From
Sep 28, 2009 to Sep 26, 2010
|
5.7525%
|
Yantai
Ka Wah Medical Equipment Co. Ltd
|
286,065 | |||||||
Yantai
Laishan Rural Credit Union
|
From
Sep 28, 2009 to Sep 26, 2010
|
7.5225%
|
Bohai’s
machinery and vehicle
|
586,800 | |||||||
Shanghai
Pudong Development Limited
|
From
Oct 29, 2009 to Jan 28, 2010
|
5.8320%
|
Haiyang
Construction Industry Training Centre and personal guarantee by equity
holders
|
2,200,500 | |||||||
$ | 4,393,665 |
Short-term
borrowings as of June 30, 2009 are consist of the following :
Loan
from
financial institution
|
Loan
period
|
Annual
Interest
rate
|
Secured
by
|
Amount
(Audited)
|
|||||||
Shanghai
Pudong Development Limited
|
From
Dec 12, 2008 to Dec 11, 2009
|
6.6960%
|
Haiyang
Construction Industry Training Centre and personal guarantee by equity
holders
|
$ | 2,197,500 | ||||||
Yantai
City Commercial Bank
|
From
Jan 20, 2009 to Jan 20, 2010
|
6.9030%
|
Yantai
Hai Pu Can End Making Co. Ltd
|
1,318,500 | |||||||
Yantai
Laishan Rural Credit Union
|
From
Sep 27, 2008 to Sep 26, 2009
|
9.3600%
|
Yantai
Ka Wah Medical Equipment Co. Ltd
|
293,000 | |||||||
Yantai
Laishan Rural Credit Union
|
From
Sep 27, 2008 to Sep 26, 2009
|
12.2400%
|
Company’s
machinery and vehicle
|
586,000 | |||||||
China
Construction Bank
|
From
May 12, 2009 to Nov 11, 2009
|
0.0000%
|
Personal
guarantee by equity holders
|
1,465,000 | |||||||
$ | 5,860,000 |
F-16
9.
|
NOTES
PAYABLE
|
In June
2009, the Company issued four promissory notes for an aggregate of
$400,000. The funds had been raised previously on the Company’s
behalf by counsel in a private placement and held in trust
accounts. Funds were expended from the trusts for professional fees
and due diligence related to an ongoing search for suitable business
opportunities, anticipating merger. In June 2009, the Company assumed
responsibility for the fees and due diligence costs. Subsequent to
December 31, 2009, these notes were converted into Common Stock pursuant to
their terms (see Note 18).
10.
|
OTHER
ACCRUED LIABILITIES
|
Other
accrued liabilities consist of the following :
As
of
|
As
of
|
|||||||
December
31,
|
June
30,
|
|||||||
2009
|
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
Accrued
selling expenses
|
$ | 2,303,903 | $ | 1,677,026 | ||||
Accrued
staff costs
|
183,605 | 173,130 | ||||||
Value
added tax payable
|
934,016 | 709,688 | ||||||
Other
taxes payable
|
93,800 | 77,374 | ||||||
Other
accrued expenses
|
9,755,034 | 9,702,137 | ||||||
$ | 13,270,358 | $ | 12,339,355 |
F-17
11. SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES
Selling,
general and administrative expenses consist of the following:
Three
months
ended
December
31,
2009
|
Three
months
ended
December
31,
2008
|
Six
months
ended
December
31,
2009
|
Six
months
ended
December
31,
2008
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||
Accommodation
|
$ | 1,146,093 | $ | 738,484 | $ | 1,773,167 | $ | 1,204,621 | ||||||||
Advertising
and promotion
|
3,346,014 | 1,710,750 | 5,964,703 | 4,591,684 | ||||||||||||
Commission
|
682,002 | 204,999 | 2,403,953 | 658,935 | ||||||||||||
Conference
|
1,280,228 | 1,322,197 | 2,331,599 | 2,005,290 | ||||||||||||
Depreciation
|
9,101 | 1,687 | 18,476 | 10,235 | ||||||||||||
Staff
costs
|
305,460 | 287,093 | 963,137 | 704,016 | ||||||||||||
Travelling
|
695,738 | 909,902 | 1,283,010 | 1,300,466 | ||||||||||||
Research
and development cost
|
- | - | 2,126 | - | ||||||||||||
Other
operating expenses
|
2,348,581 | 2,319,068 | 4,329,118 | 3,594,139 | ||||||||||||
$ | 9,813,217 | $ | 7,494,180 | $ | 19,069,289 | $ | 4,069,386 |
12.
|
INTEREST
EXPENSES
|
Three
months
|
Three
months
|
Six
months
|
Six
months
|
|||||||||||||
ended
|
ended
|
ended
|
ended
|
|||||||||||||
December
31,
|
December
31,
|
December
31,
|
December
31,
|
|||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||
Interest
on short-term bank borrowings wholly repayable within the three-month
periods
|
49,819 | 50,293 | 145,911 | 101,029 | ||||||||||||
Interest
on notes payable
|
1,995 | - | 3,683 | - | ||||||||||||
$ | 51,814 | $ | 50,293 | $ | 149,594 | $ | 101,029 |
13.
|
INCOME
TAXES
|
The PRC’s
legislative body, the National People’s Congress, adopted the unified Enterprise
Income Tax (“EIT”) Law on March 16, 2007. This new tax law replaces the existing
separate income tax laws for domestic enterprises and foreign-invested
enterprises and became effective on January 1, 2008. Under the new tax law, a
unified income tax rate is set at 25% for both domestic enterprises and
foreign-invested enterprises. However, there will be a transition period for
enterprises, whether foreign-invested or domestic, that are currently receiving
preferential tax treatments granted by relevant tax authorities. Enterprises
that are subject to an enterprise income tax rate lower than 25% may continue to
enjoy the lower rate and will transit into the new rate over a five year period
beginning on the effective date of the EIT Law. Enterprises that are currently
entitled to exemptions for a fixed term may continue to enjoy such treatment
until the exemption term expires. Preferential tax treatments may continue to be
granted to industries and projects that qualify for such preferential treatments
under the new law.
F-18
Three
months
ended
December
31,
2009
|
Three
months
ended
December
31,
2008
|
Six
months
ended
December
31,
2009
|
|
Six
months
ended
December
31,
2008
|
||||||||||||
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|||||||||||||
Income
before tax
|
$ | 4,335,429 | $ | 2,288,391 | $ | 6,692,616 | $ | 4,926,859 | ||||||||
Income
tax expense
|
$ | 1,057,890 | $ | 203,764 | $ | 1,613,261 | $ | 804,085 |
The
deferred tax asset and liability has not been recognized because of no valuation
allowance to be established as of December 31, 2009 and June 30,
2009.
14.
|
COMMITMENTS
AND CONTINGENCIES
|
There are
no foreseeable commitments or contingencies as of December 31, 2009 and June 30,
2009.
15.
|
COMMON
EQUITY
|
As
of
|
As
of
|
|||||||
December
31,
|
June
30,
|
|||||||
2009
|
2009
|
|||||||
(Unaudited)
|
(Audited)
|
|||||||
The
Company:
|
||||||||
Common
Stock, $0.001 par value,
|
||||||||
150,000,000
shares authorized,
|
||||||||
3,450,000
shares issued and outstanding
|
3,450 | 3,450 | ||||||
Additional
paid-in capital
|
2,974,520 | 2,974,520 | ||||||
$ | 2,977,970 | $ | 2,977,970 |
As of
December 31, 2009, the Company has authorized 150,000,000 of $0.001 par common
stock, of which 3,450,000 shares were issued and outstanding.
16.
|
STATUTORY
RESERVES
|
According
to the laws and regulations in the PRC, Bohai is required to provide for certain
statutory funds, namely, reserve fund by an appropriation from net profit after
taxes but before dividend distribution based on the local statutory financial
statements of the PRC company prepared in accordance with the accounting
principles and relevant financial regulations.
Bohai in
PRC is required to allocate at least 10% of its net profit to the reserve fund
until the balance of such fund has reached 50% of its registered capital.
Appropriation of enterprise expansion fund are determined at the discretion of
it directors.
F-19
The
reserve fund can only be used, upon approval by the relevant authority, to
offset accumulated losses or increase capital. The enterprise expansion fund can
only be used to increase capital upon approval by the relevant
authority.
17.
|
FINANCIAL
INSTRUMENTS
|
(a)
|
Credit
Risk
|
The
potential credit risk of the company is mainly attributable to its debtors and
bank balances. In respect of debtors, the Group has policies in place
to ensure that it will only accept customers from countries which are
politically stable and customers with an appropriate credit
history. In addition, all the bank balances were made with financial
institutions with high-credit quality. Thus, the Group is not
considered to be subject to significant credit risk.
(b)
|
Interest
Rate Risk
|
The
Group’s interest rate risk is primarily attributable to its short-term
borrowings, loan to a third party and loan to equity holders. The
Group’s borrowings carry interest at fixed rate. The management has not used any
interest rate swaps to hedge its exposure to interest rate risk.
(c)
|
Fair
Value Estimation
|
All of
the carrying amounts of the Group’s financial assets and liabilities of short
term maturities approximate their fair values.
18.
|
SUBSEQUENT
EVENTS
|
On
January 5, 2010, the Company completed the Share Exchange and a concurrent US$12
million private placement (the “Private Placement”) pursuant to which the
Company acquired Chance High. In the Share Exchange, the shareholders
of Chance High exchanged all of their Chance High equity for 13,162,500 newly
issued shares of Common Stock, representing approximately 81% of the outstanding
shares of Company common stock prior to the Private Placement. As a
result of the Share Exchange, Chance High became a directly held, wholly-owned
subsidiary within the Group. Also as a result of the Share Exchange,
a change of control of the Company for purposes of the Company’s promissory
notes described in Note 9 above occurred and such notes were converted as a
result into an aggregate of 200,000 shares of Common Stock to the holders
thereof.
As part
of the Share Exchange, the Company’s sole director and officer, Anthony Zaradic,
resigned and Qu, Bohai’s Executive Director, was appointed President, Chief
Executive Officer, interim Chief Financial Officer, Secretary and Treasurer of
the Company, as well as, effective January 16, 2010, the Company’s sole
director.
In the
Private Placement, the Company issued 6,000,000 units at $2.00 per unit,
resulting in gross proceeds of $12,000,000. Net proceeds to the
Company were approximately $9,700,000, which will be utilized to support the
business of Bohai. Each unit consisted of a $2.00 principal amount,
two year convertible note and a three year warrant to purchase one share of
Common Stock at $2.40 per share, subject to certain conditions.
F-20
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To: The
Board of Directors and Stockholders of Bohai Pharmaceuticals Group,
Inc.
We have
audited the accompanying consolidated balance sheets of Bohai Pharmaceuticals
Group, Inc. (the “Company”) as of June 30, 2009 and 2008 and the related
statements of income, stockholders' equity and cash flow for each of the two
years in the years ended June 30, 2009 and 2008. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We
conducted our audit in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our
opinion, the consolidated financial statements referred to above present fairly,
in all material respects, the financial position of the Company as of June 30,
2009 and 2008, and the results of its operations and its cash flow for each of
the two years in the years ended June 30, 2009 and 2008, in conformity with
accounting principles generally accepted in the United States of
America.
s/ Parker Randall CF (H.K.) CPA
Limited
|
|
Parker
Randall CF (H.K.) CPA Limited
|
|
Certified
Public Accountants
|
|
Hong
Kong
|
|
26
February 2010
|
F-21
BOHAI
PHARMACEUTICALS GROUP, INC.
CONSOLIDATED
BALANCE SHEETS
AS
OF JUNE 30, 2009 AND 2008
(Stated
in US Dollars)
As
of
|
As
of
|
|||||||||||
June
30,
|
June
30,
|
|||||||||||
Notes
|
2009
|
2008
|
||||||||||
ASSETS
|
||||||||||||
Current
assets
|
||||||||||||
Cash
and cash equivalents
|
2,494,166 | 829,050 | ||||||||||
Accounts
receivable
|
11,070,129 | 8,918,209 | ||||||||||
Other
receivables and prepayments
|
4
|
14,458,800 | 10,557,082 | |||||||||
Inventories
|
5
|
307,834 | 1,049,191 | |||||||||
Total
current assets
|
28,330,929 | 21,353,532 | ||||||||||
Non-current
assets
|
||||||||||||
Property,
plant and equipment, net
|
7
|
8,149,279 | 7,663,164 | |||||||||
Intangible
assets
|
6
|
17,298,720 | 17,227,872 | |||||||||
Total
non-current assets
|
25,447,999 | 24,891,036 | ||||||||||
25,447,999 | 24,891,036 | |||||||||||
TOTAL
ASSETS
|
53,778,928 | 46,244,568 | ||||||||||
LIABILITES
AND STOCKHOLDERS' EQUITY
|
||||||||||||
Current
liabilities
|
||||||||||||
Short-term
borrowings
|
8
|
5,860,000 | 1,896,700 | |||||||||
Accounts
payable
|
971,208 | 3,065,389 | ||||||||||
Other
accrued liabilities
|
9
|
12,335,672 | 14,804,040 | |||||||||
Income
taxes payable
|
677,666 | 598,190 | ||||||||||
Total
current liabilities
|
19,844,546 | 20,364,319 | ||||||||||
|
||||||||||||
STOCKHOLDERS'
EQUITY
|
||||||||||||
Common
stock, $0.001 par value, 150,000,000 shares authorized, 3,450,000 shares
issued and outstanding
|
14
|
3,450 | 3,450 | |||||||||
Additional
paid-in capital
|
2,968,550 | 2,968,550 | ||||||||||
Capital
reserve
|
5,836,000 | 5,836,000 | ||||||||||
Accumulated
other comprehensive income
|
490,931 | 384,698 | ||||||||||
Statutory
reserves
|
15
|
2,201,811 | 1,464,861 | |||||||||
Retained
earnings
|
22,433,640 | 15,222,690 | ||||||||||
Total
stockholders' equity
|
33,934,382 | 25,880,249 | ||||||||||
33,934,382 | 25,880,249 | |||||||||||
TOTAL
LIABILITIES AND SHAREHOLDERS' EQUITY
|
53,778,928 | 46,244,568 |
See
accompanying notes to the financial statements
F-22
BOHAI
PHARMACEUTICALS GROUP, INC.
CONSOLIDATED
STATEMENT OF INCOME
FOR
THE YEARS ENDED JUNE 2009 AND 2008
(STATED
IN US DOLLARS)
Notes
|
2009
|
2008
|
||||||||||
$
|
$
|
|||||||||||
Sales
|
50,170,014 | 38,172,513 | ||||||||||
Less:
Sales Tax
|
(821,400 | ) | (629,489 | ) | ||||||||
|
|
|||||||||||
Net
sales
|
49,348,614 | 37,543,024 | ||||||||||
Cost
of sales
|
(7,975,267 | ) | (5,950,680 | ) | ||||||||
Gross
profit
|
41,373,347 | 31,592,344 | ||||||||||
Selling,
general and administrative expenses
|
10
|
(31,347,139 | ) | (22,608,164 | ) | |||||||
Interest
expenses
|
11
|
(184,404 | ) | (234,101 | ) | |||||||
Operating
income
|
9,841,804 | 8,750,079 | ||||||||||
Non-operating
income
|
49,447 | 8 | ||||||||||
Non-operating
costs
|
(36,366 | ) | (835 | ) | ||||||||
Income
before taxes
|
9,854,885 | 8,749,252 | ||||||||||
Income
taxes
|
12
|
(1,906,985 | ) | (2,303,712 | ) | |||||||
Net
income
|
7,947,900 | 6,445,540 |
See
accompanying notes to the financial statements
F-23
BOHAI
PHARMACEUTICALS GROUP, INC.
STATEMENT
OF STOCKHOLDERS’ EQUITY
FOR
THE YEARS ENDED JUNE 30, 2009 AND 2008
(Stated
in US Dollars)
Accumulated
|
||||||||||||||||||||||||||||
Additional
|
other
|
|||||||||||||||||||||||||||
Common
|
Paid-in
|
Capital
|
comprehensive
|
Statutory
|
Retained
|
|||||||||||||||||||||||
stock
|
Capital
|
reserve
|
income
|
reserves
|
earnings
|
Total
|
||||||||||||||||||||||
$
|
$
|
$
|
$
|
$
|
$
|
$
|
||||||||||||||||||||||
Balance,
July 1, 2007
|
3,450 | 2,968,550 | 5,836,000 | - | 885,025 | 9,356,986 | 19,050,011 | |||||||||||||||||||||
Net
income for the year
|
- | - | - | - | 579,836 | 5,865,704 | 6,445,540 | |||||||||||||||||||||
Foreign
currency translation adjustment
|
- | - | - | 384,698 | - | - | 384,698 | |||||||||||||||||||||
Balance,
June 30, 2008
|
3,450 | 2,968,550 | 5,836,000 | 384,698 | 1,464,861 | 15,222,690 | 25,880,249 | |||||||||||||||||||||
Net
income for the year
|
- | - | - | - | 736,950 | 7,256,278 | 7,947,900 | |||||||||||||||||||||
Foreign
currency translation adjustment
|
- | - | - | 106,233 | - | - | 106,233 | |||||||||||||||||||||
Balance,
June 30, 2009
|
3,450 | 2,968,550 | 5,836,000 | 490,931 | 2,201,811 | 22,478,968 | 33,934,382 |
See
accompanying notes to the financial statements
F-24
BOHAI
PHARMACEUTICALS GROUP, INC.
CONSOLIDATED
STATEMENT OF CASH FLOWS
FOR
THE YEAR ENDED JUNE 30, 2009 AND 2008
(Stated
in US Dollars)
2009
|
2008
|
|||||||
$
|
$
|
|||||||
Cash
flows from operating activities
|
||||||||
Net
income
|
7,947,900 | 6,445,540 | ||||||
Adjustments
to reconcile net income to net cash provided by operating
activities
|
||||||||
Depreciation
|
302,762 | 283,417 | ||||||
Loss
on disposals of property, plant and equipment
|
31,630 | - | ||||||
Changes
in assets and liabilities
|
||||||||
Increase
in accounts receivable
|
(2,151,920 | ) | (1,885,681 | ) | ||||
(Increase)/decrease
in other receivables and prepayments
|
(3,901,718 | ) | 1,244,060 | |||||
Decrease
in inventories
|
741,357 | 655,446 | ||||||
Decrease/(increase)
in accounts payable
|
(2,094,181 | ) | 242,734 | |||||
Decrease
in accrued liabilities
|
(2,468,368 | ) | (4,786,934 | ) | ||||
Increase
in income taxes payable
|
79,476 | 160,490 | ||||||
Net
cash provided by operating activities
|
(1,513,062 | ) | 2,359,072 | |||||
Cash
flows from investing activities
|
||||||||
Proceeds
from sales of common stock
|
- | 54,000 | ||||||
Purchases
of property, plant and equipment
|
(803,643 | ) | (80,647 | ) | ||||
Proceeds
from disposals of property, plant and equipment
|
14,650 | - | ||||||
Net
cash used in investing activities
|
(788,993 | ) | (26,647 | ) | ||||
Cash
flows from financing activities
|
||||||||
Proceeds
of borrowings
|
5,860,000 | 1,896,700 | ||||||
Repayment
of borrowings
|
(1,896,700 | ) | (4,085,200 | ) | ||||
Net
cash provided by/(used in) financing activities
|
3,963,300 | (2,188,500 | ) | |||||
Net
increase in cash and cash equivalents
|
1,661,245 | 143,925 | ||||||
Effect
of foreign currency translation on cash and cash
equivalents
|
3,871 | 384,698 | ||||||
Cash
and cash equivalents at beginning of year
|
829,050 | 300,427 | ||||||
Cash
and cash equivalents at end of year
|
2,494,166 | 829,050 |
See
accompanying notes to the financial statements
F-25
BOHAI
PHARMACEUTICALS GROUP, INC.
FOR
THE YEAR ENDED JUNE 30, 2009 AND 2008
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Stated
in US Dollars)
1.
|
ORGANIZATION
AND PRINCIPAL ACTIVITIES
|
Bohai
Pharmaceuticals Group, Inc. (formerly known as Link Resources, Inc.) was
incorporated under the laws of the State of Nevada on January 9,
2008. Until January 5, 2010, its principal office was located in
Calgary, Alberta, Canada. The Company was a public “shell” company in
the exploration stage since its formation and had not yet realized any revenues
from its planned operations. The Company entered into a Mineral Lease
Agreement on April 1, 2008 for two mining claims in Pershing County, Nevada, in
an area known as the Goldbanks East Prospect. The Company terminated
the lease on July 7, 2009.
Pursuant
to a Share Exchange Agreement, dated January 5, 2010 (the “Share Exchange
Agreement” and the transactions contemplated thereby, the “Share Exchange”), the
Company acquired Chance High International Limited, a British Virgin Islands
company (“Chance High”) from Chance High’s shareholders (the “Chance High
Shareholders”) and, as a result, acquired Chance High’s indirect, controlled
subsidiary, Yantai Bohai Pharmaceuticals Group Co., Ltd. (“Bohai”), a Chinese
company engaged the production, manufacturing and distribution in the People’s
Republic of China (“China” or “the PRC”) of herbal medicines, including capsules
and other products, based on traditional Chinese medicine. The
closing of the Share Exchange (the “Closing”) took place on January 5, 2010 (the
“Closing Date”).
On the
Closing Date, pursuant to the terms of the Share Exchange Agreement, the Company
acquired all of the outstanding equity securities (the “Chance High Shares”) of
Chance High from the Chance High Shareholders, and the Chance High Shareholders
transferred and contributed all of their Chance High Shares to the
Company. In exchange, the Company issued to Chance High Shareholders
an aggregate of 13,162,500 newly issued shares of common stock, par value $0.001
per share (the “Common Stock”). In addition, pursuant to the terms of
the Share Exchange Agreement, Anthony Zaradic, the former President and Chief
Executive Officer of the Company, cancelled a total of 1,500,000 shares of
Common Stock.
Chance
High owns 100% of the issued and outstanding capital stock of the Yantai
Shencaojishi Pharmaceuticals Co., Ltd. (“WOFE”). On December 7, 2009,
the WOFE entered into a series of variable interest entity contractual
agreements (the “VIE Agreements”) with Bohai and its three shareholders,
including Mr. Hongwei Qu, currently the Company’s Chairman, Chief Executive
Officer and President (“Qu”), pursuant to which WOFE effectively assumed
management of the business activities of Bohai and has the right to appoint all
executives and senior management and the members of the board of directors of
Bohai. Chance High, WOFE and Bohai are referred to herein
collectively as the “Group”.
The VIE
Agreements are comprised of a series of agreements, including a Consulting
Services Agreement, Operating Agreement and Proxy Agreement, through which WOFE
has the right to advise, consult, manage and operate Bohai for an annual fee in
the amount of Bohai’s yearly net profits after tax. Additionally,
Bohai’s shareholders pledged their rights, titles and equity interest in Bohai
as security for WOFE to collect consulting and services fees provided to Bohai
through an Equity Pledge Agreement. In order to further reinforce
WOFE’s rights to control and operate Bohai, Bohai’s shareholders granted WOFE an
exclusive right and option to acquire all of their equity interests in Bohai
through an Option Agreement. As all of the companies in the Group are
under common control, this has been accounted for as a reorganization of
entities and the financial statements have been prepared as if the
reorganization had occurred retroactively. The Company has
consolidated Bohai’s operating results, assets and liabilities within its
financial statements.
F-26
2.
|
BASIS
OF PRESENTATION
|
The Group
maintains its general ledger and journals with the accrual method accounting for
financial reporting purposes. Accounting policies adopted by the Group
conform to generally accepted accounting principles in the United States of
America (“US GAAP”) and have been consistently applied in the presentation of
financial statements, which are compiled on the accrual basis of
accounting.
This
basis of accounting differs in certain material respects from that used for the
preparation of the books of account of the Group, which are prepared in
accordance with the accounting principles and the relevant financial regulations
applicable to enterprises with limited liabilities established in the PRC (“PRC
GAAP”), the accounting standards used in the places of their domicile. The
accompanying financial statements reflect necessary adjustments not recorded in
the books of account of the Group to present them in conformity with US
GAAP.
The
interim financial statements as of and for the six months ended December 31,
2009 reflect all adjustments which, in the opinion of management, are necessary
to present fairly the financial position, results of operations and cash flows
for the period presented in accordance with the accounting principles generally
accepted in the United States of America. All adjustments are of a normal
recurring nature.
3.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
|
(a)
|
Basis
of Presentation and consolidation
|
The
condensed consolidated financial statements are prepared on the basis with
assumption the Share Exchange was undergone at the beginning of July 1,
2008. The historical condensed consolidated financial statements of the
Group will be those of Bohai Pharmaceuticals Group, Inc. and of the consolidated
entities from the July 1, 2008, the deemed date of Share Exchange, and
subsequent. The consolidated financial statements for the Company for the
six months ended December 31, 2009 and 2008, include the financial statements of
Chance High, and its wholly owned subsidiary, WOFE, and Bohai, the Company’s
principal operating subsidiary, which is a Chinese variable interest entity that
WOFE controls through certain contractual arrangements. Intercompany
transactions and balances are eliminated in consolidation.
As of
December 31, 2009, the particulars of the Company’s subsidiaries are as
follows:
Name
of
Company
|
Place
of
incorporation
|
Date
of
incorporation
|
Attributable
equity
interest
|
Issued
capital
|
||||
Chance
High International Limited
|
British
Virgin Islands
|
July
02, 2009
|
100%
|
USD50,000
|
||||
Yantai
Shencaojishi Pharmaceuticals Co., Ltd.
|
People’s
Republic of China
|
November
25, 2009
|
100%
|
USD9,500,000
|
||||
Yantai
Bohai Pharmaceuticals Group Co., Ltd.
|
People’s
Republic of China
|
July
8, 2004
|
*
|
USD2,918,000
(RMB20,000,000) |
*
The Group has indirect controlling interest of
Bohai under the VIE Agreements entered on December 7, 2009, which are described
in Note 1 above.
F-27
(b)
|
Economic
and Political Risks
|
The
Group’s operations are conducted solely in the PRC. There are significant
risks associated with doing business in the PRC, among others, political,
economic, legal and foreign currency exchange risks. The Group’s results
may be adversely affected by changes in the political and social conditions in
the PRC, and by changes in governmental policies with respect to laws and
regulations, anti-inflationary measures, currency conversion, remittances
abroad, and rates and methods of taxation, among other things.
(c)
|
Use
of Estimates
|
In
preparing of the financial statements in conformity with US GAAP, management
makes estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosures of contingent assets and liabilities at the dates of
the financial statements, as well as the reported amounts of revenues and
expenses during the reporting periods. These accounts and estimates
include, but are not limited to, the valuation of accounts receivable,
inventories, deferred income taxes and the estimation on useful lives of plant
and machinery. Actual results could differ from those
estimates.
(d)
|
Cash
and Cash Equivalents
|
The Group
considers all highly liquid investments purchased with original maturities of
three months or less to be cash equivalents. The Group maintains bank
accounts only in the PRC. The Company does not maintain any bank accounts
in the United States of America. As of December 31, 2009 and June 30,
2009, there were cash and cash equivalents of $7,892,908 and $2,493,510
respectively.
(e)
|
Accounts
Receivable
|
Accounts
receivable consists of amounts due from customers. The Group extends unsecured
credit to its customers in the ordinary course of business but mitigates the
associated risks by performing credit checks and actively pursuing past due
accounts. An allowance for doubtful accounts is established and determined
based on management’s assessment of known requirements, aging of receivables,
payment history, the customer’s current credit worthiness and the economic
environment.
(f)
|
Inventories
|
Inventories
are valued at the lower of cost or market with cost is determined on the
weighted average method. Finished goods inventories consist of raw materials,
direct labour and overhead associated with the manufacturing process. In
assessing the ultimate realization of inventories, the management makes
judgments as to future demand requirements compared to current or committed
inventory levels. The Group’s reserve requirements generally
increase/decrease due to management projected demand requirements, market
conditions and product life cycle changes. As of December 31, 2009 and June 30,
2009, the Group did not make any allowance for slow-moving or defective
inventories.
F-28
(g)
|
Fair
value of Financial Instruments
|
The
carrying values of the Group’s financial instruments, including cash and cash
equivalents, accounts receivables, other receivables and prepayments, short-term
borrowings, accounts payables, and other accrued liabilities their fair values
due to the short-term maturity of such instruments.
(h)
|
Intangible
Assets
|
Intangible
assets as “Pharmaceutical Formulas”, which acquired and with indefinite useful
live are measured initially at cost and not subject to amortization shall be
tested for impairment annually or more frequently if there is indication of
impairment. If the carrying amount exceeds fair value, an impairment loss should
be recognized. Subsequently reversal of a recognized impairment loss is
prohibited.
(i)
|
Property,
plant and equipment
|
Property,
plant and equipment, other than construction in progress, are stated at cost
less depreciation and amortization and accumulated impairment loss. Cost
represents the purchase price of the asset and other costs incurred to bring the
asset into its existing use. Maintenance, repairs and betterments,
including replacement of minor items, are charged to expense; major additions to
physical properties are capitalized.
Depreciation
of property, plant and equipment is calculated to written off the cost, less
their estimated residual value, if any, using the straight-line method over
their estimated useful lives. The principal annual rates are as
follows:-
Leasehold
land and buildings
|
30
to 40 years
|
Motor
vehicles
|
10
years
|
Plant
and machinery
|
10
years
|
Office
equipment
|
5
years
|
Upon sale
or disposition, the applicable amounts of asset cost and accumulated
depreciation are removed from the accounts and the net amount less proceeds from
disposal is charged or credited to income.
Construction
in progress mainly represents expenditures in respect of the Group’s corporate
campus and machinery under construction, which the campus was completed and at
which production began in 2009. Assets under construction are not
depreciated until the construction is completed and the assets are ready for
their intended use.
(j)
|
Accounting
for the Impairment of Long-Lived
Assets
|
The Group
adopted Statement of Financial Accounting Standards No. 144, “Accounting for the
Impairment or Disposal of Long-Live Assets” (“SFAS 144”), which addresses
financial accounting and reporting for the impairment or disposal of long-lived
assets. The Group periodically evaluates the carrying value of long-lived
assets to be held and used in accordance with SFAS 144. SFAS 144 requires
impairment losses to be recorded on long-lived assets used in operations when
indicators of impairment are present and the undiscounted cash flows estimated
to be generated by those assets are less than the assets’ carrying amounts. In
that event, a loss is recognized based on the amount by which the carrying
amount exceeds the fair market value of the long-lived assets. Loss on
long-lived assets to be disposed of is determined in a similar manner, except
that fair market values are reduced for the cost of disposal. Based on its
review, the Group believes that, as of December 31, 2009 and June 30, 2009,
there were no significant impairments of its long-lived assets.
F-29
(k)
|
Foreign
Currency Translation
|
The Group
maintains its financial statements in the functional currency. The
functional currency of the Group is the Chinese Renminbi (RMB). Monetary
assets and liabilities denominated in currencies other than the functional
currency are translated into the functional currency at rates of exchange
prevailing at the balance sheet dates. Transactions denominated in
currencies other than the functional currency are translated into the functional
currency at the exchanges rates prevailing at the dates of the
transaction. Exchange gains or losses arising from foreign currency
transactions are included in the determination of net income for the respective
periods.
For
financial reporting purposes, the financial statements of the Group which are
prepared using the functional currency have been translated into United States
dollars. Assets and liabilities are translated at the exchange rates at the
balance sheet dates and revenue and expenses are translated at the average
exchange rates and stockholders’ equity is translated at historical exchange
rates. Any translation adjustments resulting are not included in determining net
income but are included in foreign exchange adjustment to other comprehensive
income, a component of stockholders’ equity.
6.30.2009
|
6.30.2008
|
|||||||
Period
end US$ : RMB exchange rate
|
6.84480 | 6.87180 | ||||||
Average
periodic US$ : RMB exchange rate
|
6.84819 | 7.29062 |
RMB is
not freely convertible into foreign currency and all foreign exchange
transactions must take place through authorized institutions. No
representation is made that the RMB amounts could have been, or could be,
converted into US$ at the rates used in translation.
(l)
|
Revenue
Recognition
|
Revenue
represents the invoiced value of goods sold recognized upon the delivery of
goods to customers. Revenue is recognized when all of the following criteria are
met:
|
·
|
Persuasive
evidence of an arrangement exists;
|
|
·
|
Delivery
has occurred or services have been
rendered;
|
|
·
|
The
seller’s price to the buyer is fixed or determinable;
and
|
|
·
|
Collectability
is reasonably assured. Payments have been
established.
|
(n)
|
Cost
of Revenue
|
Regarding
the trading of medicine, the respective cost of revenue consists primarily of
material cost, labour cost, overhead associated with the manufacturing process
and related expenses which are directly attributable to the
trading.
(n)
|
Research
and Development Costs
|
Research
and development costs are charged as expense when incurred and included in
operating expenses.
F-30
(o)
|
Income
Taxes
|
Income
taxes are accounted for under the asset and liability method. Deferred tax
assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and operating
loss and tax credit carry-forwards. Deferred tax assets are reduced by a
valuation allowance to the extent management concludes it is more likely than
not that the assets will not be realized. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of
a change in tax rates is recognized in the statements of income and
comprehensive income in the periods that includes the enactment
date.
(t)
|
Comprehensive
Income
|
Comprehensive
income is defined to include all changes in equity except those resulting from
investments by owners and distributions to owners. Among other
disclosures, all items that are required to be recognized under current
accounting standards as components of comprehensive income are required to be
reported in a financial statement that is presented with the same prominence as
other financial statements. The Group’s current components of other
comprehensive income are the foreign currency translation
adjustment.
(u)
|
Commitments
and Contingencies
|
Liabilities
for loss contingencies arising from claims, assessments, litigation, fines and
penalties and other sources are recorded when it is probable that a liability
has been incurred and the amount of the assessment can be reasonably
estimated.
(v)
|
Earning
per Shares
|
The Group
reports basic earnings per share in accordance with SFAS 128, “Earnings Per
Share”. Basic earnings/(loss) per share is computed by dividing net
income/(loss) by weighted average number of shares of common stock outstanding
during the period. Diluted earnings per share is computed by dividing net income
by the weighted average number of shares of common stock, common stock
equivalents and potentially dilutive securities outstanding during the period.
At December 31, 2009, the Group had no common stock equivalents that could
potentially dilute future earnings per share.
(w)
|
Recent
Accounting Pronouncements
|
In March
2008, the FASB issued SFAS No. 161, DISCLOSURES ABOUT DERIVATIVE INSTRUMENTS AND
HEDGING ACTIVITIES (an amendment to SFAS No. 133). This statement is effective
for financial statements issued for fiscal year and interim periods beginning
after November 15, 2008 and requires enhanced disclosures with respect to
derivative and hedging activities. The Group will comply with the disclosure
requirements of this statement if it utilizes derivative instruments or engages
in hedging activities upon its effectiveness.
In April
2008, the FASB issued FASB Staff Position No. 142-3, DETERMINATION OF THE USEFUL
LIFE OF INTANGIBLE ASSETS (“FSP No. 142-3”) to improve the consistency between
the useful life of a recognized intangible asset (under SFAS No. 142) and the
period of expected cash flows used to measure the fair value of the intangible
asset (under SFAS No. 141(R)). FSP No. 142-3 amends the factors to be considered
when developing renewal or extension assumptions that are used to estimate an
intangible asset’s useful life under SFAS No. 142. The guidance in the new staff
position is to be applied prospectively to intangible assets acquired after
December 31, 2008. In addition, FSP No.142-3 increases the disclosure
requirements related to renewal or extension assumptions. The Company does not
believe implementation of FSP No. 142-3 have a material impact on its financial
statements.
F-31
In May
2008, the FASB issued statement No. 162, THE HIERARCHY OF GENERALLY ACCEPTED
ACCOUNTING PRINCIPLES. This statement identifies the sources of accounting
principles and the framework for selecting the principles to be used in the
preparation of financial statements of nongovernmental entities that are
presented in conformity with generally accepted accounting principles (GAAP) in
the United States (the GAAP hierarchy). This statement is effective 60 days
following the SEC’s approval of the Public Company Accounting Oversight Board
amendments to AU Section 411, “the Meaning of Present Fairly in Conformity With
Generally Accepted Accounting Principles”.
In May
2008, the FASB issued FSP Accounting Principles Board (“APB”) 14-1 “Accounting
for Convertible Debt instruments That May Be Settled in Cash upon Conversion
(Including Partial Cash Settlement)” (“FSP APB 14-1”). FSP APB 14-1 requires the
issuer of certain convertible debt instruments that may be settled in cash (or
other assets) on conversion to separately account for the liability (debt) and
equity (conversion option) components of the instrument in a manner that
reflects the issuer’s non-convertible debt borrowing rate. FSP APB 14-1 is
effective for fiscal years beginning after December 15, 2008 on a retroactive
basis. As we do not have convertible debt at this time, we currently believe the
adoption of FSP APB 14-1 will have no effect on our combined results of
operations and financial condition.
In May
2008, the FASB issued Statement No. 163, ACCOUNTING FOR FINANCE GUARANTEE
INSURANCE CONTRACTS - AN INTERPRETATION OF FASB STATEMENT NO. 60. The premium
revenue recognition approach for a financial guarantee insurance contract links
premium revenue recognition to the amount of insurance protection and the period
in which it is provided. For purposes of this statement, the amount of insurance
protection provided is assumed to be a function of the insured principal amount
outstanding, since the premium received requires the insurance enterprise to
stand ready to protect holders of an insured financial obligation from loss due
to default over the period of the insured financial obligation. This Statement
is effective for financial statements issued for fiscal years beginning after
December 15, 2008.
In June
2008, the FASB issued FASB Staff Position Emerging Issues Task Force (EITF) No.
03-6-1, DETERMINING WHETHER INSTRUMENTS GRANTED IN SHARE-BASED PAYMENT
TRANSACTIONS ARE PARTICIPATING SECURITIES (“FSP EITF No. 03-6-1”). Under FSP
EITF No. 03-6-1, unvested share-based payment awards that contain rights to
receive nonforfeitable dividends (whether paid or unpaid) are participating
securities, and should be included in the two-class method of computing EPS. FSP
EITF No. 03-6-1 is effective for fiscal years beginning after December 15, 2008,
and interim periods within those years, and is not expected to have a
significant impact on the Company’s financial statements.
In April
2009, the FASB issued FSP 157-4, DETERMINING FAIR VALUE WHEN THE VOLUME AND
LEVEL OF ACTIVITY FOR THE ASSET OR LIABILITY HAVE SIGNIFICANTLY DECREASED AND
IDENTIFYING TRANSACTIONS THAT ARE NOT ORDERLY (“FSP 157-4”). FSP 157-4 provides
additional guidance for estimating fair value in accordance with SFAS 157 when
the volume and level of activity for the asset or liability have significantly
decreased. FSP 157-4 also includes guidance on identifying circumstances that
indicate a transaction is not orderly. FSP 157-4 is effective for interim and
annual reporting periods ending after June 15, 2009, with early adoption
permitted for periods ending after March 15, 2009. FSP 157-4 does not require
disclosures for earlier periods presented for comparative purposes at initial
adoption. In periods after initial adoption, FSP 157-4 requires comparative
disclosures only for periods ending after initial adoption. The adoption of the
provisions of FSP 157-4 is not anticipated to materially impact on the Company’s
results of operations or the fair values of its assets and
liabilities.
F-32
In May
2009, the FASB issued SFAS No. 165, SUBSEQUENT EVENTS (“SFAS 165”). SFAS 165
establishes general standards for accounting for and disclosure of events that
occur after the balance sheet date but before financial statements are issued or
available to be issued and was effective for interim and annual periods ending
after June 15, 2009. The adoption of SFAS No. 165 did not have an impact on the
Company’s results of operations or financial condition. The Company evaluated
all subsequent events that occurred from January 1, 2010 through January 30,
2010, inclusive, and does not found any material subsequent events are required
to disclose.
In June
2009, the FASB issued SFAS No. 166 ACCOUNTING FOR TRANSFERS OF FINANCIAL ASSETS
(“SFAS 166). This statement is intended to improve the relevance,
representational faithfulness, and comparability of the information that a
reporting entity provides in its financial reports about a transfer of financial
assets; the effects of a transfer on its financial position, financial
performance, and cash flows; and a transferor’s continuing involvement in
transferred financial assets. This Statement must be applied as of the beginning
of each reporting entity’s first annual reporting period that begins after
November 15, 2009, and is required to be adopted by the Company in the first
quarter of fiscal year 2011. Earlier application is prohibited. This Statement
must be applied to transfers occurring on or after the effective date. The
Company does not expect the adoption of SFAS 166 to have a material impact on
the Company’s financial position, results of operations and cash
flows.
In June
2009, the FASB issued SFAS No.167, “Amendments to FASB Interpretation No.46(R)”,
which is codified as ASC 810. ASC 810 amends FASB Interpretation No.46(R),
“Variable Interest Entities” for determining whether an entity is a variable
interest entity (“VIE”) and requires an enterprise to perform an analysis to
determine whether the enterprise’s variable interest or interests give it a
controlling financial interest in a VIE. Under ASC 810, an enterprise has a
controlling financial interest when it has a) the power to direct the activities
of a VIE that most significantly impact the entity’s economic performance and b)
the obligation to absorb losses of the entity or the right to receive benefits
from the entity that could potentially be significant to the VIE. ASC 810 also
requires an enterprise to assess whether it has an implicit financial
responsibility to ensure that a VIE operates as designed when determining
whether it has power to direct the activities of the VIE that most significantly
impact the entity’s economic performance. ASC 810 also requires ongoing
assessments of whether an enterprise is the primary beneficiary of a VIE,
requires enhanced disclosures and eliminates the scope exclusion for qualifying
special-purpose entities. ASC 810 shall be effective as of the beginning of each
reporting entity’s first annual reporting period that begins after November 15,
2009, for interim periods within that first annual reporting period, and for
interim and annual reporting periods thereafter. Earlier application is
prohibited. ASC 810 is effective for the Company in the first quarter of fiscal
2011. The Company is currently evaluating the effect of ASC 810 on its financial
statements and results of operation and is currently not yet in a position to
determine such effects.
In August
2009, the FASB issued Accounting Standards Update (“ASU”) No. 2009-05,
“Measuring Liabilities at Fair Value”, which is codified as ASC 820, “Fair Value
Measurements and Disclosures”. This Update provides amendments to ASC 820-10,
Fair Value Measurements and Disclosures –Overall, for the fair value measurement
of liabilities. This Update provides clarification that in circumstances in
which a quoted price in an active market for the identical liability is not
available, a reporting entity is required to measure fair value using a
valuation technique that uses the quoted price of the identical liability when
traded as an asset, quoted prices for similar liabilities or similar liabilities
when traded as assets, or that is consistent with the principles of ASC 820. The
amendments in this Update also clarify that when estimating the fair value of a
liability, a reporting entity is not required to include a separate input or
adjustment to other inputs relating to the existence of a restriction that
prevents transfer of the liability. The amendments in this Update also clarify
that both a quoted price in an active market for the identical liability at the
measurement date and the quoted price for the identical liability when traded as
an asset in an active market when no adjustments to the quoted price of the
assets are required are Level 1 fair value measurements. ASC 820 is effective
for the first reporting period (including interim periods) beginning after
August 28, 2009. The adoption of this Update did not have a significant impact
to the Company’s financial statements.
F-33
In
December 2009, the FASB issued ASU No. 2009-17, “Improvements to Financial
Reporting by Enterprises Involved with Variable Interest Entities (“ASU
2009-17”)”. ASU 2009-17 amends the variable-interest entity guidance in FASB ASC
810-10-05-8 to clarify the accounting treatment for legal entities in which
equity investors do not have sufficient equity at risk for the entity to finance
its activities without financial support. ASU 2009-17 shall be effective as of
the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009. ASU 2009-17 is effective for the Company in the
first quarter of fiscal 2011. The Company is currently evaluating the effect of
ASU 2009-17 on its financial statements and results of operation and is
currently not yet in a position to determine such effects.
None of
the above new pronouncements has current application to the Company, but may be
applicable to the Company’s future financial reporting.
4.
|
OTHER
RECEIVABLES AND PREPAYMENTS
|
Other
receivables and prepayments consisted of the following :
As of
|
As of
|
|||||||
June 30,
|
June 30,
|
|||||||
2009
|
2008
|
|||||||
Prepayment
for advertising and promotion
|
$ | 1,736,025 | $ | 45,958 | ||||
Amount
due from a equity holder
|
1,465,000 | - | ||||||
Loan
to a third party
|
1,465,000 | - | ||||||
Loans
interest receivable
|
18,459 | - | ||||||
Other
receivables
|
9,774,316 | 10,511,124 | ||||||
$ | 14,458,800 | $ | 10,557,082 |
The
amount due from a equity holder is unsecured, interest bearing at 3.93% per
annum and has no fixed term of repayment.
Loan to a
third party is unsecured, interest bearing at 4.32% per annum and repayable on
November 11, 2009.
F-34
5.
|
INVENTORIES
|
Inventories
consisted of the following :
As of
|
As of
|
|||||||
June 30,
|
June 30,
|
|||||||
2009
|
2008
|
|||||||
Raw
materials
|
$ | 250,405 | $ | 716,303 | ||||
Finished
goods
|
57,429 | 332,888 | ||||||
Total
inventories
|
$ | 307,834 | $ | 1,049,191 |
6.
|
INTANGIBLE
ASSETS
|
Intangible
assets consisted of the following:
As
of
|
As
of
|
|||||||
June
30,
|
June
30,
|
|||||||
2009
|
2008
|
|||||||
Pharmaceuticals
formulas, at cost
|
$ | 17,298,720 | $ | 17,227,872 |
7.
|
PROPERTY,
PLANT AND EQUIPMENT, NET
|
Property,
plant and equipment consisted of the following :
As
of
|
As
of
|
|||||||
June
30,
|
June
30,
|
|||||||
2009
|
2008
|
|||||||
Cost
|
||||||||
Leasehold
land and buildings
|
$ | 7,447,211 | $ | 7,416,710 | ||||
Plant
and equipment
|
1,156,557 | 988,491 | ||||||
Office
equipment
|
74,700 | 15,179 | ||||||
Motor
vehicles
|
389,075 | 277,210 | ||||||
Total
|
9,067,543 | 8,697,590 | ||||||
Accumulated
depreciation
|
||||||||
Leasehold
land and buildings
|
414,133 | 229,132 | ||||||
Plant
and equipment
|
617,279 | 571,539 | ||||||
Office
equipment
|
10,681 | 5,956 | ||||||
Motor
vehicles
|
112,768 | 248,292 | ||||||
Total
|
1,154,861 | 1,054,919 | ||||||
Net
|
||||||||
Leasehold
land and buildings
|
7,033,078 | 7,187,578 | ||||||
Plant
and equipment
|
775,875 | 437,445 | ||||||
Office
equipment
|
64,019 | 9,223 | ||||||
Motor
vehicles
|
276,307 | 28,918 | ||||||
Total
|
8,149,279 | 7,663,164 | ||||||
Construction
in progress
|
236,597 | 20,493 | ||||||
Property,
plant and equipment, net
|
$ | 8,149,279 | $ | 7,663,164 |
F-35
Depreciation
expense for the year ended June 30, 2009 was $302,762 and for the year ended
June 30, 2008, was $283,417 respectively.
As of
June 30, 2009 and June 30, 2008, the Company has pledged plant and machinery
having a carrying amount of $562,331 and $Nil to secure a bank loan to
Bohai.
8.
|
SHORT-TERM
BORROWINGS
|
The
Company obtained several short-term loan facilities from financial institution
in the PRC.
Short-term
borrowings as of June 30, 2009 consisted of the following :
Loan
from
|
Annual
|
||||||||||
financial
institution
|
Loan
period
|
Interest rate
|
Secured
by
|
Amount
|
|||||||
Shanghai
Pudong
|
From
Dec 12, 2008
|
6.6960%
|
Haiyang
Construction
|
$ | 2,197,500 | ||||||
Development Limited
|
to
Dec 11, 2009
|
Industry
Training Centre
|
|||||||||
and
personal guarantee
|
|||||||||||
by
equity holders
|
|||||||||||
Yantai
City
|
From
Jan 20, 2009
|
6.9030%
|
Yantai
Hai Pu Can End
|
1,318,500 | |||||||
Commercial
Bank
|
to
Jan 20, 2010
|
Making
Co. Ltd
|
|||||||||
Yantai
Laishan Rural
|
From
Sep 27, 2008
|
9.3600%
|
Yantai
Ka Wah Medical
|
293,000 | |||||||
Credit
Union
|
to
Sep 26, 2009
|
Equipment
Co. Ltd
|
|||||||||
Yantai
Laishan Rural
|
From
Sep 27, 2008
|
12.2400%
|
Company's
machinery and
|
586,000 | |||||||
Credit
Union
|
to
Sep 26, 2009
|
vehicle
|
|||||||||
China
Construction
|
From
May 12, 2009
|
0.0000%
|
Personal
guarantee by
|
1,465,000 | |||||||
Bank
|
to
Nov 11, 2009
|
equity
holders
|
|||||||||
$ | 5,860,000 |
F-36
Short-term
borrowings as of June 30, 2008 consisted of the following :
Loan
from
|
Annual
|
||||||||||
financial
institution
|
Loan
period
|
Interest
rate
|
Secured
by
|
Amount
|
|||||||
Yantai
City
|
From
Jan 31, 2008
|
8.0925%
|
Yantai
Hai Pu Can End
|
1,313,100 | |||||||
Commercial
Bank
|
to
Jan 20, 2009
|
Making Co. Ltd
|
|||||||||
Industrial and Commercial
|
From
Jan 25, 2008
|
7.4700%
|
Shan
Dong Shui Hong
|
583,600 | |||||||
Bank
of China
|
to
Jan 24, 2009
|
Pharmaceutical
Co. Ltd
|
|||||||||
$ | 1,896,700 |
9.
|
OTHER
ACCRUED LIABILITIES
|
Other
accrued liabilities consisted of the following :
As of
|
As of
|
|||||||
June 30,
|
June 30,
|
|||||||
2009
|
2008
|
|||||||
Advanced
from customers
|
$ | - | $ | 735,680 | ||||
Accrued
selling expenses
|
1,677,026 | 321,717 | ||||||
Accrued
staff costs
|
173,130 | 200,135 | ||||||
Value
added tax payable
|
709,688 | 541,152 | ||||||
Amount
due to a equity holder
|
- | 108,426 | ||||||
Other
taxes payable
|
77,374 | 58,863 | ||||||
Payable
to Pharmaceutical formulas vendors
|
- | 2,724,087 | ||||||
Other
accrued expenses
|
9,702,137 | 10,113,980 | ||||||
$ | 12,339,355 | $ | 14,804,040 |
F-37
10.
|
SELLING,
GENERAL AND ADMINISTRATIVE EXPENSES
|
Selling,
general and administrative expenses consisted of the followings :
Year ended
|
Year ended
|
|||||||
June 30,
|
June 30,
|
|||||||
2009
|
2008
|
|||||||
Accommodation
|
$ | 5,151,876 | $ | 4,593,639 | ||||
Advertising
and promotion
|
10,959,424 | 8,679,512 | ||||||
Audit
fee
|
8,937 | 1,928 | ||||||
Commission
|
1,419,478 | 135,453 | ||||||
Conference
|
5,089,283 | 3,877,918 | ||||||
Depreciation
|
20,514 | 9,033 | ||||||
Staff
costs
|
1,536,496 | 998,763 | ||||||
Travelling
|
2,755,259 | 1,649,162 | ||||||
Research
and development cost
|
293,000 | 344 | ||||||
Other
operating expenses
|
4,112,872 | 2,662,412 | ||||||
$ | 31,347,139 | $ | 22,608,164 |
11.
|
INTEREST
EXPENSES
|
Year
ended
|
Year
ended
|
|||||||
June
30,
|
June
30,
|
|||||||
2009
|
2008
|
|||||||
Interest
on short-term bank borrowings wholly repayable within one
year
|
$ | 184,404 | $ | 234,101 |
12.
|
INCOME
TAXES
|
United States
Tax
As of
June 30, 2009, the Company incurred $45,328 of net operating losses carry
forwards available for federal tax purposes that may be used to offset future
taxable income and will begin to expire in 2028, if unutilized. The Company has
provided for a full valuation allowance against the deferred tax assets of
$15,412 on the expected future tax benefits from the net operating loss carry
forwards as the management believes it is more likely than not that these assets
will not be realized in the future.
F-38
PRC Tax
PRC's
legislative body, the National People's Congress, adopted the unified Enterprise
Income Tax ("EIT") Law on March 16, 2007. This new tax law replaces the existing
separate income tax laws for domestic enterprises and foreign-invested
enterprises and became effective on January 1, 2008. Under the new tax law, a
unified income tax rate is set at 25% for both domestic enterprises and
foreign-invested enterprises. However, there will be a transition period for
enterprises, whether foreign-invested or domestic, that are currently receiving
preferential tax treatments granted by relevant tax authorities. Enterprises
that are subject to an enterprise income tax rate lower than 25% may continue to
enjoy the lower rate and will transit into the new rate over a five year period
beginning on the effective date of the EIT Law. Enterprises that are currently
entitled to exemptions for a fixed term may continue to enjoy such treatment
until the exemption term expires. Preferential tax treatments may continue to be
granted to industries and projects that qualify for such preferential treatments
under the new law.
Year ended
|
Year ended
|
|||||||
June 30,
|
June 30,
|
|||||||
2009
|
2008
|
|||||||
Income
before tax
|
$ | 9,900,213 | $ | 8,755,484 | ||||
Income
tax expense
|
$ | 1,906,985 | $ | 2,303,712 |
The
deferred tax asset and liability has not been recognized because of no valuation
allowance to be established as of June 30, 2009 and June 30, 2008.
13.
|
COMMITMENTS
AND CONTINGENCIES
|
There is
no foreseeable commitments or contingencies for the year ended June 30, 2009 and
June 30, 2008.
14.
|
SHARE
CAPITAL
|
As of
June 30, 2009, the Company has authorized 75,000,000 of $0.001 par common stock,
of which 3,450,000 shares were issued and outstanding.
15.
|
STATUTORY
RESERVES
|
According
to the laws and regulations in the PRC, Bohai is required to provide for
certain statutory funds, namely, reserve fund by an appropriation from net
profit after taxes but before dividend distribution based on the local statutory
financial statements of the PRC company prepared in accordance with the
accounting principles and relevant financial regulations.
Bohai in
PRC is required to allocate at least 10% of its net profit to the reserve fund
until the balance of such fund has reached 50% of its registered capital.
Appropriation of enterprise expansion fund are determined at the discretion of
it directors.
F-39
The
reserve fund can only be used, upon approval by the relevant authority, to
offset accumulated losses or increase capital. The enterprise expansion fund can
only be used to increase capital upon approval by the relevant
authority.
16.
|
FINANCIAL
INSTRUMENTS
|
(a)
|
Credit
risk
|
The
potential credit risk of the company is mainly attributable to its debtors and
bank balances. In respect of debtors, the Group has policies in place to
ensure that it will only accept customers from countries which are politically
stable and customers with an appropriate credit history. In addition, all
the bank balances were made with financial institutions with high-credit
quality. Thus, the Group is not considered to be subject to significant
credit risk.
(b)
|
Interest
rate risk
|
The
Group's interest rate risk is primarily attributable to its short-term
borrowings, loan to a third party and loan to equity holders. The Group’s
borrowings carry interest at fixed rate. The management has not used any
interest rate swaps to hedge its exposure to interest rate risk.
(c)
|
Fair
value estimation
|
All of
the carrying amounts of the Group's financial assets and liabilities of short
term maturities approximate their fair values.
17.
|
SUBSEQUENT
EVENTS
|
Share
exchange transaction
On
January 5, 2010, the Company completed a share exchange transaction (the “Share
Exchange”) and concurrent US$12 million private placement (the “Private
Placement”) pursuant to which it acquired the parent company of Yantai Bohai
Pharmaceuticals Group Co., Ltd. (“Bohai”). Based in Yantai, Shandong
Province, China, Bohai is engaged in the production, manufacturing and
distribution of traditional Chinese herbal medicines, including capsules and
other products, in China.
In the
Share Exchange, the shareholders of Chance High International Limited, Bohai’s
indirect parent company organized in the British Virgin Islands (“Chance High”),
exchanged all of their Chance High equity for 13,162,500 newly issued shares of
the Company, representing approximately 81% of the outstanding shares of Company
common stock prior to the Private Placement. As a result of the Share
Exchange, Chance High became a directly held, wholly-owned subsidiary of the
Company. Also as a result of the Share Exchange, a change of control of
the Company for purposes of the Company's promissory notes occurred and such
notes were converted as a result into an aggregate of 200,000 shares of common
stock of the Company.
F-40
As part
of the share exchange transaction, the Company's sole director and officer,
Anthony Zaradic, resigned and Hongwei Qu, Bohai’s Executive Director, was
appointed President, Chief Executive Officer and interim Chief Financial Officer
of the Group as well as, effective January 16, 2010, the Group’s sole
director.
In the
Private Placement, the Group issued 6,000,000 units at $2.00 per unit, resulting
in gross proceeds of $12,000,000. Net proceeds to the Company were
approximately $9,700,000, which will be utilized to support the business of
Bohai. Each unit consists of a $2.00 principal amount, two year
convertible note and a three year warrant to purchase one share of Company
common stock at $2.40 per share, subject to certain conditions.
F-41
|
You
should rely only on the information contained in this document. We have
not authorized anyone to provide you with information that is different.
This document may only be used where it is legal to sell these securities.
The information in this document may only be accurate on the date of this
document.
Additional
risks and uncertainties not presently known or that are currently deemed
immaterial may also impair our business operations. The risks and
uncertainties described in this document and other risks and uncertainties which
we may face in the future will have a greater impact on those who purchase our
common stock. These purchasers will purchase our common stock at the
market price or at a privately negotiated price and will run the risk of losing
their entire investment.
BOHAI
PHARMACEUTICALS GROUP, INC.
19,632,529
Shares of
Common
Stock
PROSPECTUS
,
2010
|
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution
The
following table sets forth an itemization of all estimated expenses, all of
which we will pay, in connection with the issuance and distribution of the
securities being registered:
Nature of Expense
|
Amount
|
|||
SEC
registration fee
|
$ | 2,484.092 | ||
Legal
fees and expenses
|
$ | 55,000 | ||
Accounting
fees and expenses
|
15,000 | |||
TOTAL
|
$ | 72,484.092 |
Item
14. Indemnification of Directors and Officers
Charter
Provisions and Other Agreement of the Company
The
current bylaws of the Company provides that the Board of the Company shall cause
the Company to indemnify a current or former director, officer and Secretary of
the Company, or a current or former director, officer and Company of a
corporation of which the Company is or was a stockholder and the heirs and
personal representative of any such person against all costs, charges and
expenses to settle an action, judgment or proceeding to which they are made a
party by reason of their position of director or officer of the
Company.
The
Company is permitted by the Bylaws to purchase and maintain insurance for any
director, officer, employee or agent of the Company or as a director, officer,
employee or agent of the Company of which the Company is or was a stockholder
and his or her heirs or personal representatives against a liability incurred by
him as a Director, officer, employee or agent.
Nevada
Law
Our company is incorporated under the
laws of the State of Nevada. Section 78.7502 of the Nevada Revised Statutes
provides that a Nevada corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative, except an action by or in the right of the corporation, by reason
of the fact that he is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, including attorneys’ fees,
judgments, fines and amounts paid in settlement actually and reasonably incurred
by him in connection with the action, suit or proceeding if he acted in good
faith and in a manner which he reasonably believed to be in or not opposed to
the best interests of the corporation, and, with respect to any criminal action
or proceeding, had no reasonable cause to believe his conduct was unlawful. The
termination of any action, suit or proceeding by judgment, order, settlement,
conviction or upon a plea of nolo contendere or its
equivalent, does not, of itself, create a presumption that the person did not
act in good faith and in a manner which he reasonably believed to be in or not
opposed to the best interests of the corporation, and that, with respect to any
criminal action or proceeding, he had reasonable cause to believe that his
conduct was unlawful.
Section 78.7502 further provides a
Nevada corporation may indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action or
suit by or in the right of the corporation to procure a judgment in its favor by
reason of the fact that he is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the corporation as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise against expenses, including amounts paid in
settlement and attorneys' fees actually and reasonably incurred by him in
connection with the defense or settlement of the action or suit if he acted in
good faith and in a manner which he reasonably believed to be in or not opposed
to the best interests of the corporation. Indemnification may not be made for
any claim, issue or matter as to which such a person has been adjudged by a
court of competent jurisdiction, after exhaustion of all appeals therefrom, to
be liable to the corporation or for amounts paid in settlement to the
corporation, unless and only to the extent that the court in which the action or
suit was brought or other court of competent jurisdiction determines upon
application that in view of all the circumstances of the case, the person is
fairly and reasonably entitled to indemnity for such expenses as the court deems
proper.
Section
78.751 of the Nevada Revised Statutes provides that discretionary
indemnification under Section 78.7502 unless ordered by a court or advanced
pursuant to subsection 2 of section 78.751, may be the corporation only as
authorized in the specific case upon a determination that indemnification of the
director, officer, employee or agent is proper in the circumstances. The
determination must be made by:
|
·
|
By
the stockholders;
|
|
·
|
By
the board of directors by majority vote of a quorum consisting of
directors - who were not parties to the action, suit or
proceeding;
|
|
·
|
If
a majority vote of a quorum consisting of directors who were not parties
to the action, suit or proceeding so orders, by independent legal counsel
in a written opinion; or
|
|
·
|
If
a quorum consisting of directors who were not parties to the action, suit
or proceeding cannot be obtained, by independent legal counsel in a
written opinion.
|
The
Articles of Incorporation, the Bylaws or an agreement made by the corporation
may provide that the expenses of officers and directors incurred in defending a
civil or criminal action, suit or proceeding must be paid by the corporation as
they are incurred and in advance of the final disposition of the action, suit or
proceeding, upon receipt of an undertaking by or on behalf of the director or
officer to repay the amount if it is ultimately determined by a court of
competent jurisdiction that he is not entitled to be indemnified by the
corporation. The provisions of this subsection do not affect any rights to
advancement of expenses to which corporate personnel other than directors or
officers may be entitled under any contract or otherwise by law.
The
indemnification and advancement of expenses authorized in or ordered by a court
pursuant to NRS Section 78.751:
|
·
|
does
not exclude any other rights to which a person seeking indemnification or
advancement of expenses may be entitled under the articles of
incorporation or any bylaw, agreement, vote of stockholders or
disinterested directors or otherwise, for either an action in his official
capacity or an action in another capacity while holding his office, except
that indemnification, unless ordered by a court pursuant to section
78.7502 or for the advancement of expenses made pursuant to subsection 2
of section 78.751, may not be made to or on behalf of any director or
officer if a final adjudication establishes that his acts or omissions
involved intentional misconduct, fraud or a knowing violation of the law
and was material to the cause of action;
and
|
|
·
|
continues
for a person who has ceased to be a director, officer, employee or agent
and inures to the benefit of the heirs, executors and administrators of
such a person.
|
Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as
amended (the “Securities Act”), may be permitted to directors, officers and
controlling persons of our company under Nevada law or otherwise, we have been
advised the opinion of the Securities and Exchange Commission is that such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event a claim for
indemnification against such liabilities (other than payment by us for expenses
incurred or paid by a director, officer or controlling person of our company in
successful defense of any action, suit, or proceeding) is asserted by a
director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction,
the question of whether such indemnification by it is against public policy in
the Securities Act and will be governed by the final adjudication of such
issue.
Item
15. Recent Sales of Unregistered Securities
The
following private placements of the Company’s securities were made in reliance
upon the exemption from registration under Section 4(2) of the Securities Act of
1933, as amended and/or Rule 506 of Regulation D promulgated under the
Securities Act.
In
connection with the consummation of the transactions contemplated by our January
5, 2010 Share Exchange and private placement:
(i) Pursuant
to the Share Exchange Agreement, the Company issued 13,162,500 shares of common
stock to Chance High Shareholders in exchange for 100% of the outstanding shares
of Chance High. Such securities were not registered under the
Securities Act. These securities qualified for exemption under
Section 4(2) of the Securities Act since the issuance securities by us did not
involve a public offering. The offering was not a “public offering”
as defined in Section 4(2) of the Securities Act and met the requirements to
qualify for exemption under Section 4(2) of the Securities Act.
(ii) Pursuant
to the Securities Purchase Agreement, the Company issued to the Investors a
total of 6,000,000 Units for $12 million with each Unit consisting of a
unsecured $2 principal amount Notes payable 24 months from January 5, 2010 with
an interest rate of 8% per annum payable quarterly in arrears, and a three year
Warrant to purchase one share of Common Stock. The Notes and Warrants
were not registered under the Securities Act. The issuance of these
securities was exempt from registration under Regulation D and Section 4(2)
of the Securities Act. The Company made this determination based on
the representations of Investors, which included, in pertinent part, that such
Investors were “accredited investors” within the meaning of Rule 501 of
Regulation D promulgated under the Securities Act and that such Investors were
acquiring the Notes and Warrants for investment purposes for their own
respective accounts and not as nominees or agents, and not with a view to the
resale or distribution thereof, and that the Investors understood that the Notes
and Warrants may not be sold or otherwise disposed of without registration under
the Securities Act or an applicable exemption therefrom.
(iii) In
connection with the Private Placement, on January 5, 2010, the Company issued to
affiliates of Euro Pacific and to Chardan three-year Placement Agent Warrants to
purchase 600,000 shares of Common Stock at an exercise price of $2.40 per
share. 31,500 placement agent warrants were issued to Chardan and
568,500 placement agent warrants were issued to affiliates of Euro
Pacific. The Agent Warrants are substantially identical to the
Warrants issued to the Investors in the Private Placement, except that such
warrants may not be exercised until June 5, 2010. Such issuance of
the Agent Warrants was not registered under the Securities Act. The
issuance of the Agent Warrants was exempt from registration under
Section 4(2) of the Securities Act.
Outstanding Convertible
Notes. On June 15, 2009, the Company issued four convertible
notes for an aggregate of $400,000, which notes were amended on August 7,
2009. The principal of such notes shall, automatically and without
any action on the part of the holders, convert into one share of Common Stock
for each two dollars converted, upon the occurrence of Change in Control as
defined in the notes. All of such outstanding convertible notes were converted
into Common Stock upon the Share Exchange, resulting in the issuance of 200,000
shares of Common Stock.
Notes Issued in Connection with the
Private Placement. In connection with the Private Placement,
the Company offered and sold $12,000,000 worth of Notes convertible into
6,000,000 shares of Common Stock. The issuance of the Notes was not
registered under the Securities Act as such issuance was exempt from
registration under Section 4(2) of the Securities Act and Regulation D
promulgated thereunder.
The Notes
are unsecured, payable 24 months from the date of Closing with an interest rate
of 8% per annum payable quarterly in arrears. The Company has placed
in escrow with the Escrow Agent an amount of the proceeds of the Private
Placement equal to one quarter worth of interest payments on the Notes to secure
prompt interest payments, or $240,000. Until such time as 75% of the
Notes are converted into shares of Common Stock, if such escrow is depleted in
order to make interest payments, Bohai will replenish such escrow
amount. At the option of the holder, the Notes may be converted into
Common Stock at a price of $2 per share, which conversion price is subject to
customary weighted average and stock based anti-dilution
protection.
The Notes
contains standard events of default, including: (i) failure to file the
Registration Statement (as defined in Item 1.01 of this Current Report) with the
SEC within the prescribed period; (ii) failure to have the Registration
Statement deemed effective by the SEC within the prescribed period; (iii)
failure to maintain the effectiveness of the Registration Statement thereafter;
(iv) nonpayment of principal or interest; (v) termination of registration or
suspension of reporting obligations under the Exchange Act, suspension from
trading on the OTCBB (or an exchange), or failure to file reports with the SEC
on a timely basis as required by the Exchange Act; (vi) material breach of
representations, warranties and other obligations under the transaction
documents associated with the Securities Purchase Agreement; (vii) enforcement
proceedings; (viii) cross default and cross acceleration; (ix) insolvency,
winding up and other market standard analogous events; (x) moratorium and
nationalization; (xi) proceedings against the Company or its consolidated
subsidiaries with potential loss/damage of U.S.$5 million or more; and (xii)
illegality of Notes under any applicable law.
The Notes
also contain customary affirmative and negative covenants of the Company,
including negative covenants which restrict the Company’s ability to do the
following without the consent of Euro Pacific, as representative of the
Investors: (i) incur, or permit to exist, any indebtedness for
borrowed money in excess of (A) US$10,000,000 during the twelve (12) month
period beginning on January 5, 2010, or (B) US$15,000,000 during period
beginning on January 5, 2010 and ending on January 5, 2012 (the maturity date of
the Notes), except in the ordinary course of the Company’s business; (ii) lend
or advance money, credit or property to or invest in (by capital contribution,
loan, purchase or otherwise) any person or entity in excess of US$2,000,000 except: (A) investments
in United States Government obligations, certificates of deposit of any banking
institution with combined capital and surplus of at least $200,000,000; (B)
accounts receivable arising out of sales in the ordinary course of business; and
(C) inter-company loans between and among the Company and its subsidiaries;
(iii) pay dividends or make any other distribution on shares of the capital
stock of the Company; (iv) create, assume or permit to exist, any lien on any of
the Company’s property or assets now owned or hereafter acquired, subject to
existing liens and certain exceptions; (v) assume guarantees, subject to certain
exceptions; (vi) engage in “sale-leaseback” transactions, subject to certain
exceptions; (vii) make capital expenditures in excess of US$5,000,000 in any
fiscal year, subject to certain exceptions; and (viii) materially alter the
Company’s business.
Warrants. The
Warrants to purchase Common Stock were issued in conjunction with the Private
Placement. The Company offered and sold Warrants to purchase
6,000,000 shares of Common Stock. The issuance of the Warrants was
not registered under the Securities Act as such issuance was exempt from
registration under Section 4(2) of the Securities Act and Regulation D
promulgated thereunder. Each Warrant entitles the holder to purchase
one share of Common Stock. The Warrants shall be exercisable in whole
or in part, at an initial exercise price per share of $2.40, which exercise
price is subject to customary weighted average and stock based anti-dilution
protection. The Warrants may be exercised at any time upon the
election of the holder, beginning on the date of issuance and ending of the
third anniversary of the closing of the Private Placement. The
Warrants shall not be redeemable.
In the
event of the Company’s liquidation, dissolution or winding up, the holders of
Warrants will not be entitled to participate in the distribution of assets of
the Company. In addition, holders of Warrants do not have voting,
pre-emptive, subscription or other rights of stockholders in respect of the
Warrants, nor shall the Holders be entitled to receive dividends.
Item
16. Exhibits
Exhibit No.
|
Description
|
|
2.1
|
Share
Exchange Agreement, dated January 5, 2010, by and among the Company,
Chance High and Shareholders of Chance High (1)
|
|
3.1
|
Articles
of Incorporation of the Company (2)
|
|
3.2
|
Bylaws
of the Company (3)
|
|
3.3
|
Certificate
of Amendment to Articles of Incorporation (4)
|
|
3.4
|
Articles
of Merger and Agreement and Plan of Merger as filed with the Secretary of
State of Nevada on January 29, 2010 (5)
|
|
4.1
|
Form
of Note issued to the Investors in the Private Placement, dated January 5,
2010 (1)
|
|
4.2
|
Form
of Warrant issued to the Investors in the Private Placement, dated January
5, 2010 (1)
|
|
4.3
|
Form
of Placement Agent Warrant issued to affiliates of Euro Pacific Capital,
Inc. and to Chardan Capital Markets, LLC, dated January 5, 2010
(1)
|
|
5.1
|
Opinion
of Ellenoff Grossman & Schole LLP*
|
|
10.1
|
Securities
Purchase Agreement, dated January 5, 2010, by and among the Company, the
Investors in the Private Placement and Euro Pacific Capital, Inc. as
representative of the Investors (1)
|
|
10.2
|
Registration
Rights Agreement, dated January 5, 2010, by and among the Company and the
Investors in the Private Placement (1)
|
|
10.3
|
Securities
Escrow Agreement, dated January 5, 2010, by and among the Company, Euro
Pacific Capital, Inc., as representative of the Investors, Glory Period
Limited and Escrow, LLC, as escrow agent (1)
|
|
10.4
|
Closing
Escrow Agreement, dated December 10, 2009, by and among the Company, Euro
Pacific Capital, Inc., as representative of the Investors, and Escrow,
LLC, as escrow agent (1)
|
|
21.1
|
Subsidiaries
of the Registrant*
|
|
23.1
|
Consent
of Parker Randall CF (H.K.) CPA Limited
*
|
23.2
|
Consent
of Ellenoff Grossman & Schole LLP (included in Exhibit
5.1)
|
|
99.1
|
Unofficial
English translation of Consulting Services Agreement, dated December 7,
2009, between Bohai and the WFOE (1)
|
|
99.2
|
Unofficial
English translation of Operating Agreement, dated December 7, 2009, by and
among Bohai, its shareholders and the WFOE (1)
|
|
99.3
|
Unofficial
English translation of Voting Rights Proxy Agreement, dated December 7,
2009, by and among Bohai, its shareholders and the WFOE
(1)
|
|
99.4
|
Unofficial
English translation of Equity Pledge Agreement, dated December 7, 2009, by
and among Bohai, its shareholders and the WFOE (1)
|
|
99.5
|
Unofficial
English translation of Option Agreement, dated December 7, 2009, by and
among Bohai, its shareholders and the WFOE (1)
|
|
99.6
|
Unofficial
English translation of Call Option Agreement dated December 7, 2009
(1)
|
*
|
Filed
herewith
|
(1)
|
Incorporated
by reference to the Company’s Current Report of Form 8-K, filed on January
11, 2010.
|
(2)
|
Incorporated
by reference to Exhibit 3.1 to the Company’s Registration Statement of
Form S-1 (File Number 333-153102), filed on August 20,
2008.
|
(3)
|
Incorporated
by reference to Exhibit 3.2 to the Company’s Registration Statement of
Form S-1 (File Number 333-153102), filed on August 20,
2008.
|
(4)
|
Incorporated
by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K
filed on December 17, 2009.
|
(5)
|
Incorporated
by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K,
filed on February 4, 2010.
|
Item
17. Undertakings
The
undersigned registrant hereby undertakes:
(1) To
file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To
include any prospectus required by section 10(a)(3) of the Securities
Act;
(ii) To
reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding the
foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with
the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum aggregate offering
price set forth in the “Calculation of Registration Fee” table in the effective
registration statement; and
(iii) To
include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to
such information in the registration statement;
(2) That,
for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof.
(3) To
remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the
offering.
(4) That,
for the purpose of determining liability under the Securities Act to any
purchaser:
(i) If
the registrant is relying on Rule 430B:
(A) Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to
be part of the registration statement as of the date the filed prospectus was
deemed part of and included in the registration statement; and
(B) Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as
part of a registration statement in reliance on Rule 430B relating to an
offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of
providing the information required by section 10(a) of the Securities Act shall
be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or
the date of the first contract of sale of securities in the offering described
in the prospectus. As provided in Rule 430B, for liability purposes of the
issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the
securities in the registration statement to which that prospectus relates, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however, that no statement made in a
registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective
date, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date; or
(ii) If
the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than
registration statements relying on Rule 430B or other than prospectuses filed in
reliance on Rule 430A, shall be deemed to be part of and included in the
registration statement as of the date it is first used after effectiveness.
Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately
prior to such date of first use.
(5) That,
for the purpose of determining liability of the registrant under the Securities
Act to any purchaser in the initial distribution of the securities, the
undersigned registrant undertakes that in a primary offering of securities of
the undersigned registrant pursuant to this registration statement, regardless
of the underwriting method used to sell the securities to the purchaser, if the
securities are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrant will be a seller to the
purchaser and will be considered to offer or sell such securities to such
purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating to
the offering required to be filed pursuant to Rule 424;
(ii) Any
free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned
registrant;
(iii) The
portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and
(iv) Any
other communication that is an offer in the offering made by the undersigned
registrant to the purchaser.
Insofar
as indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the SEC such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such
issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly
caused this registration statement to be signed on its behalf by the
undersigned, in the City of Yantai, Shandong Province, China on March 2,
2010.
Bohai
Pharmaceuticals Group, Inc.
|
|
By:
|
/s/ Hongwei
Qu
|
Hongwei
Qu
|
|
Chief
Executive Officer, President, Interim Chief Financial Officer, Treasurer
and Secretary
|
|
(Principal
Executive Officer)
|
|
(Principal
Financial and Accounting
Officer)
|
Pursuant
to the requirements of the Securities Act of 1933, this registration statement
has been signed by the following persons in the capacities and on the dates
indicated.
Signature
|
Title
|
Date
|
||
/s/ Hongwei Qu
|
Chairman
of the Board, Chief Executive
|
March
2, 2010
|
||
Hongwei
Qu
|
Officer,
President, Interim Chief
Financial Officer, Treasurer and Secretary |